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Abstract 
The prevalence of diabetes worldwide continues to rise and with it the burden of 
cardiovascular disease (CVD). This is related to clustering of cardiovascular risk 
factors in diabetes, coupled with a deranged haemostatic system, generating a 
pro-thrombotic environment. Matters are compounded further by increased 
incorporation of proteins such as plasmin inhibitor (PI) and complement C3 into 
the clot contributing to a hypofibrinolytic state. C3 is a key component of the 
complement pathways and elevated plasma levels are seen in diabetes and 
correlate with clot lysis time in type 1 patients, which may relate to increased 
incorporation of C3 into the clot compared to controls. Ex-vivo analysis 
demonstrates that C3 causes a prolongation in clot lysis, and this is more 
pronounced in diabetes. Targeted interference with fibrinolysis, such as 
inhibition of fibrinogen interactions with C3, may lead to the development of 
diabetes specific therapeutic agents. The aims of my work were therefore to i) 
further study the role of C3 in hypofibrinolysis in relation to diabetes ii) elucidate 
potential binding sites between fibrinogen and C3 and iii) modulate fibrin clot 
lysis by targeted interference with fibrinogen-PI and fibrinogen-C3 interactions. 
 
My work has helped demonstrate that complement C3 plays an important role in 
hypofibrinolysis in type 2 as well as type 1 diabetes, an effect that shows wide 
inter-individual variability and may relate to differing rates of glycation of C3 in 
diabetes. I have also identified potential interaction sites of this protein with the 
β chain of fibrinogen. Moreover, I have helped develop a new method, using 
Adhiron technology, for the identification of novel therapeutic targets that can be 
used to enhance the fibrinolytic process and reduce thrombosis risk.  
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Chapter 1  
Introduction 
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Cardiovascular disease (CVD) is a major cause of death in Western 
populations. In the UK in 2013, CVD was eclipsed only by cancer as the leading 
cause of death, accounting for 28% of all deaths registered (ons.gov.uk). 
Diabetes mellitus (DM) is known to increase the risk of developing CVD, which 
remains the main cause of mortality in these individuals1. Not only is the risk of 
developing a first cardiovascular event increased in diabetes, these individuals 
also have a poorer prognosis following treatment compared to those without 
diabetes, regardless of the treatment given in the acute stage 2-5. With the 
number of patients with diabetes reaching 3 million in the UK alone in 2012 
(www.diabetes.org.uk) an increased understanding of the disease processes 
involved in DM and improved therapeutic strategies will be required to reverse 
this unnerving trend, This strong association between DM and CVD is 
multifactorial and is related to clustering of classical cardiovascular risk factors, 
including hyperglycaemia, obesity, hypertension, dyslipidaemia and increased 
thrombotic potential. The pro-thrombotic environment that is associated with DM 
arises secondary to a combination of increased platelet activation and 
enhanced fibrin clot formation along with compromised clot breakdown, or 
hypofibrinolysis. Chronic inflammation contributes to these disease processes 
and is also involved in the development of atherosclerotic plaques. Recent 
evidence suggests a close link between the inflammatory and coagulation 
pathways6, and therefore inflammation plays key roles early and in late stages 
of the atherothrombotic process. 
1.1 Coagulation and fibrinolysis 
The formation of blood clots and their subsequent destruction, or lysis, is a vital 
physiological function aimed at preventing acute blood loss following trauma. 
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This is termed haemostasis, and comprises finely balanced interactions 
between the vessel wall (in particular the endothelium), platelets, along with 
procoagulant and anticoagulant proteins. The resultant plug of platelets, red 
blood cells, leucocytes and fibrin fibres seals the vessel and prevents leakage 
of blood from the vascular tree, and subsequently allows the formation of new 
tissue and wound healing. In contrast to this, thrombosis should be viewed as a 
pathological state, where the formation of a blood clot in a diseased blood 
vessel results in partial or complete blood flow obstruction, consequently 
resulting in end organ damage. 
1.1.1 Blood vessels 
The blood vessel provides the setting and personnel essential to the ordered 
sequence of events involved in coagulation and haemostasis, and is also the 
scene of deleterious thrombosis related to atherosclerotic plaque rupture. 
Knowledge of blood vessel biology and anatomy is therefore crucial to 
understanding these mechanisms. Arteries and veins throughout the body are 
lined by a single layer of endothelial cells (EC). Supporting the EC is a loose 
network of tissue, the extracellular matrix and together they form the intima. 
Below this layer is the media (consisting mainly of smooth muscle cells) and 
then the adventitia. The latter two layers are less developed in veins compared 
to large and intermediate arteries and are not visible in smaller arterioles and 
capillaries7. 
1.1.1.1 Endothelial cells 
EC play a vital role in haemostasis through the production of numerous proteins 
and surface receptors that help regulate vascular tone, clot formation and cell 
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adhesion. Constriction and dilation of blood vessels is controlled by the release 
of several proteins, the most important of which are endothelin, and angiotensin 
II, which mediate vasoconstriction, whereas nitric oxide (NO) and prostacyclin 
are responsible for vasodilation. They synthesise and secrete coagulation 
proteins von Willebrand factor (vWf) and tissue factor (TF) essential for the 
initiation of clot formation and platelet activation. Several anticoagulant proteins 
and those involved in clot lysis are also produced including tissue factor 
pathway inhibitor (TFPI), thrombomodulin and tissue plasminogen activator 
(tPA). Receptors present on the surface of EC also help activate other 
fibrinolytic and anti-fibrinolytic proteins such as protein C and thrombin 
activatable fibrinolytic inhibitor (TAFI). These proteins will be discussed in more 
detail in section 1.3. The EC are therefore equipped to initiate the coagulation 
pathway plugging the breached vessel wall and help confine the clot to the site 
of injury through regulatory pathways. Adhesive receptors are also present and 
these are responsible for adhesion of inflammatory cells to EC. The function of 
EC and their morphology can vary depending on their anatomical position, for 
example cells within the brain form very tight junctions, contributing to the blood 
brain barrier, whereas in the liver, gaps between cells are much wider to 
facilitate soluble and cellular flow between blood and the extravascular space7.  
1.1.1.2 Extracellular matrix 
The extra cellular matrix (ECM) is a complex structure that contains numerous 
proteins, which are involved in maintaining vessel wall structure, platelet 
adhesion and sustaining of matrix proteins. The most abundant protein is 
collagen (of which there are numerous types) which together with elastin 
provides structural support to the blood vessels. Numerous adhesion proteins, 
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such vWf, fibronectin, vitronectin and laminin (together with collagen) promote 
platelet adhesion and contribute towards fibrinolysis. Proteoglycans such as 
heparin sulphate also exhibit anticoagulant properties and may also contribute 
to the structural integrity of the vessel by combining with collagen. A group of 
enzymes, named matrix metalloproteinases (MMP) are responsible for the 
degradation and repair of most of the ECM proteins7. 
1.1.1.3 Smooth muscle cells 
Smooth muscle cells contained within the media layer play a role in vessel 
contractility in response to molecules such as NO and endothelin. They produce 
a number of the proteins seen within the ECM such as collagens, elastin, 
glycoproteins, proteoglycans and TF. They also produce several growth factors 
including vascular endothelial growth factor (VEGF) and insulin-like growth 
factors (IGF) that are involved in smooth muscle cell generation7.  
1.1.1.4 Adventitia 
This final layer consists of a loose network of cells made up of fibroblasts, 
adipocytes and mast cells. These cells are responsible for synthesising 
collagens, glycoproteins, elastin, TF and lipids7. 
1.1.2 The coagulation cascade 
The final step of the coagulation cascade is the formation of a cross-linked fibrin 
clot, which follows a sequence of enzymatic reactions and activation of inactive 
precursors. Until recently, these reactions were divided into two separate 
pathways, intrinsic and extrinsic, with differing coagulation proteins, or factors 
involved in each pathway, which ultimately converge to a common pathway 
culminating in the conversion of soluble fibrinogen into insoluble fibrin networks. 
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The intrinsic pathway results in sequential activation of factors (F) XII, XI, IX, VII 
and V, whereby the extrinsic pathway is dependent upon FVII being activated 
by tissue factor (TF). The common pathway involves activation of FX which 
converts prothrombin (II) to thrombin (IIa) and finally the formation of fibrin8. 
Although these systems represented in vitro coagulation, it failed to explain the 
clinical manifestations of clotting disorders such as a defect in FVIII seen in 
haemophilia. Increased understanding of the interplay between different 
coagulation factors and also their interaction with platelets, particularly thrombin 
generation, has led to a more contemporary model of coagulation9. This model 
is divided into three phases, initiation, amplification and propagation, 
underpinned by plasma exposure to TF10 (Figure 1-1).  
Following injury to the vascular system, EC bearing activated TF are exposed to 
the circulating plasma which contains all the necessary zymogens and cofactors 
required for clot formation. Initiation occurs following the formation of a FVIIa/TF 
complex on the cell surface with subsequent activation of factors IX and X. A 
second complex is formed, Xa/Va which is able to produce a small amount of 
thrombin. Amplification of this process occurs following the activation of 
platelets by thrombin, releasing activated vWF and clotting factors V, VIII and 
XI. The propagation phase take place on the surface of activated platelets 
which are now able to bind factors IXa, VIIIa, Va and Xa. In similar fashion to 
the initial TF bearing cell, Xa is formed following the formation of a FIXa/VIIIa 
complex which then forms a complex with Va thus generating a surge in 
thrombin production if sufficient platelets are recruited to the site of injury9. The 
generation of thrombin causes the production of an insoluble fibrin clot through 
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its action on fibrinogen and also through activation of FXIII which will be 
discussed below.    
 
Figure 1-1 Illustration of coagulation cascade following tissue injury.  
Cells bearing TF bind FVII and activates factors X, IX and thrombin (IIa). 
Insufficient thrombin is produced to permit fibrin formation. Amplification sees 
activation of platelets by thrombin, releasing vWF, FVIIIa and FVa. On the 
surfaces of activated platelets complexes of FIXa-VIIIa are formed, activating 
FX and forming FVa-Xa complex which is able to produce increased quantities 
of thrombin (assuming sufficient platelets are recruited) and thus fibrin clot 
formation. 
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1.1.3 Platelets 
As described above, platelets play a crucial role in the formation of the fibrin 
clot. Despite their diminutive appearance they are complex cells without which 
haemostasis would not be possible. Their roles can be divided into three 
separate functions, namely 1) platelet adhesion (at the site of vessel injury), 2) 
activation and 3) aggregation, resulting in an insoluble plug10. The three phases 
will be described in more detail below. 
1.1.3.1 Adhesion 
At the site of vessel injury, platelets rolling along the endothelium adhere to the 
subendothelial matrix through the interaction of numerous surface receptors on 
platelets and proteins within the subendothelial matrix, such as vWF, collagen, 
and fibronectin. These receptors include integrins (such as glycoproteins (GP) 
IIb/IIIa and GP Ia/IIa) leucine rich glycoproteins and immunoglobulins7. 
1.1.3.2 Activation 
Activation of platelets occurs following adhesion to matrix bound proteins and 
interaction with soluble agonists such as thrombin which binds to the GP IIb/IIIa 
receptor10. This triggers a cascade of complex reactions that exposes surface 
phospholipids, alters the structure of the platelets and culminates in the release 
of granules. Numerous coagulation factors are now able to bind platelets via the 
GP receptors or phospholipids9. A variety of compounds are released from the 
granules including ADP, ATP, calcium, platelet derived growth factors (PDGF) 
and transforming growth factor beta (TGFβ), fibrinogen, FV, platelet factor 4, 
vWf and thrombospondin. These molecules cause further platelet adhesion and 
activation, promote tissue repair and initiate platelet aggregation. One of the key 
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reactions within platelets following activation is the conversion of arachidonic 
acid to prostaglandin endoperoxides G2 and H2 (PGG2 and PGH2) by the action 
of cyclo-oxygenase 1 (COX-1). PGG2 and PGH2 in turn are converted to 
thromboxane A2 (by thromboxane synthesis) which is thought to be involved in 
granule secretion by aiding the fusion of intra-cellular granules with the cell 
membrane7;11. Thromboxane A2 is also involved in platelet aggregation and 
causes vasoconstriction of smooth muscles. The antiplatelet agent aspirin 
(acetylsalicylic acid) acts by acetylating COX-1 thus inhibiting its action, 
reducing thromboxane A2 synthesis and platelet aggregation, generating fibrin 
clots that are less resistant to lysis.12;13   
1.1.3.3 Aggregation 
The final role of platelets in the formation of the haemostatic fibrin plug is to 
aggregate and form a dense mass. This occurs again via the action of one of its 
GP receptors. GP IIb/IIIa of one platelet binds to a fibrin molecule within the clot 
which in turn binds to the GP IIb/IIIa receptor of another platelet. The end result 
of these interactions is a dense accumulation of platelets which forms a physical 
plug around the site of injury9. Therefore, in addition to forming the skeleton of 
the blood clot, fibrin acts as a bridge between platelets facilitating growth of the 
platelet plug. 
1.2 The fibrin network 
As mentioned earlier, the fibrin network forms the backbone of the blood clot 
and is essential for maintaining integrity of the thrombus. Until recently, 
fibrinolysis was the main treatment modality for acute myocardial infarction4, 
emphasising the importance of the fibrin clot in disease pathogenesis. The main 
 
 
10 
 
proteins involved in clot formation and resistance to fibrinolysis are discussed in 
this section.   
1.2.1 Fibrinogen  
Fibrinogen is a glycoprotein that is synthesised in the liver (a process which 
takes roughly 5 minutes) and circulates in the plasma at concentrations of 2-4 
mg/ml (~6-12µM) but can reach double these concentrations in pathological 
states. It is a dimeric protein made up of two symmetrical sets of identical 
polypeptide chains, Aα,Bβ and γ. The α chain contains 610 residues, the β 
chain 461 and γ chain 411 residues. The presence of 4 carbohydrate clusters 
(one on each β and γ chain) combine to form a protein of 340,000Da.  All 6 
chains are held together by a total of 29 disulfide bonds 14;15. Three separate 
regions make up the molecular structure of fibrinogen, a central, E region and 
two peripheral, D regions. The amino termini of all six chains are contained in 
the E region, while the carboxy termini of the Bβ and γ chains are found in the D 
region. The α chain carboxy termini end in a separate αC domain16. Extending 
from the E region, the chains intertwine and from a helical coiled coil structure 
which lead to the D regions. The alpha chains extend back from the D regions 
and are thought to bind to β chain residues 1-66 within the E region17 (Figure 
1-2). 
1.2.1.1 Conversion to fibrin and clot formation 
Following activation of the coagulation cascade fibrinogen is converted to a 
fibrin monomer and subsequent insoluble fibrin clot through the actions of 
thrombin. Thrombin binds to the central E region and removes peptides from 
the N-termini of the α and β chains. Cleavage of the α chain occurs first, 
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Figure 1-2 Structure of the fibrinogen molecule  
A) Schematic representation of the fibrinogen molecule with the central E 
domain and 2 peripheral D domains from which the αC regions originate. B) 
ribbon representation of the crystallised fibrinogen molecule (Protein Data Bank 
[PDB] code: 3GHG)18. The αC regions are not obvious due to their mobile 
properties. 
releasing a 16 amino acid peptide, fibrinopeptide A (FpA), thus generating a 
new N terminal sequence which is termed the “A” site. A non-covalent bond 
occurs between this “A” site within the E region and an “a” pocket within the γ 
chain of the D region of a neighbouring fibrin molecule. This initial interaction 
produces a half-staggered chain of double stranded protofibrils and elongates 
the fibrin chain. A second peptide, fibrinopeptide B (FpB) is now released from 
the N terminal of the β chain again by the action of thrombin. The removal of 
these terminal 14 amino acids again produces a new N terminal sequence; this 
time termed the “B” site. In a similar manner to the A:a interaction of the α and γ 
chains, the “B” site binds to a “b” pocket found within the β chain of the D region 
of another molecule 19-21 ( 
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Figure 1-3). It is thought that this B: b interaction of 2 fibrin molecules promotes 
lateral aggregation of protofibrils and thereby generates thick fibrin fibres. 
Interestingly, however, lateral aggregation may occur in the absence of FpB 
release, casting doubt on the exact role of FpB in clot formation22. Around the 
time FpB is released the αC domains disengage with the central E region and 
subsequently interact with other protofibrils, and in so doing lateral aggregation 
occurs and a fibrin scaffold is formed14.  
1.2.1.2 Stabilisation of the fibrin clot 
1.2.1.2.1 Factor XIII 
Much needed stability is added to the clot through the action of factor XIII, a 
member of the transglutaminase family. It is a tetrameric proenzyme 
(320,000Da) that contains 2 A chains and 2 B chains, and circulates in plasma 
bound to fibrinogen. The B chains are produced in the liver and are inert acting 
primarily as a carrier for the A chains. The latter are produced largely in the 
bone marrow and combine with the B chains upon contact in plasma14. In 
addition to its action in cross linking fibrin fibres, activated FXIII can also bind to 
platelets and is thought to supplement other ECM proteins in the adhesion of 
platelets to the damaged EC wall23. This coagulation factor is also unique in that 
it appears to have extra- and intracellular functions. FXIII exists as a dimer of 
the active A chains within platelets, monocytes, macrophages, dendritic cells, 
chondrocytes, osteoblasts and osteocytes24;25.    
1.2.1.2.2 Activation of FXIII 
The active, cysteine, site of FXIII is concealed within the A chain of inactive 
FXIII and thus a series of activation steps are required to form the 
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transglutaminase. Firstly thrombin cleaves a 37 residue peptide from the N 
terminal of the A chain, weakening the bond between the A and B chains, a 
process that occurs at the same time as fibrinopeptides are released from 
fibrinogen26.  The B chain is dissociated from the A chain following the binding 
of 2 calcium ions to the A subunits, and in doing so fully exposes the active 
cysteine site, producing active FXIIIA. The B subunits also play an important 
role in correctly orientating the A subunits within the fibrin matrix14. 
1.2.1.2.3 Cross linking 
Once activated, FXIIIa is able to form covalent bonds between the γ and α 
chains of neighbouring fibrin molecules. The γ chains are cross linked first in a 
very timely fashion. Dimeric γ chain structures are produced through the 
formation of a bond between lysine 406 of one gamma chain and glutamine 398 
(or 399) of another. The cross linking of α chains proceeds at a relatively slower 
pace and results mainly in the formation of large α chain polymers27. Numerous 
glutamine and lysine residues have been identified as possible cross linking 
sites within the α chain and this is speculated to be an evolutionary adaptation 
to the heterogeneous nature of the αC domain14. The physical presence of 
these crosslinks increases the fibrin fibre thickness, conferring stability and 
elasticity to the clot, as well as making the clot more resistant to lysis by 
interfering with the action of plasmin within the D and E regions as it attempts to 
degrade fibrin. Further resistance to fibrinolysis is provided by the cross linking 
of the anti-fibrinolytic proteins plasmin inhibitor (PI), plasminogen activator 
inhibitor-2 (PAI-2) and thrombin activatable fibrinolysis inhibitor (TAFI) to the α 
chain of fibrin26, and these are further discussed below.  
 
 
14 
 
 
Figure 1-3 Protofibril formation following action of thrombin.  
Cleavage of fibrinopeptide A (FpA) generates a new N terminal sequence, 
termed the “A” site. A non-covalent bond occurs between this “A” site within the 
E region and an “a” pocket within the γ chain of the D region of a neighbouring 
fibrin molecule. This produces a half-staggered chain of double stranded 
protofibrils and causes elongation of the fibrin chain. Following the release of 
fibrinopeptide B (FpB) from the β chains a new N terminal sequence is formed, 
this time termed the “B” site. In a similar manner to the A:a interaction of the α 
and γ chains, the “B” site binds to a “b” pocket found within the β chain of the D 
region of another molecule. 
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1.3 Control of clot formation 
1.3.1 Natural anticoagulants 
1.3.1.1 Protein C pathway 
Protein C is a vitamin K dependant zymogen, similar to factors VII, IX, X and 
prothrombin and is synthesised in the liver with a molecular weight of 59,000 
Da. However, upon activation on the surface of EC, protein C acts as an 
anticoagulant rather than a procoagulant. In order for it to be activated, thrombin 
has to form a complex with thrombomodulin on the surface of EC28. This alters 
the structure of thrombin abolishing its ability to activate platelets or convert 
fibrinogen to fibrin, but can activate protein C which subsequently proteolytically 
cleaves factors Va and VIIIa. The major function of this pathway is to control 
coagulation and prevent extension of the clot beyond the site of injury within the 
vessel wall29. 
1.3.1.2 TF pathway inhibitor (TFPI) 
As its name suggests TFPI inhibits TF and thus the initiation of coagulation. It is 
also able to inhibit FXa and TF-VIIa-Xa complex to lesser degrees9. It is 
synthesised by EC and can circulate bound to plasma lipoproteins, on vessel 
wall proteoglycans or in platelets. Two isoforms exist, TFPIα and TFPIβ, with 
only the former present in platelets which may be ideally placed to inhibit 
thrombin generation that follows platelet activation. The β isoform is expressed 
on endothelial cells where its inhibitory actions are likely to be important when 
endothelial TF is present, for example during inflammation30.  
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1.3.1.3 Heparin-antithrombin pathway 
This pathway involves another of the serine protease inhibitors, antithrombin III. 
It is also produced in the liver, and is found predominantly on the vascular 
endothelium. Along with its ability to inhibit thrombin, it is also able to inhibit 
clotting factors, Xa, IXa, Xia, XIIa and VIIa when in complex with TF and with 
varying efficacy28;29. By combining with heparin, the activity of antithrombin is 
increased by a factor of around 1000, and thrombin inhibition is also only 
achievable if thrombin itself is in complex with heparin, which is in contrast to 
the other clotting factors. Antithrombin deficiency represents the most severe 
clinical manifestation of all natural anticoagulant deficiencies31.  
1.3.1.4 Other pathways 
Other molecules secreted by EC which have an anticoagulant effect are 
prostacyclin and nitric oxide (NO) which are potent vasodilators and are 
instrumental in the control of vascular tone. They can also exert and 
anticoagulant effect by inhibiting platelet aggregation7;32.  
1.3.2 Fibrinolysis 
The fibrinolytic system is triggered following the generation of fibrin and ensures 
that coagulation does not continue unchecked14.  
1.3.2.1 Plasminogen  
Plasminogen is a single chain zymogen (92,000 Da) that is synthesised in the 
liver. It is converted to its active form, plasmin, by the action of tissue 
plasminogen activator (tPA), which cleaves the Arg561-Val562 peptide bond, 
removing a 77 residue peptide. Plasmin consists of a heavy (residue 79-562) 
and light chain (residue 562-791) which are linked by a disulphide bond33. An 
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active serine site is contained within the heavy chain. Plasminogen binds 
fibrinogen but the affinity to fibrin is increased 1000 fold, to prevent unwanted 
and excessive clot formation. Plasmin begins dissolution of the fibrin clot by 
hydrolysis of arginyl and lysyl bonds within the coiled coil region of the D and E 
domains as well as the αC region. The first consequence of plasmin digestion 
cleaves a 4kDa fragment from the Aα chain, producing fragment X (which may 
still be clotted by thrombin). Further cleavage within the D and E regions 
produces fragments Y and D, the former is further degraded to produce a 
second fragement D and fragment E. Thus each fibrin molecule yields 2 
molecules of fragment D and one of fragment E (Figure 1-4) 34. Plasmin is also 
able to degrade other proteins involved in coagulation such as FVIII, FV and 
vWf.  
1.3.2.2 tPa  
This serine protease is predominantly produced within EC as a single chain 
glycoprotein and circulates in plasma at 5-10ug/ml. It is activated into a 2 chain 
protein by the cleavage of bond Arg275-Ile276 by plasmin and FXa and the 
formation of a disulphide bridge between the 2 chains33. It usually circulates in 
association with its inhibitor plasminogen activator inhibitor-1 (PAI-1), and the 
initiation of coagulation causes this complex to dissociate. Upon formation of a 
fibrin clot, free tPA and plasminogen bind to fibrin and this complex increases 
the action of tPA by a factor of 100035.  
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Figure 1-4 Schematic representation of fibrin degradation by plasmin.  
Initial cleavage produces two fragments, Y and D. Further cleavage of fragment 
Y produces a second D fragment and fragment E. The dashed lines represent 
site of plasmin cleavage. 
1.3.2.3 uPa 
Urokinase plasminogen activator (uPA) is another serine protease and like tPA 
is also able to activate plasminogen to produce plasmin but to a lesser degree. 
It is synthesised in the lung, kidney and EC and is also converted from an 
inactive single chain protein to an active 2 chain serine protease by the actions 
of plasmin and FXIIa causing cleavage of the Lys158-Ile159 bond36. It has a 
larger role in the proteolysis of the extracellular matrix and is involved in wound 
healing as well as new vessel formation7.  
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1.3.3 Inhibition of fibrinolysis 
Fibrinolysis is closely regulated through the action of several different proteins. 
1.3.3.1 PAI-1  
Plasminogen activator inhibitor-1 (PAI-1) is a 43,000Da serine protease inhibitor 
(serpin) and is the physiological inhibitor of tPA and uPA. It is secreted from 
numerous cells including EC, vascular smooth muscle cells, hepatocytes and 
adipocytes and circulates in the plasma at approximately 2-20ng/ml (40-
400nM)37. It irreversibly binds to the plasminogen activators thereby reducing 
plasmin generation and modifying the rate of clot lysis. Plasma levels vary 
during the day, with highest levels observed on waking, falling to a nadir by the 
afternoon. Numerous factors such as plasma insulin and transforming growth 
factor β are known to induce transcription of PAI-1, and plasma levels can rise 
rapidly when stimulated. It is a relatively unstable molecule and is rapidly 
degraded to a latent, inactive form and has a plasma half-life of around 10-120 
minutes38-40. Although the latent form appears to have no clinical relevance, 
antigen testing kits may not be sufficiently sensitive to differentiate the two 
forms, thus giving inaccurate plasma levels of the active and physiologically 
relevant PAI-139.   
1.3.3.2 PAI-2  
PAI-2 is less efficient at inhibiting tPA compared with PAI-1. It is mainly 
synthesised during pregnancy where it is involved in embryonic development 
and maintaining the placenta.  
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1.3.3.3 Plasmin Inhibitor 
The activity of plasmin is inhibited by the actions of plasmin inhibitor (PI), also 
known as α2-antiplasmin (α2-AP), which is produced in the liver and has a 
molecular weight of 58,000 Da. Its actions are multiple, in that it can directly 
bind plasminogen and plasmin, thus reducing their ability to bind fibrin(ogen). It 
also competitively inhibits plasminogen by directly binding to fibrin. It may do 
this non-covalently to fibrin D regions and αC domains or through cross linking 
to Lys303 within the αC region of the α chain, a process facilitated by FXIIIa 16. 
The inhibition in clot lysis is directly proportional to the circulating levels of α2-
AP, and its importance in maintaining haemostasis is emphasised by the 
bleeding tendency exhibited by homozygous deficiency of the PI gene41. More 
detailed description of the role of PI can be found in Chapter 5. 
1.3.3.4 Thrombin activatable fibrinolysis inhibitor 
 A third inhibitor of fibrinolysis is thrombin activatable fibrinolysis inhibitor (TAFI), 
which becomes activated by thrombin/thrombomodulin to TAFIa (also known as 
carboxypeptidase B). This is able to cleave the c-terminal lysine residues of 
partially degraded fibrin fibres, which serves to greatly reduce the binding 
affinity, and therefore activation of plasminogen 42-44.  
 Molecular 
weight (kDa) 
Plasma 
concentration 
Actions 
PAI-1 43 2-20ng/ml Inhibits tPA and uPA 
PAI-2 47 <0.01µg/ml36 As above but to a lesser degree 
PI 58 70µg/ml36 Inhibits activation of plasminogen and 
activity of plasmin 
TAFI 5645 4-15µg/ml45 Reduces activation of plasminogen 
 Table 1-1 Summary of inhibitors of fibrinolysis 
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1.4 Factors affecting coagulation proteins 
Several factors are known to affect the plasma levels of various clotting factors 
and also directly impact on its function without altering levels. These can be 
broadly divided into genetic and environmental effects.  
1.4.1 Quantitative 
1.4.1.1 Genetic  
Several polymorphisms within genes encoding clotting factors have been 
described resulting in elevated or reduced plasma levels of the protein. The 
most recognised are those affecting TF, FVII, FXIII and fibrinogen16. TF 
polymorphisms do not appear to have major clinical implications, except for 603 
A/G polymorphism in the promoter region, which may be associated with 
myocardial infarction (MI). However, the reason for this association is unclear 
and it is not related to elevated TF levels46. Reduced levels of FVII are 
associated with coding polymorphisms but the clinical relevance of this is 
association is unclear. Mutations within the promoter region which increase 
(402 G/A) or decrease (323 A1/A2) FVII plasma levels have been associated 
with elevated or reduced risk of MI respectively47-49. Increased plasma levels of 
fibrinogen are associated with polymorphisms within the β chain of fibrinogen, 
such as G to A substitutions at 455 and 854. Longitudinal studies to 
conclusively demonstrate a link between these polymorphisms and CVD are 
contradictory50. A relatively common coding polymorphism affecting the A 
subunit of FXIII (FXIIIVal34Leu) appears to affect its activity rather than directly 
alter plasma levels and the clinical consequences of such a polymorphism is 
variable16. In some individuals the increased activity appears protective against 
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CVD, possibly due to depletion of the protein or through disordered clot 
formation caused by early cross linking. However, in vitro work demonstrates 
that this polymorphism generates clots with thinner fibres which are classically 
more difficult to lyse51 and may help explain reduced efficacy of thrombolytic 
therapy following MI and stroke in these individuals52;53.  
 
Figure 1-5 Formation of fibrin clot and proteins involved in fibrinolysis.  
Thrombin cleaves fibrinopeptides A and B from fibrinogen to form fibrin and also 
activates FXIII which causes cross linking of the fibrin chains. The insoluble clot 
is broken down by plasmin (produced following cleavage of plasminogen by t-
PA). The anti-fibrinolytic proteins PAI-1 and α2-ap inhibit clot lysis by inhibiting t-
PA and plasmin. 
To date it has proven difficult to confidently ascertain the role each 
polymorphism affecting coagulation factors has upon the development of CVD. 
This is due to the difficulties encountered in recruiting large number of 
individuals into longitudinal studies, necessary in studies investigating genetic 
polymorphisms. Also, the multifactorial pathogenic mechanisms involved in 
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atherothrombosis question the role and the clinical relevance of a single 
polymorphism. Finally, concrete conclusions are usually difficult to achieve with 
such studies, given the complexity involved in gene-gene as well as gene-
environment interactions. 
1.4.1.2 Environmental 
Elevated levels of coagulation factors such as fibrinogen, FXIII, FVII, TF, and 
PAI-1 are associated with environmental factors such as diabetes, obesity, 
smoking, and hyperlipidaemia16. This leads to a pro-thrombotic environment 
and an increased risk of CVD. Medical intervention can ameliorate this 
thrombotic tendency. Improving glycaemic control lowers TF activity and 
reduces levels of fibrinogen, the latter being less consistent with insulin therapy 
however35;37. Treatment with the oral hypoglycaemic agent, metformin also 
lowers PAI-1 and FVII levels, the former effect being over and above its glucose 
lowering capabilities37. Lowering cholesterol and triglyceride levels through the 
use of statin and fibrate medications can reduce levels of TF, PAI-1, and FVII16. 
Adopting a healthy lifestyle through regular exercise, cessation of smoking, 
moderate alcohol consumption and losing weight can all lower levels of 
fibrinogen, PAI-1 and FVII and help reduce cardiovascular risk54. 
1.4.2 Qualitative 
The formation of certain coagulation factors can be affected to various degrees 
whilst having no affect on the overall plasma levels. These qualitative changes 
can also alter the individuals’ thrombotic potential as outlined below.  
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1.4.2.1 Genetic 
Although less numerous than quantitative changes to plasma levels of 
coagulation factors, polymorphisms that affect clot structure are also clinically 
significant and adversely affect CVD risk. Two polymorphisms of the fibrinogen 
molecule are well recognised affecting the α chain (312 A/T) and β chain (488 
G/A) produce clots with increased stiffness and in the latter, increased clot 
density, thinner fibrin fibres and decreased permeability. Substitution of arginine 
to lysine at position 488 is associated with more severe CAD and is seen with 
increasing frequency in patients with triple vessels coronary artery disease.  
As mentioned in section 1.4.4.1.1, a polymorphism within the A subunit of FXIII, 
(FXIIIVal34Leu) in which valine is substituted for leucine at position 34, 
increases the activation of FXIII by thrombin. This single amino acid substitution 
alters the structure of the clot as cross linking of the fibrin molecule occurs 
earlier, reducing the lateral aggregation and forming clots with thinner fibres51.  
1.4.2.2 Environmental 
Coagulation proteins can be affected qualitatively after synthesis by various 
post-translational modifications (PTM) which covalently attach functional groups 
to amino acid side chains. The effect of PTMs on fibrinogen molecules has 
been investigated most extensively and thus is the main focus of the following 
section. 
1.4.2.2.1 Glycation 
Several proteins are known to undergo glycation and fibrinogen is one example. 
Glycation occurs through non-enzymatic formation of fructosamines and 
advanced glycation endproducts (AGE) following an interaction between amino 
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groups (typically lysine) on the target protein and an aldehyde group from 
glucose55. In diabetes elevated levels of plasma glucose increases the glycation 
of fibrinogen and ex-vivo clots made with this fibrinogen form a tighter, rigid clot 
network compared to fibrinogen from patients without diabetes. Plasminogen is 
also increasingly glycated in diabetes patients which appears to decrease 
plasmin generation and also reduce the efficacy of the plasmin produced56.  
1.4.2.2.2 Oxidation 
Many circulating plasma proteins can be oxidised by compounds such as 
reactive oxygen species (ROS) and AGEs, both of which are increased as a 
results of  oxidative stress, inflammation and hyperglycaemia57. Following 
oxidation, fibrinogen may be more readily transformed to fibrin, and along with 
other consequences of oxidation such as enhanced platelet aggregation and 
decreased plasminogen activation, contribute to a pro-thrombotic 
environment58;59. 
1.4.2.2.3 Acetylation 
Aspirin is capable of acetylating lysine residues on the α-chain of fibrinogen, 
resulting in clots composed of thick fibres and large pores with reduced rigidity 
which are less resistant to lysis. Changes in charge distribution and fibrin 
conformation as a result of acetylation may explain these alterations to clot 
structure16.  It has been demonstrated that Lys539, 429, 224 and 208 are sites 
of  acetylation on fibrinogen, and interestingly all are involved in FXIIIa 
crosslinking of fibrin fibres60. 
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1.4.2.2.4 Phosphorylation 
Phosphorylation of fibrinogen readily occurs, affecting the Aα-chain at Ser3 and 
Ser345 leading to fibrinogen circulating in its phosphorylated form in plasma.  
Ser3 lies within FpA and shows increased phosphorylation under conditions of 
acute stress which is thought to modulate FpA release by enhancing thrombin 
binding. The degree of protein phosphorylation is also associated with an 
increase in resistance to plasmin-induced fibrinolysis61. 
1.4.2.2.5 Homocysteinylation 
Certain lysine residues within fibrinogen can also be modulated by the 
introduction of sulfhydryl groups following the action of homocysteine 
thiolactone, a metabolite of homocysteine. Fibrinolytic proteins bind at lysine 
residues, which are also the sites of plasmin cleavage and thus modification of 
lysine residues in this manner leads to fibrin that is unable to support 
plasminogen activation by tPA and generates clots that are resistant to lysis62. 
1.4.2.2.6 Nitration 
The in-vivo nitration of fibrinogen molecules is thought to occur on tyrosine 
residues 292 and 422 within the β chain. This PTM leads to accelerated clot 
formation with an altered ultrastructure, increased fibrin stiffness as a result of 
increased cross linking by FXIII and ultimately hypofibrinolysis63. 
 
1.5 Inflammation and atherothrombosis 
Inflammatory molecules, such as tissue necrosis factor α (TNFα) and 
interleukin- 6 (IL6) are instrumental in the development of atherosclerotic 
plaques contributing to endothelial cell damage, the formation of lipid dense 
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macrophages, termed foam cells, plaque formation and eventually plaque 
rupture. This is discussed in greater detail in section 1.8. Several components 
of the complement system are also thought to contribute to this process, given 
their presence within atherosclerotic plaques and also the fibrin network. The 
key protein, complement C3 is independently associated with the development 
of myocardial infarction (MI) and has been implemented in the formation of fibrin 
clots with an increased resistance to fibrinolysis6,64.  
1.5.1 The complement system 
1.5.1.1 Overview 
Our knowledge and understanding of the complement system has developed 
through the study of its role in providing a defence against invading pathogens 
and was named following the discovery that it is able to “complement” host 
antibodies in their efforts of killing bacteria65. It contains greater than 30 proteins 
and cell surface receptors, that form vital components in mammalian immunity 
and inflammation66. Evidence is emerging that it also plays a pivotal role in the 
homeostasis of cells and tissues67 and that activation of the pathway and 
subsequent inflammation in damaged tissue may be detrimental rather than 
protective; tissue ischemia that follows myocardial infarction (MI) is one 
example68. 
The complement system is activated by three distinct pathways, all of which 
share the same three physiological goals: 1) defending the host against 
invading pathogens, 2) providing a link between the innate and adaptive 
immune responses, and 3) removing the resultant immune complexes and 
apoptotic cells69. The pathways involved are termed, classical, alternative and 
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mannose binding lectin (MBL) pathways. In a similar manner to the coagulation 
and fibrinolytic pathways, each involves a series of cascading enzymatic 
reactions, and although they are triggered by differing methods, they all share 
the common feature of activating complement protein C3 (Figure 1-6) 
1.5.2  Classical pathway 
1.5.2.1 Activation 
The classical pathway contains proteins labelled C1 – C9 and is activated 
following antibody/antigen attachment to cell surface. C1 binds the antibody-
antigen complex and is activated to C1r which in turn activates C1s. This allows 
cleavage of C4 to C4a and C4b, and C2 to C2a and C2b.  
1.5.2.2 Action 
On the surface of invading bacteria, C4b and C2a form a complex which acts as 
a serine protease, termed C3 convertase, and this converts C3 into C3a, a 
potent anaphylatoxin, and the larger protein C3b, which promotes opsonisation 
by binding to the cell surface of pathogens. C3b also has a key role in 
continuation of the complement cascade, forming, together with C4b and C2a, 
C5 convertase (C3bC4bC2a), and releasing C5b from C5. On cell surfaces, 
C5b forms the membrane attack complex (MAC), a transmembrane pore or 
channel consisting of C5b, C6, C7, C8, C9, which causes membrane 
perforation and cell lysis.  
1.5.2.3 Amplification 
Amplification of the pathway occurs following the attachment of C3b molecules 
to a pathogen, and subsequent binding of factor B, which in turn is activated to 
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another C3 convertase (C3bBb) through the action of the enzyme factor D, thus 
generating further C3b and amplifying the cascade65. 
 
Figure 1-6 Simplified illustration of complement activation.  
The C3 convertase (C4bC2a) is formed following activation of C1 and MASP by 
the classical and lectin pathways respectively whereas a modified version 
(C3bBbP) is formed by the alternative pathway. Both enzymes act upon C3 
producing C3a and C3b. The latter of these molecules can form further C3 
convertase and produce more C3b or may form C5 convertase enzymes 
(C3bC4bC2a and C3bBbC3bP), generating C5a and C5b, which is involved in 
the terminal pathway, namely the production of the membrane attack complex 
(C5bC6C7C8C9) 
. 
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1.5.2.4 Regulation 
Regulation of the cascade is achieved through interaction with other 
complement proteins 70. For example, C1 inhibitor protein inactivates C1r and 
C1s, which can modulate survival rates in animal models of septic shock. 
Physiological breaks can also be applied to the amplification stages. The 
formation of C3b activates an internal thioester bond, allowing it to covalently 
attach to hydroxyl groups on carbohydrates and proteins. Once bound to a cell 
surface it may combine with factor B or factor H and a host cell would favour 
C3b to bind factor H much more readily, allowing the formation of the inactive 
compound iC3b following the action of factor I65. Other membrane and plasma 
proteins such as C4-binding protein (C4bp), decay accelerating factor (CD55) 
and membrane cofactor protein (CD46) are also able to control amplification. 
The MAC can be inactivated in plasma before it is inserted into the membrane 
of a cell by S-protein binding to the C5b-7 complex and by the protein CD59 
(protectin), which is able to bind C8 and C9. Anaphylatoxins such as C3a, C4a 
and C5a can be inactivated by the removal of the carboxyl-terminal arginyl 
residues by carboxypeptidase-N and R71. 
1.5.3 Mannose-binding Lectin pathway 
This pathway is similar to the classical pathway, albeit with slightly different 
personnel72. Antibodies are substituted for lectin proteins, such as MBL which is 
structurally similar to C1q. They are able to bind sugar residues found on 
pathogens but are unable to bind the sugars found naturally on mammalian 
cells73. The pathogen’s sugars, such as mannose, therefore act as the antigens 
in this variation of the classical pathway. 
 
 
 
31 
 
Activity Complement protein involved 
1) Defending host against pathogens 
Opsonisation 
Chemotaxis 
Lysis of bacteria 
 
2) Link between innate and adaptive 
immune response 
Arrange antibody response 
 
3) Removal of debris 
Clearing immune complexes  
Clearing dead cells 
 
 
C3b, C4b 
C3a, C4a, C5a (anaphylatoxins) 
C5b-C9 (MAC) 
 
 
 
C3b, C4b, C3 receptors on B 
cells 
 
 
C1q, C3b, C4b 
C1q, C3b, C4b 
Table 1-2 The three main activities of the complement system and the 
proteins responsible 
In order for the cascade to be activated, one further player is required, namely 
MBL – associated serine proteases (MASP). These enzymes form complexes 
with MBL, thus replacing C1s74. The cascade of events that follows is identical 
to that of the classical pathway.  
1.5.4 Alternative pathway 
The alternative pathway differs from above by the ability to initiate the cascade 
without contact with proteins75;76. The labile thioester bond of C3 produces a 
small but constant amount of auto activated C3 (iC3) which marshals the 
surrounding environment. Upon contact with bacteria or foreign organisms, 
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activated C3 binds factor B as described previously, which in turn is cleaved by 
factor D producing Bb and Ba77. The C3 convertase C3bBb is formed and is 
stabilised by properdin forming the complex C3bBbP, which produces more 
C3b from C3 cleavage and is deposited onto foreign cells. This results in 
amplification of the alternative pathway and exponential production of C3b 
molecules. A further C3b molecule attaches to this C3 convertase, forming a C5 
convertase, C3bBbC3bP. The pathway beyond the cleavage of C5 follows the 
same pattern as the classical and MBL pathways, resulting in the assembly of 
the MAC. The C3b proteins produced by the classical and MBL pathway are 
also able to form the same C3 convertase (C3bBbP) and thus benefit from this 
positive feedback loop. 
1.5.5 Other pathways of activation 
A fourth pathway may exist involving other serine proteases from the 
coagulation and fibrinolytic cascades. Studies have demonstrated the 
generation of biologically active C3a and C5a by FXa, plasmin, thrombin, FIXa 
and FXIa independently from the classical, alternative and MBL pathways 78-80. 
The acute phase protein, C-reactive protein (CRP) is also able to activate the 
classical complement pathway by binding the C1q region of complement protein 
C1 which in turn activates C1r and C1s81(Figure 1-7). Oxidative stress following 
tissue hypoxia is also able to activate the complement pathway and increase 
iC3b deposition on vascular endothelial cells through activation of the MBL 
pathway82;83. 
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Figure 1-7 Other pathways of complement activation.  
The coagulation proteins FXa, plasmin, thrombin, FIXa, FXIa are able to 
produce C3a and C5a independently of the classical, alternative and MBL 
pathways. The acute phase protein CRP is able to activate the classical 
pathway through its action on C1 The shaded text represents the conventional 
activation pathways. 
1.5.6 Complement C3  
1.5.6.1 Structure of C3 
Activation of complement protein C3 (187,000Da) is a key step in each of the 
three pathways that make up the complement system. It is synthesised mainly 
in the liver, and, to a lesser degree, in adipose tissue and is present in plasma 
at 550-1200 µg/ml. The crystal structure of C3 has been determined66 (as 
shown in Figure 1-8) and contains 1641 residues consisting of two chains, ß 
(residues 1-645) and α (residues 650-164). These chains combine to form 13 
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domains which are termed macroglobulin domains (MG) 1-8, with the 5 
remaining domains appearing to be either inserted between domains or 
extending from an existing domain. The β chain is composed of domains MG1-5 
and part of MG6 which is shared with residues from the α-chain. These 6 
domains form the core, stable portion of the protein, onto which is formed the 
flexible α chain66, 86. 
 
Figure 1-8 Structure of complement component C3 
Ribbon representation of C3 (A) and the domain sequences and arrangements 
(B). Reprinted by permission from Macmillan Publishers Ltd: Nature Janssen 
BJC et al, copyright 2005. 
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1.5.6.2 C3 interactions 
Complement C3 is able to interact with numerous components of the 
complement pathway, along with non-complement proteins such as pathogens. 
Cleavage by different convertase enzymes produces conformational changes 
within mature C3 that exposes cryptic binding sites and alters its binding affinity 
for different complement proteins and receptors. The first major conformational 
change occurs following cleavage by C3 convertase, resulting in the generation 
of the anaphylatoxin C3a (9kDa) and C3b (177kDa)84. The action of C3 
convertase not only produces large movements of domains, thus altering the 
structure of native C3, but also appears to alter the structures of the domains 
themselves. As detailed above, this triggers a cascade of events, generating 
numerous proteins, which act as anaphylatoxins (C3a, C4a, C5a), inducing 
inflammation; opsonins (C3b, C4b), aiding antigen clearance through binding to 
macrophages, lymphocytes, erythrocytes and other peripheral blood cells85, as 
well as culminating in terminal complement complexes (TCCs) such as the 
membrane attack complex (MAC) which promotes cell lysis67. The different 
conformation of C3b exposes hidden binding sites along with a thioester bond, 
the latter enables C3b to bind to cell surfaces. The thioester containing domain 
(TED), which forms part of the α-chain, rotates vertically and rests in greater 
proximity to MG1 of the β chain, thus exposing the thioester moiety (Figure 1-9). 
The hidden binding sites promote interaction with proteins such as factor B 
producing C3 convertase C3bBb and subsequent amplification of the alternative 
complement pathway. This activity is regulated by largely through the action of 
factor I which mediates cleavages within the α chain and generates iC3b which 
is further cleaved to produce C3f (2kDa), the main proteolytic component C3c 
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(135kDa) and C3dg (40kDa)84. The binding of these proteins is thought to 
largely occur in the flexible α-chain86. 
1.5.7 Factors affecting complement system 
Alterations in the levels of numerous complement proteins or in their function 
are strongly associated with several disease states. These effects can be 
divided into those caused by environmental pressures and from genetic defects. 
1.5.7.1 Quantitative changes 
1.5.7.1.1 Genetic 
Numerous inherited deficiencies of proteins, enzymes and receptors of the 
complement pathway have been described with varying clinical courses. These 
include C3 and mannose binding lectin deficiency which increases susceptibility 
to pyogenic infections65 A deficiency in any of the components required to form 
the MAC is associated with Neisserial infection as extracellular lysis of the 
pathogen through the formation of a lytic channel within the pathogen is 
essential to kill the organism which is capable of surviving intracelluarly87. Total 
deficiency of a complement protein causes predisposition to autoimmune 
conditions, the most commonly occurring of which is systemic lupus 
erythematosus (SLE)65. The autosomal dominant disease, C1 inhibitor 
deficiency is also known as hereditary angiodema which can cause recurrent 
and potentially life threatening attacks of angiodema. This serine protease 
inhibitor inactivates C1r and C1s along with kallikrein and factors XI and XII of 
the coagulation system. The angiodema is a result of unregulated action of 
kallikrein which is generally triggered by plasmin activation which consumes the 
small amount of C1 inhibitor that is present in these patients88. Elevated levels 
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of C3 have been demonstrated with single nucleotide polymorphisms (SNP) 
affecting the C3 gene89. 
 
Figure 1-9  Conformational changes of C3  
a) Hypothesised conformational changes of C3 following attachment to a cell 
surface (reprinted by permission from Macmillan Publishers Ltd: Nature 
Janssen BJC et al, copyright 2006). b) Ribbon representation of native C3 and 
C3b illustrating the vertical rotation of the thioester containing domain (TED) 
which exposed the thioester moiety to the cell surface. The α chain is in green 
and β chain in red. The colour scheme in a) matches that in Figure1-8. 
1.5.7.1.2 Environmental 
Elevated levels of complement proteins such as C3 and C4 are associated with 
inflammatory diseases and acute infections as a result of increased hepatic 
synthesis90;91. Elevated levels of C3 are associated with type 1 and type 2 
diabetes and are also seen in patients with coronary artery disease. In addition 
to increased hepatic synthesis, C3 levels are also increase in obese individuals 
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due to increases adipose tissue production of C36. Many diseases associated 
with circulating immune complexes of autoantibodies of IgG or IgM class may 
cause acquired complement deficiency through complement consumption. 
These conditions include SLE, Sjogrens disease, anticardiolipin and others 90. 
Complement deficiency may also be due to reduced hepatic synthesis, and is 
typically seen in advanced chronic liver failure, and also by loss of complement 
proteins in the urine which can occur with severe forms of nephritic syndrome. 
The latter mechanism is a rare cause as only factor D (the smallest complement 
protein) is lost in large quantities, and does not appear to be associated with 
adverse clinical outcome. 
1.5.7.2 Qualitative changes 
Qualitative changes to numerous complement proteins have been described 
which lead to significant clinical consequences 
1.5.7.2.1 Genetic 
The function of the C3 convertase C3bBb is altered by an autoantibody, C3 
nephritic factor. This antibody stabilises the enzyme leading to increased 
cleavage of C3. The clinical manifestations are membranoproliferative 
glomerluonephritis and partial lipodystophy. The loss of fat is linked to adipose 
cell production of factor D, suggesting increased levels of the C3 convertase 
within adipose tissue which is then stabilised by C3 nephritic factor generating 
sufficient components of the MAC which subsequently lyses adipose cells65. 
SNP within the C3 gene has been associated with ischaemic stroke, 
independent of risk factor such as diabetes, hypertension and smoking, and 
with increased risk of developing metabolic syndrome 89;92. Alterations to genes 
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encoding complement receptors also manifest clinically with SNP of the C3a 
receptor gene associated with increased severity of childhood bronchial 
asthma93.  
1.5.7.2.2 Environmental 
Studies investigating qualitative changes in complement proteins are limited 
and focus mainly on post-translational modifications such as glycation. In vitro 
and in vivo glycation of lysine residues on complement proteins C3, CD59 and 
factor B has been demonstrated with some attempts made to correlate this 
glycation to clinical findings.94-98. Glycation of C3 may alter its structure and thus 
interaction with bacteria, reducing opsonisation of pathogens such as 
Staphylococcus aureus, partly explaining increased susceptibility to infections in 
diabetes patients96. The function of C3 may also be altered through glycation of 
the concealed thioester bond which is exposed upon activation of C3 to C3b99. 
In vivo glycation of CD59 appears to inactivate this complement regulatory 
protein thus increasing the formation of MAC and cell lysis. This phenomenon 
may play a role in the pathogenesis of the vascular complications associated 
with diabetes, such as nephropathy, neuropathy and retinopathy given that 
MACs are increasingly deposited in renal, nerve and retinal cells of diabetes 
patients compared to control subjects100;101. Unregulated complement lysis of 
erythrocytes may also contribute to anaemia associated with diabetes97.  
1.6 Diabetes and cardiovascular disease 
1.6.1 Incidence and mortality 
The link between diabetes and CVD is irrefutable, with a two to 3 fold increase 
in the incidence of coronary artery disease and stroke compared to non-
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diabetes sufferers 1;102. Those with diabetes also have a worse outcome than 
non-diabetics following a myocardial infarction (MI) or stroke, with studies 
demonstrating a 2-4 fold increase in death from CVD103;104. The use of 
advanced treatments such as primary percutaneous intervention following acute 
myocardial infarction appears unable to buck this trend4. The apparent strength 
of this association has led many to conclude that diabetes sufferers without a 
prior history of MI, are at the same risk of coronary artery disease (CAD) as a 
non-diabetic who has a history of MI105-108. Recent treatment of diabetes has 
therefore encompassed more than glucose homeostasis alone with increasing 
emphasis being placed on targeting other modifiable cardiovascular risk factors 
such as hypertension, elevated lipid profile and obesity, and using anti-platelet 
medication as if they had pre-existing CAD. Several studies have shed doubt on 
this concept of diabetes as a coronary risk equivalent, and that treatment should 
be based on the individuals calculated risk of CAD rather than a one size fits all 
approach1;109-112.With the introduction of modern treatment regimens following 
MI, the mortality rate has fallen significantly for non-diabetes subjects, however 
this does not appear to be the case with diabetes patients5, highlighting the 
increased risk of CVD in these individuals and the multifactorial approach 
required to improve outcomes. 
1.6.2 Development of atherosclerosis 
The acute, clinical entities of myocardial infarction, unstable angina, stroke and 
lower limb ischaemia are the consequence of longstanding atherosclerotic 
plaque formation. These plaques are the result of chronic inflammation and 
develop over several years, influenced by factors such as insulin resistance, 
shearing stress and oxidation which cause endothelial dysfunction. They consist 
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of macrophages, lymphocytes, collagen and proliferated smooth muscle cells 
and are protected by a fibrous cap consisting of collagen, elastin and 
proteoglycans11. The plaques will often remain quiescent for several years, with 
the clinical complications described above occurring following rupture of the 
plaque and subsequent thrombus formation. Plaque rupture is followed by 
platelet adhesion, activation and aggregation at the site of injury and the 
generation of a cross linked fibrin clot. Further platelet adherence forms an 
occlusive fibrin mesh, with subsequent vascular occlusion and tissue necrosis.  
Insulin resistance and hyperglycaemia alter the composition of these plaques by 
altering endothelial function, which together with a more lipid rich, macrophage 
laden plaque seen in diabetes, increases their susceptibility to rupture35. When 
combined with the hypercoagulable environment that is associated with 
diabetes, this leads to a perfect storm, and increased risk of CVD. It is also 
likely that the complement pathway is activated during myocardial ischaemia as 
numerous components of the complement pathway such as C3, C5a and the 
membrane attack complex (MAC), along with CRP and macrophages have 
been identified within atheromatous plaques of patients with unstable angina 
compared with stable disease113;114. 
1.6.2.1 Diabetes and endothelial dysfunction  
 It is thought that chronic, low grade inflammation seen in diabetes leads to 
endothelial dysfunction and is the initial step in the development of 
atherothrombosis. EC dysfunction results in a reduction in the bioavailability of 
NO, and subsequently increased platelet activation11, increased smooth muscle 
cell proliferation and increased expression of adhesion molecules32. The latter 
leads to an increase in inflammatory cells such as macrophages and T-
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lymphocytes within the vessel wall, the formation of a fatty streak and eventually 
the atherosclerotic plaque as well as releasing cytokines including interleukin-6 
(IL-6) and tumour necrosis factor (TNF) α, which increase the release of tissue 
factor (TF) from endothelial cells115-117. Obesity contributes in a similar manner 
to this inflammation as adipose tissue releases pro-inflammatory cytokines from 
macrophages and T-lymphocytes118-122. Hyperglycaemia is likely to contribute 
significantly to the inflammation process, but insulin resistance, which leads to 
hyperinsulinaemia, is also of importance. Studies have demonstrated 
endothelial dysfunction, through impaired vasodilation, in T2DM patients123, 
healthy individuals with insulin resistance124;125 and first degree relatives of 
patients with T2DM126. Weight loss is associated with increased insulin 
sensitivity and improvement in endothelial function127;128. EC dysfunction may 
also be characterised by increased levels of vWf35 which have been 
demonstrated to correlate with diabetes129;129. This link may be explained by the 
development of insulin resistance following loss of EC function 130;131.  
Numerous mechanisms therefore contribute to endothelial dysfunction and the 
resulting disruption to vascular homeostasis is the beginning of a pro-
atherothrombotic state.  
1.7 Effect of Diabetes on coagulation and CVD risk 
Diabetes affects haemostasis in a variety of ways resulting ultimately in 
thrombosis and hypofibrinolysis. This occurs through increased levels of 
numerous key elements of coagulation and fibrinolysis along with post-
translational modifications and alteration of the clot structure itself leading to a 
pro-thrombotic state. Many of the changes seen are also associated with 
increased risk of cardiovascular disease. The changes associated with diabetes 
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outlined below contribute to the formation of dense clot with thinner fibres and 
fewer pores ex vivo, that prove more resistant to lysis by plasmin132;133. 
Improving glycaemic control can favourably alter the clot structure 134.  
1.7.1 Quantitative changes in coagulation and fibrinolysis proteins 
Both diabetes and CVD are independently associated with alterations in the 
level of coagulation and fibrinolysis proteins.   
1.7.1.1 Thrombin  
Hyperglycaemia is linked with increased thrombin production and elevated 
levels are seen in T1DM and T2DM. Reducing glucose levels has been shown 
to reduce thrombin production135-137. Thrombin levels are also involved in clot 
structure and enhanced concentrations play a role in the dense clots described 
above37. 
1.7.1.2  Fibrinogen 
Elevated levels of fibrinogen are associated with increased risk for CVD and 
have been used as a marker of clinical and subclinical disease 138-141. Both 
T1DM and T2DM are associated with high levels of fibrinogen142 which may be 
a result of inflammation causing hepatocyte stimulation9. Elevated insulin levels 
associated with insulin resistance is also likely to play a part in T2DM through 
increased hepatic production of fibrinogen 143;144. This is supported by the 
finding of higher levels of fibrinogen in healthy first degree relatives of T2DM 
patients145  and that plasma levels were able to predict development of T2DM in 
healthy individuals which implies that hyperinsulinaemia rather than 
hyperglycaemia alone is important 146. This finding may also explain why 
improving glucose levels through the use of insulin does not correlate with a 
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reduction in fibrinogen levels147;148 whereas metformin use has been associated 
with lowering plasma levels149. Higher levels of fibrinogen also alter final clot 
structure and, in part at least, help explain the differences seen in clot structure 
in CVD and DM as above.   
1.7.1.3 Tissue Factor 
The levels of TF have been shown to be elevated in patients with CAD, with 
highest levels seen in those with unstable angina or MI compared with stable 
angina9. Diabetes is also associated with elevated levels of TF 137, possibly as a 
result from diminished inhibition of TF synthesis by insulin in diabetes compared 
with non-diabetes subjects 150.  
1.7.1.4 Plasminogen activator inhibitor-1 
Elevated levels are seen in CAD, and levels are strongly correlated with risk 
factors for  the MetS, namely BMI, blood pressure, plasma triglycerides and 
insulin levels35. In diabetes subjects there are increased levels of PAI-1, which 
is positively correlated with glycaemic control151, and elevated levels are also 
thought to be an independent risk factor for the development of T2DM146, 
adding further weight to the suggestion that insulin resistance and 
hyperinsulinaemia, in the face of normoglycaemia, is sufficient to trigger 
hypofibrinolysis152. A combination of inflammatory cytokines, insulin, free fatty 
acids and very low density lipoproteins are likely to cause increased release of 
PAI-1 from the liver and also adipocytes11;153-157. It has not been clearly 
demonstrated that elevated PAI-1 levels are a risk factor for CVD158, however 
tPA/PAI-1complexes, which correlates with PAI-1 activity, has been shown to 
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be a risk factor for MI, supporting the role of PAI-1 in reduced fibrinolysis and 
CVD159;160. 
1.7.1.5 Factor VII 
Factor VII forms a complex with TF and initiates the formation of thrombin. 
Studies investigating the effect of coagulant activity of FVII (FVII:c) on 
cardiovascular events have yielded conflicting results although there is a 
suggestion that elevated FVII:c levels are associated with fatal cardiovascular 
events35;161;162. Levels of FVII:c are raised in T2DM and also in healthy first 
degree relatives of T2DM and those with the MetS163-165, again suggesting that 
observed changes precede the development of T2DM and hyperglycaemia. 
Possible explanations for this observation is that triglycerides (TG), which are 
associated with elevated FVII:c163;164;166 along with poor glycaemic control and 
MetS, are involved in activation of FVII167. FVII is also thought to bind to TG rich 
particles and reduced post-prandial breakdown of these fatty proteins lead to 
increased plasma FVII levels35.   
1.7.1.6  Factor VIII and vWf 
The clotting factor VIII circulates in the plasma bound to vWf, which offers 
stability and increases half life of the protein 11. Elevated levels of FVIII and vWf 
have been associated with CVD but as with other clotting factors, this 
association is lost following adjustment for traditional CVS risk factors 168;169. 
Levels are elevated in diabetes and in these individuals the correlation with 
CVD remains after adjustment for cardiovascular risk factors 129;170;171. It is likely 
that raised levels of FVIII and vWf are an indication of EC damage resulting 
from inflammation and insulin resistance 130;131.  
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Table 1-3 Summary of changes to haemostatic components in diabetes 
1.7.1.7 Plasmin  
As described in section 1.4.2.2.1, plasminogen conversion to plasmin is 
reduced in diabetes as a result of increased glycation, along with the efficacy of 
plasmin itself once generated. Lower levels of plasmin are also expected due to 
increased activity of PAI-1 and cross linking of PI in diabetes, all of which 
contributes to the hypofibrinolytic environment associated with diabetes. 
Haemostatic 
component 
Function 
Changes in 
DM 
Effect in DM 
TF Initiates clotting 
cascade 
↑levels ↑ thrombosis 
FVII 
 
Forms complex with TF ↑levels ↑thrombosis 
FVIII & vWf 
complex 
 
Adherence of platelets 
to endothelial cell wall 
↑levels ↑platelet 
activation 
Thrombin Converts fibrinogen to 
fibrin 
↑ levels Altered clot 
structure 
 
Fibrinogen Forms fibrin clot ↑levels 
↑glycation 
Altered clot 
structure 
↓fibrinolysis 
Plasmin 
 
Breaks down fibrin clot ↓levels ↓fibrinolysis 
PAI-1 Inhibits production of 
plasmin 
↑levels ↓fibrinolysis 
Platelets Activation of 
coagulation factors and 
forms fibrin mesh 
↑activation ↑thrombosis 
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1.7.2 Qualitative changes in coagulation and fibrinolysis proteins 
1.7.2.1 Fibrinogen 
In vivo hyperglycaemia in poorly controlled diabetes patients in known to cause 
glycation of fibrinogen172;173 which causes an alteration in the structure and 
function of the molecule and contributes to the development of the rigid clot 
architecture seen in diabetes132;174 which is associated with premature 
CVD175;176. Improving blood glucose control can modulate fibrinogen glycation 
134;172. 
1.7.2.2 Plasminogen  
Increased glycation of plasminogen has been observed in diabetes compared 
with healthy controls, with lysine residues 107 and 557 preferentially glycated. 
These sites are involved in fibrin binding and cleavage of plasminogen to form 
plasmin which may explain the reduction in plasmin generation and activity56. 
1.7.2.3 Plasmin inhibitor 
The glycation of PI in diabetes has not been reported, but its anti-fibrinolytic 
properties may be enhanced in these patients by increased FXIII mediated 
cross linking to fibrinogen during clot formation133. The mechanism 
underpinning this has not been elucidated but it may be related to structural 
changes that occur within the fibrinogen molecule as a result of hyperglycaemia 
or through increased activation of FXIII by thrombin133.  
1.8 The Role of inflammation in Diabetes  
A tantalising glimpse of the association between inflammation and diabetes was 
first noted around the turn of the last century, with evidence that sodium 
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salicylate lowered levels of glycosuria in patients with “mild” forms of diabetes. 
This concept failed to fully capture the imagination of the scientific world at the 
time, and it was not until the end of the 1950s that further evidence emerged. 
High dose aspirin was found to improve blood glucose control in T2DM patients 
such that insulin treatment could be withdrawn177. However, researchers 
attempted to link their observations to the secretion of insulin rather than 
resistance to its action, secondary to an inflammatory milieu, and therefore the 
association between inflammation and diabetes was once again dismissed. The 
discovery in the 1990s that adipose cells were capable of secreting the pro-
inflammatory cytokine, TNF-α, which was subsequently able to induce insulin 
resistance, revolutionised thinking at the time 178. There was now direct 
evidence that adipose cells were metabolically active, rather than mere energy 
storage cells with the potential to impair cellular responses to insulin and 
therefore ultimately lead to the hyperinsulinaemic hyperglycaemic state 
characteristic of T2DM. 
Current theories linking diabetes and inflammation revolve around the nuclear 
factor NF-ĸB which once activated by IĸB kinase (IKK), promotes and maintains 
inflammation, and that this pathway is stimulated by hyperglycaemia179. 
Elevated levels of circulating pro-inflammatory cytokines exert varied effects 
within different tissue cells. Within hepatocytes and adipocytes there is 
increased monocyte recruitment and macrophage formation leading to further 
cytokine secretion. This is associated with insulin resistance through impairment 
of adipocyte differentiation and insulin signalling along with hepatic and skeletal 
muscle lipid accumulation180. Insulin resistance and obesity are not associated 
with T1DM and so it is likely that other mechanisms are involved. However, 
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insulin-treated T1DM subjects can acquire later in life a type 2 phenotype, and 
therefore distinguishing pathogenic mechanisms in T1DM and T2DM is not that 
straightforward. 
Inflammation has been linked to both T1DM and T2DM through elevated 
plasma levels of inflammatory markers such as CRP, C3 and IL-66;181-183. In 
addition both CRP and C3 levels have been demonstrated to predict the 
development of T2DM 184-186. Both proteins have also been closely linked with 
features of the MetS 187-189, which may suggest that obesity and insulin 
resistance may account for much of this observed inflammation in T2DM 
subjects. Inflammatory cytokines, released from macrophages and adipocytes 
induce CRP release from the liver. CRP is able to activate the complement 
pathway, and may also play a functional role in inducing further inflammation, 
atheromatous formation and haemostasis as described previously. Complement 
C3 is secreted by adipocytes which may explain the elevated plasma levels 
observed in obesity, and reductions in C3 levels following weight loss via diet 
and lifestyle modifications or through bariatric surgery in non-diabetes 
individuals 190-192. Hyperglycaemia, common to all forms of diabetes, is likely to 
induce inflammation through increased mitochondrial reactive oxygen species 
(ROS) formation193.  
Studies have shown that improving glycaemic control can reduce plasma C3 
levels and other inflammatory proteins 6;194. The hypoglycaemic agent, 
rosiglitazone, has been shown to reduce C3 levels195, whereas treatment with 
the biguanide, metformin appears to lower CRP and not C3196. Both 
medications improve insulin sensitivity and so the differences observed may be 
related to the direct effect of rosiglitazone on adipose cells. The use of bariatric 
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surgery to treat poorly controlled diabetes in obese T2DM patients, 
demonstrated a reduction in highly sensitive CRP compared with intensive 
medical treatment. Major differences were seen in the degree of weight loss 
and reduction in glycated haemoglobin between the medical and surgical 
groups, along with reduced markers of insulin resistance, but not for lipid 
indices197. A summary of the contributing factors that lead to increased risk of 
CVD in diabetes can be seen in Figure 1-10.  
1.8.1 Inflammation and CVD  
The link between inflammatory markers such as C-reactive protein (CRP) and 
CVD is not a new concept, with elevated levels known to be associated with 
CVD and also predicting the risk of developing the condition 198;199. Other 
inflammatory molecules such as C3, C4, C5a and IL-6 have been demonstrated 
to be elevated in coronary artery disease200. Of these, C3 appears most 
strongly and independently associated with MI, and is thought to be a more 
specific marker for inflammation than CRP 64;188;201-206. As well as elevated 
plasma levels of complement proteins, elevated levels of C3 and C5a, CRP, 
MAC and macrophages have also been found in atherosclerotic plaques of 
patients with unstable angina compared with stable disease, indicating 
activation of the complement pathway during myocardial ischaemia113;114;207;208. 
The complement proteins C1q, C3, C4 and C5b-9 have also been found within 
the fibrin clots209. These proteins can directly influence the composition of 
atheromatous plaques and induce a pro-thrombotic state by activating the 
clotting cascade. The uptake of oxidised low density lipoprotein (LDL) 
molecules into macrophages (producing foam cells with the vessel wall) is 
enhanced by CRP210. These macrophages produce matrix metalloproteinases 
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which reduce plaque stability and make them increasingly prone to rupture211, 
triggering acute cardiovascular events. Cytokines released from macrophages, 
along with CRP, C3a and C5a are able to induce TF expression within EC, 
initiating the generation of the fibrin clot115;117;212;213. Within the ischaemic 
myocardium the activated complement pathway is thought to be the major 
mediator of immune and inflammatory responses. Further ischemia ensues due 
to activation of leucocytes, EC and up-regulation of genes involved in cytokine 
production along with reduced NO production203 
1.8.2 Effect of Diabetes on the complement system  
The effect of diabetes on the components of the complement system is much 
less understood and studied in comparison to the coagulation system. 
1.8.2.1 Quantitative changes 
As described in 1.3.7.1.2, levels of the key protein C3 are elevated in patients 
with T1DM and T2DM and improving glycaemic control can lower these levels. 
The incorporation of C3 into a fibrin clot slows its subsequent lysis ex vivo, and 
this incorporation appears to be increased in clots prepared from diabetes 
patients. The reason for this increased incorporation is unclear but may be 
related to enhanced interaction between C3 and fibrin(ogen) in diabetes as a 
results of glycation of one or both molecules6;214. Oxidative stress and increased 
ROS, are associated with chronic hyperglycaemia and both play a role in the 
activation of the MBL pathway within the EC11;215.   
1.8.2.2 Qualitative changes 
The glycation of complement proteins CD59 and C3 have been associated with 
an increased susceptibility to infection as described in 1.3.7.2.2 and may also 
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be implicated in the microvascular complication of diabetes in the case of CD59 
due to dysregulation of the MAC. Moreover, a recent study suggests that 
diabetes-induced post-translational modifications in C3 may increase its 
antifibrinolytic activity6, although further work is required to conclusively prove 
these preliminary findings.  
1.9  Interaction between coagulation and complement 
The enzymes responsible for the cascade of events within the complement 
cascade are serine proteases, and many of the proteins involved in coagulation 
and fibrinolysis also belong to this family. In vitro production of biologically 
active C3a and C5a have been demonstrated by factors Xa and XIa as well as 
thrombin and plasmin, suggesting that proteins involved in haemostasis are 
also able to activate the complement pathway independently of the recognised 
and established pathways78-80. Complement proteins may also activate and 
inhibit the formation of a fibrin clot as C3a and C5a have been shown to induce 
expression of TF within the EC and C1 esterase inhibitor is able to inhibit the 
action of FXIa. This indicates that both haemostasis and inflammation are 
interlinked and may combine to create a prothrombotic environment within 
certain at risk individuals. 
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Figure 1-10 Summary of the contributing factors to increased CVD in 
diabetes.  
There is a pro-thrombotic, hypofibrinolytic environment due to alterations in 
numerous proteins involved in coagulation and fibrinolysis and also platelets. 
Chronic, low level inflammation and activation of the complement system 
contributes to this and increases the atherosclerotic burden predominantly 
through EC dysfunction.  
1.10 Complement inhibition to treat CVD 
Given the evidence that activated complement proteins can activate the 
coagulation cascade and have further deleterious effects on an already 
damaged and ischaemic myocardium, its inhibition as a treatment for CVD 
would seem a logical approach. Trials using pexelizumab, an anti-C5 
monoclonal antibody, to block the action of C5,  following MI and post coronary 
artery bypass grafting have had mixed results with inconsistent reductions in 
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mortality and major cardiac events216-218. The use of a C1 esterase inhibitor, 
TP10, has also been trialled. Given as a bolus at least 6 hours following the 
onset of acute myocardial infarction symptoms, and subsequent infusion for 48 
hours it demonstrated reductions in the release of myocardial enzymes troponin 
T and creatinine kinase, elevated levels of C1 inhibitor activity and reduced 
levels of C4219;220. Its use following emergency reperfusion with coronary artery 
bypass grafting demonstrated improved cardiac function compared to placebo 
but with no improvement on early mortality221. The mixed results of these trials 
in the acute setting may indicate that inhibition of complement may be better 
directed at preventing the progression of unstable atherosclerotic plaques222. 
Activation of the complement system following oxidative stress has been 
demonstrated in animal studies in vivo, as a result of myocardial reperfusion, 
and is a possible mechanism for increased tissue injury observed as a result of 
reperfusion following ischaemia. Inhibition of the MBL pathway through the use 
of anti-MBL monoclonal antibodies has been shown to significantly reduce 
deposition of MBL and C3b on human endothelial cells in vitro and may form 
the basis of novel therapeutic strategies to prevent further tissue injury following 
MI82. 
Another option for preventing activation of the MBL pathway would be inhibition 
of MASP-2. Mice deficient in MASP-2 demonstrated significantly smaller 
volumes of myocardial infarction in a model of post-ischaemia reperfusion 
injury. The generation of a similar monoclonal antibody to MASP-2 may inhibit 
its function in-vivo and thus activation of the MBL pathway223. 
It is likely that mechanisms involved in inflammation in diabetes are a complex 
interplay between hyperglycaemia, insulin resistance and obesity. Activation of 
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the complement pathway results in communication with the coagulation 
pathway and vice versa. Limiting their activation may lead to a lower incidence 
of CVD and improved outcomes in these high risk individuals. Increased 
incorporation of C3 into the fibrin clot occurs in diabetes, resulting in prolonged 
lysis time. A better understanding of the mechanisms involved in this interaction 
may lead to the generation of novel therapeutic targets.  
 
Hypothesis and aims of the work 
It is clear that delayed or inadequate breakdown of fibrin clots occurring within 
the arterial tree increases an individual’s risk of developing CVD. Up until the 
last decade or so, the most effective treatment of an acute myocardial infarction 
was the intravenous administration of recombinant fibrinolytic agents, such as 
tPA, in order to restore blood flow within an occluded coronary artery. This 
practice has largely been superseded by primary percutaneous coronary 
angioplasty, however fibrinolytic therapy is still administered to acute ischaemic 
strokes with proven efficacy224. Patients with diabetes are at increased risk of 
CVD as outlined previously, and hypofibrinolysis is one of several factors 
implicated. This pathological resistance to clot breakdown is explained in part 
by increased incorporation of anti-fibrinolytic proteins C3 and PI into the fibrin 
network. Interference with the incorporation of these two proteins into the clot 
may be a potential, diabetes specific, target for the development of novel 
therapeutic agents to reduce the thrombosis potential and cardiovascular risk in 
this population. This leads to my hypothesis that the incorporation of C3 into the 
clot is an important factor in hypofibrinolysis associated with T1DM and T2DM 
and that interfering with C3-fibrniogen interactions will modulate clot lysis. 
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My work investigates new pathways responsible for hypofibrinolysis in diabetes 
and employs alternative methodologies in an attempt to modulate the fibrinolytic 
process in this condition. The thesis is therefore largely presented in two distinct 
parts. In the first, I examine the role of complement C3 in hypofibrinolysis in 
diabetes and investigate the mechanisms involved. In the second part, I attempt 
to target modulation of fibrin clot lysis through disruption of the fibrinogen-PI and 
fibrinogen-C3 interactions using novel approaches.  
The aims of the study are as follows: 
A. Study the role of C3 in hypofibrinolysis in diabetes: 
1. Investigate the interaction between C3 plasma levels and clot lysis in a 
large cohort of type 2 diabetes patients. 
2. Analyse potential differences in the anti-fibrinolytic effects of C3 
comparing diabetes with control protein and investigate post-translational 
protein modifications as a potential mechanism. 
3. Elucidate potential binding sites between fibrinogen and C3. 
B. Modulate fibrin clot lysis using a targeted approach: 
1. Analyse the effects of interfering with fibrinogen-PI interaction on fibrin 
clot lysis 
2. Investigate the role of interference with fibrinogen-C3 interaction on 
fibrin clot lysis.  
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Chapter 2  
General Methods 
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Introduction  
In order to accomplish the aims of the work, a number of different 
methodologies were employed many of which are well validated and accepted 
such as protein purification, turbidimetric analysis, ELISA and mass 
spectrometry and these are described in this chapter. Other, known methods 
that were used in a novel way, such as phage display and molecular modelling, 
are also described here. More specific methodologies, that are relevant to each 
of my aims, are further detailed in the appropriate Chapter.  
2.1 Claus method for plasma fibrinogen level determination 
Plasma was diluted 1:10 in veronal buffer pH 7.35 (0.026M sodium acetate 
trihydrate, 0.026M sodium 5,5 diethylbarbiturate, 0.11M NaCl, 0.016M HCl in 
H2O) and incubated at 37°C with 5U/ml bovine thrombin in a KC10 Amelung 
Coagulometer (Amelung, UK) with stirring. The fibrinogen concentration of each 
plasma sample was deduced by comparing the time taken for the clot to form 
against a calibration curve of reference plasma (Biomereux, Hampshire, UK) 
with known concentration of fibrinogen.  
2.2 C3 ELISA 
A NUNC ELISA plate was coated with 100μl (2μg/ml) of chicken-anti-human C3 
antibody (GenWay Biotech. Inc, San Diego, USA) for 1 hour after which the 
wells were washed 3 times with 200μl of wash buffer (0.05% [v/v] Tween 20 in 
phosphate buffered saline [PBS]) and then blocked with 200μl of 1% (w/v) 
bovine serum albumin (BSA) for 1 hour at room temperature. The washing step 
was repeated, followed by the addition of 100μl of plasma samples (diluted 
x10,000 in 50mM Tris, 0.14M NaCl, 1% BSA, 0.05% Tween 20) and incubated 
for 2 hours at room temperature. The wells were washed again before adding 
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100μl (20ng/ml) of the secondary, HRP conjugated, chicken anti-human C3 
antibody (GenWay) for 1 hour. After a final washing step, the plate was 
developed by the addition of 100μl of stabilised chromogen substrate, 
tetramethylbenzidine (TMB). The reaction was stopped by the addition of 1.5M 
H2SO4, and absorbance was measured at 450nm using a MRX Microplate 
Reader (Dynex Technologies, Ashford, Middlesex, UK). A standard curve 
containing known concentrations of C3 was included with each plate to 
determine the C3 levels. 
2.3 Plasminogen activator inhibitor-1 ELISA 
Plasma levels of plasminogen activator inhibitor-1 (PAI-1) were measured using 
a PAI-1 ELISA kit (Life Technologies, Paisley, UK) as per the manufacturer’s 
instructions. ELISA plates were pre-coated with PAI-1 antibody to which 100µl 
of plasma samples (diluted 1 in 2 in sample diluent provided) were incubated for 
2 hours at room temperature. The wells were washed four times with 200μl of 
wash buffer provided, after which, 100μl of biotin labelled anti-PAI-1 was added 
to each well for a further 2 hours at room temperature. The wells were washed 
again and 100μl of streptavidin-HRP conjugate added for 30 minutes at room 
temperature. Following the final wash step, 100μl of stabilised chromogen, TMB 
was added for 30 minutes and the reaction terminated by the addition of 1M 
H2SO4 and the plate read at 450nm using the plate reader as above. A standard 
curve containing known concentrations of PAI-1 was included with each plate to 
determine the PAI-1 levels. 
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2.4 Fibrinogen purification  
2.4.1 Affinity chromatography 
Purification of fibrinogen was performed by affinity chromatography using 
calcium dependent IF-1 monoclonal antibody (Kamiya Biomedical, Seattle, WA, 
USA) and an automated chromatography system (Biocad sprint, Applied 
Biosystems, Warrington, UK).  Affinity chromatography exploits the reversible 
binding of certain ligands to their “receptor”. In this case, fibrinogen binds with 
high affinity to a monoclonal antibody (that is constrained in a resin column) in 
the presence of calcium, whilst other, unwanted plasma proteins run through 
the column. Following the addition of wash buffers an elution buffer containing 
EDTA is introduced which causes chelation of calcium and thus fibrinogen is 
released from the antibody and can be collected. 
To prepare the citrated plasma samples for purification on the IF-1 column, 
1.2ml plasma was added to a final volume of 5ml of 100U/ml heparin and 0.02M 
CaCl2 in equilibration buffer (0.02 M Tris, 0.3 M NaCl, 1 mM CaCl2, pH 7.4).  
After loading the sample, the column underwent washing using 6 column 
volumes (CV) of wash buffer 1 (0.02M Tris,1M NaCl, 1mM CaCl2, pH 7.4) and 6 
CV of wash buffer 2 (0.05M sodium acetate, 0.3M NaCl, 1mM CaCl2, pH 6). 
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Figure 2-1 Illustration of the concept of affinity chromatography 
The column containing the monoclonal antibody is equilibrated and the plasma 
sample is injected (A). The antigen of interest (fibrinogen) binds to the antibody 
and the remaining unwanted plasma proteins are washed through (B). The 
addition of an elution buffer alters the environment to allow the antigen to 
dissociate from the antibody (C) and is collected. 
Elution of fibrinogen was achieved by adding 7 column volume of elution buffer 
(0.02M Tris, 0.3M NaCl, 5mM EDTA, pH7.4). The chromatograph produced was 
used to estimate a peak of the fibrinogen eluted. Those tubes of elutant within 
this peak were tested by spectrophotometry. All those fragments with a protein 
concentration >0.02mg/ml, assessed by a ND-1000 spectrophotomer 
(Nanodrop, Wilmington, DE, USA) measuring absorbance at 280nm and 
applying mass extinction coefficient 15.1 for a 10mg/ml solution of fibrinogen. 
Samples were pooled and stored at -80˚C. 
2.4.2 Concentration 
The pooled fibrinogen eluted from the BioCad was transferred to 100,000 
MWCO vivaspin20 concentrator tubes (Generon, Maidenhead, Berkshire, UK) 
and spun at 3000rpm until the volume in the filter was approximately 1ml.  
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2.4.3 Dialysis 
Dialysis tubing (Sigma) was prepared by boiling the tubing in 1M EDTA. The 
tubing was rinsed with ddH2O and each of the fibrinogen samples dialysed 
against 50mmol Tris, 100mmol NaCl pH 7.4 at 4C for 2 consecutive hours and 
overnight with gentle stirring.  
2.4.4 Quantifying fibrinogen concentration 
The final protein concentration was determined using a ND-1000 
spectrophotomer (Nanodrop, Wilmington, DE, USA), applying mass extinction 
coefficient, 15.1 as above. 
2.5 C3 purification 
The purification from individual plasma samples was performed in three 
separate steps, namely precipitation, ion exchange chromatography and finally 
gel filtration 
2.5.1 Precipitation 
The first process involves precipitation of the plasma sample using 
polyethyleneglycol 4000 (PEG). From a stock concentration of 15% PEG 4000 , 
3ml is added to 6ml of plasma along with 90µl of 100mM PMSF and stirred for 
30 minutes at 4oC, followed by centrifugation for 30minutes at 4oC and 10,000g 
in a Beckmann centrifuge. The pellet is discarded and 8.4ml of the supernatant 
is added to 4.2ml of 26% PEG 4000 and 42µl of PMSF and stirred again for 30 
minutes at 4oC and then spun at 10,000g at 4oC for 30minutes. The supernatant 
is then discarded and the pellet is resuspended in 6ml of starting buffer (20mM 
Tris, 5mM EDTA, pH 8.7) and the protein concentration measured using a 
Nanodrop as described previously.   
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2.5.2 Ion exchange chromatography 
The technique of protein separation using ion exchange chromatography is 
dependent on the reversible interaction of a charged protein with an oppositely 
charged chromatography medium. Altering the pH of the surrounding 
environment will alter the net surface charge of a protein and thereby disrupt 
this interaction. In this instance, a stepwise increase in NaCl concentration 
causes elution of differently charged plasma proteins at differing time points.  
To separate C3 from the precipitated plasma proteins the samples were loaded 
into a MonoQ 5/50 GL column (GE Healthcare) which was equilibrated with five 
column volumes (CV) of starting buffer (SB). Approximately 25mg of protein 
was injected onto the column followed by 15 CV of SB to wash the column. The 
C3 was eluted from the column by adding increasing concentrations of elution 
buffer (EB: 20mM Tris, 5nM EDTA, 1M NaCl) in 10 sequential steps each of 10 
CV, starting at 90%SB and 10%EB and finishing with 100% EB. The C3 elution 
peak was observed at around the fourth elution step. Finally the column was 
equilibrated with 10 CV of SB. The presence of C3 within the fractions was 
confirmed by Nanodrop, by measuring absorbance at 280nm and applying 
mass extinction coefficient of 18.2 for a 10mg/ml solution of C3. The samples 
were kept at 4oC overnight and the buffer exchanged for Tris bufferd saline 
(50mM Tris, 100mM Nacl) using disposable PD-10 desalting columns (GE 
Healthcare) and the samples concentrated to around 500µl using  Vivaspin 20 
concentrating tubes (MWCO: 3000) 
2.5.3 Gel filtration 
The final step in purification of C3 is gel filtration, also known as size exclusion 
chromatography. It is a relatively simple technique that will separate substances 
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based on size by allowing them to pass through a chromatography column 
containing pores of different sizes. Smaller molecules are able to enter the 
small pores within the beads of the column and thus take longer to traverse the 
length of the column compared to larger molecules that are unable to enter the 
pores and so have a much smaller surface area through which to navigate ( 
Figure 2-2). A Superose 12 (10/300) GL column (GE Healthcare) was used 
which was loaded with 500µl of sample and eluted with 60ml tris buffered 
saline. The peak was collected and concentrated using Vivaspin 20 
concentrating tubes (MWCO: 3000) and stored at -80oC until required.  
2.5.4 Quantifying C3 concentration 
Protein concentration was determined using a ND-1000 spectrophotomer 
(Nanodrop, Wilmington, DE, USA) measuring absorbance at 280nm and 
applying mass extinction coefficient of 18.2 for a 10mg/ml solution of C3. 
2.5.5 SDS Page 
A sodium dodecyl sulphate (SDS) polyacrylamide gel (Invitrogen) was run to 
determine the quality and purity of the purified fibrinogen or C3. 20µl samples of 
fibrinogen or C3 were prepared in 10µl sample buffer and 4µl and incubated at 
70C for 10 minutes. The samples were run on a 4-12% NuPAGE Novex Bis-
Tris gel (Invitrogen) at 200V for 35 minutes using MES SDS running buffer in a 
Novex mini-cell tank (Invitrogen). 5µl of Perfect Protein marker (Novagen, 
Madison, WI, USA) was added to one well as a molecular weight marker.  
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Figure 2-2 Illustration of gel filtration.  
Larger molecules (red) are unable to enter the pores and so are eluted first as 
they have a smaller surface area to traverse compared to molecules that are 
small enough (yellow) to enter the pores. 
2.5.6 GelCode staining 
After electrophoresis, the gel was rinsed with dH2O for 15 minutes and then 
stained with GelCode Blue Stain Reagent (ThermoScientific) solution for 1 hour 
with shaking. The gel was again rinsed in dH2O for 15 minutes and visualised 
using Chemi-imager software (Alpha Innotech, San Leandro, CA, USA) and a 
trans-white light. Three bands were expected for fibrinogen (corresponding to 
the α, β and γ chains), and two for C3 (α and β chains) and correct sizes 
verified using an appropriate ladder, 66, 56 and 48 kDa respectively for the 
fibrinogen chains and approximately 115 and 70kDa for C3, as illustrated in 
Figure 2-3.  
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Figure 2-3 Purified human fibrinogen and C3 
SDS PAGE of purified human fibrinogen with the α (66kDa), β (56kDa) and γ 
chains (48kDa) and human complement C3 with α (115kDa) and β chains 
(70kDa). Lane A in each image indicates the lane marker and lane B indicates 
the purified protein. 
2.6 Turbidimetric analysis of clot formation and lysis 
2.6.1 Turbidity 
Turbidity analysis dynamically measures the formation of a clot following the 
addition of an activation mix (AM) containing thrombin and CaCl2 to plasma or 
fibrinogen. As the fibrin clot begins to form, following lateral aggregation, the 
optical density (OD) of the reaction mixture increases which can be measured 
with a plate reader. The amount of light reflected by the clot when light of a set 
wavelength is directed through it is estimated and by taking measurements at 
set time points, clot formation can be expressed graphically. 
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2.6.2 Turbidity and lysis 
Turbidity and lysis experiments are more representative of physiological 
conditions. The addition of a tpA and plasminogen to the reaction mix allows 
fibrinolysis to occur alongside clot formation. Fibrin polymerisation occurs as 
with turbidity only experiments, causing an increase in OD and as the clot is 
broken down, OD and absorbance decrease, finally reaching a baseline at 
which point the clot is fully dissolved.  
2.6.3 Turbidimetric parameters 
Several clot formation and lysis parameters can be calculated from the turbidity 
and lysis curves generated. 
The Lag phase corresponds to the initial stages of clot formation, during which 
time fibrinogen is converted to fibrin monomers and subsequently protofibrils. 
Given that lateral aggregation of protofibrils has not occurred during this phase, 
optical density remains at baseline. The end of lag phase is marked by the 
exponential rise in optical density above baseline as lateral aggregation occurs. 
Short lag times may be associated with thrombogenic clots ex vivo225-227. 
Final turbidity (FT) equates to the maximum absorbance of the reaction mix and 
represents the stage at which the clot is fully formed. FT is recorded as the 
highest reading of optical density from the turbidity and lysis trace. In plasma 
experiments this measurement reflects both the thickness of the fibrin fibres and 
clot density. In a purified system, FT only reflects fibre thickness. In terms of 
clinical relevance, higher FT of clots prepared from plasma samples results in 
more thrombogenic clots225;226;228. 
Clot formation time (CFT) represents the time between the end of the lag phase 
and the point at which FT is reached. It is an indication of the rate of fibrin fibre 
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formation, with long CFT indicating the formation of clots with higher final 
turbidity or ineffective fibrinolysis. Prolonged CFT is associated with previous 
ischaemic heart disease in men and women229.  
Lysis time (LT) represents the time from FT to the point at which 50% of the clot 
has lysed (i.e. 50% FT on the descending limb of the turbidity and lysis curve). 
A prolonged LT is an indicator of clot resistance to fibrinolysis, and is associated 
with an increased risk of CVD229;230. 
The lysis area is complex and combines clot formation time, clot final turbidity 
and lysis times and so it is unsurprising that a larger lysis area is associated 
with more thrombotic clots. 
 
Figure 2-4 Illustration of turbidity and lysis curve and parameters 
FT, final turbidity, LP, lag phase, LT, lysis time, CFT, clot formation time. The 
lysis area is indicated by dashed red lines 
2.6.4 Clots made from plasma samples 
 A total of 25µl of each plasma sample was mixed with 75µl lysis mix (LM) 
containing 0.1M NaCl, 0.05M Tris, and 2.4nM tissue plasminogen activator 
(tPA) (Tecnoclone, Vienna, Austria), at room temperature in a 96 well clear 
polystyrene flat bottom microplate (Grenier Bio-one, Gloucester, UK). 
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Polymerisation was initiated by addition of 50µl of activation mix (AM) 
containing 0.1M NaCl, 0.05M Tris, 22.5mM CaCl2 and 0.09U/ml human 
thrombin (Calbiochem, Nottingham, UK). The increase in turbidity at 340nm was 
continuously monitored every 12 seconds on a ELx-808 IU ultramicroplate 
reader (BIO-TEK Instruments INC, Winooski, VT, USA) over a period of 60 
minutes. 
2.6.5 Clots made from plasma purified or commercial protein 
A total of 50µl of purified fibrinogen or commercial fibrinogen (Calbiochem, 
Merck, Germany), at 1mg/ml (2.94µM), was mixed with 50µl LM, containing 
0.2µM plasminogen (Enzyme Research Laboratories, Swansea, UK) in 0.1M 
NaCl, 0.05M Tris, pH 7.4 (permeation buffer [PB]), in a Greiner 96 well clear 
polystyrene flat bottom microplate in duplicate. To ensure adequate cross-
linking, 5µl of FXIII (20µg/ml, 1.56nM) was added. Polymerisation and lysis 
were initiated by the addition of 50 µl AM containing 0.37U/ml thrombin, 3.3nM 
tPA and 7.5mM CaCl2 in 0.1M NaCl, 0.05M Tris, pH 7.4. Increase in turbidity at 
340nm was continuously monitored every 12 seconds on ELx-808 IU 
ultramicroplate reader over a period of 60 minutes. 
2.7 Laser scanning confocal microscopy (LSCM) 
Confocal microscopy was used to visualise hydrated clots. This technique is 
advantageous because the samples do not need special preparation such as 
fixing and dehydration, therefore the clots are imaged in a physiological and 
fully hydrated status 
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2.7.1 Clot preparation 
For plasma clots, 7.5µl plasma and 1.5µl 448 Alexa labelled fibrinogen 
(0.5mg/ml) (Invitrogen) were mixed with 21µl PB. 15µl purified/recombinant 
fibrinogen (1mg/ml) and 1.5µl 448 Alexa labelled fibrinogen (0.5mg/ml) were 
mixed with 13.5µl of PB. An AM of 35mM CaCl2 and 0.35U/ml thrombin was 
prepared in PB. 5µl AM was then added to 30µl of plasma/fibrinogen mix, mixed 
thoroughly and 30µl added to a well of an Ibidi confocal slide (Applied 
Biophysics, New York, USA). A cover was placed on to the slide which was 
stored in a humid dark box until imaging 
2.7.2 Imaging fluorescent samples 
The slide was visualised with LSM510 software on the LSM 510META 
microscope from Zeiss (Oberkochen, Germany), using the 488 Argon laser, 
green reflector and 40x 1.3 oil ph3 objective lens. The slide was loaded onto the 
specimen stage. Scan mode was then selected (LSM) and single track ‘CY2 
alexa 448’ chosen. The master gain was set to 820,digital offset to 0.1 and 
pinhole to 94μm. To view the same section of each clot the focus wheel was 
used to find the top of the clot using the ‘fast xy’ scanning mode and then the 
view moved 1.5 fine focus turns into the clot. For static images a 10242 image 
size was used and the resolution set to 8. For static Z stacks the resolution was 
reduced to 4. 3 Z-stacks of each clot were taken, with a range of 20µM at 
intervals of 2µM. 
2.7.3 LSCM clot lysis 
Time series function was used with 400 scans with 1 second between scans. 
The gain, offset and pinhole were set as above, with resolution at 8 pixels and 
picture size at 5122. 20µl LM (1.1µM plasminogen, 0.14µM tPA in PB) was 
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added to the Ibidi well and the slide tapped gently for 30 seconds to encourage 
the LM into the clot channel. The slide was then left for 30 seconds in a vertical 
position before loading onto the stage and clot visualisation. The lysis front was 
identified using fast xy scanning mode and a time series taken at 4minutes after 
addition of LM so that the lysis front just approached the edge of the first frame 
of the time series. The lysis time in this instance represents the time taken for 
the clot within the viewing filed to be dissolved completely. Images were viewed, 
edited and analysed using LSM image browser (Zeiss). 
2.8 Scanning electron microscopy 
In order to form a clot for electron microscopy (EM) a lid from a 0.5ml eppendorf 
tube was cut off and pierced with a needle several times before covering the 
bottom of the lid with parafilm in order to cover the holes.  
2.8.1 Clot preparation 
For purified experiments, 45μl of fibrinogen (0.5mg/ml) was mixed with 5μl of 
AM (0.025M CaCl2, 5U/ml thrombin in PB). For plasma clots, 50μl of plasma 
was diluted 1:2 with PB and 5µl AM (0.05M CaCl2, 11U/ml thrombin in PB) 
added. The mixture was mixed with a 200µl tip that had the end removed to 
ensure even distribution of the AM. The clots were left to form in the lids for 2 
hours in a humidity chamber.  
2.8.2 Fixing and dehydration 
After removing the parafilm, the clots were washed by placing the lids 
containing the clots in a beaker of sodium cacodylate buffer (0.078M Cacodylic 
acid (Sigma), pH7.4) for 10 minutes, which was then replaced with fresh buffer 
and left for a further 10 minutes. The clots were then fixed by transferring the 
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lids to 2% Glutaraldehyde (Sigma) in sodium cacodylate buffer for 30 minutes  
followed by washing steps as above. Once fixed, the clots were dehydrated by 
placing them in acetone at increasing concentrations, 30%, 50%, 70%, 80%, 
90% and 95% for 10 minutes each, after which they were transferred to 100% 
acetone 3 times for 10 minutes.  
2.8.3 Critical point drying  
I was unable to perform critical point drying (CPD) which was carried out by 
Martin Fuller at the University of Leeds using a E3000 critical point dryer 
(Quorum Technologies Ltd, UK). This involves dehydrating the fibrin structure in 
order for it to be coated with platinum and be detected under the EM. It is 
crucial not to disturb the surface of the fibrin network during the drying process 
as EM relies on analysing the surface morphology of biological specimens. Air 
drying is therefore unsuitable as it may lead to deformation and collapse of 
protein structures as water has a high surface tension to air, and so as liquid in 
the sample evaporates the specimen is subjected to large forces at the 
boundary between the water in the sample and surrounding air. By replacing 
the water in the sample with liquid CO2, this surface tension is reduced in CPD, 
and the surface tension between the liquid in the sample and surrounding air is 
progressively lowered. Liquid CO2 then passes from liquid to gas without an 
abrupt change in state and avoids damaging the surface of the sample. 
2.8.4 Sputter coating 
In order to prevent the clots from charging under the electron beam the samples 
were covered in a thin layer of conducting metal. The clots were mounted onto 
aluminium specimen mounts that were covered in a carbon film. They were then 
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coated with a 7nm thick layer of platinum palladium applied in a 208HR high 
resolution sputter coater (Cressington, UK).  
2.8.5 Clot imaging 
Samples were viewed and photographed using a Quanta 200F FEGESEM field-
emission scanning electron microscope (FEI, Oregon, USA) in 3 different areas 
of each clot at magnifications of x5000, x1000 and x30000. Fibre diameters of 
all clots were measured with image analysis software package ImageJ ,23y 
(National Institutes of Health, Bethesda, MD, USA).  
2.9 Phage display  
Phage display technology is being increasingly used in translational research as 
a tool for validating novel therapeutic targets and drug design. It has multiple 
uses in studying for example, protein-protein interactions, enzyme specificity, 
antibody-antigen interaction and epitope mapping231. The principle is centred on 
the construction of a phage library, approximately 3x1010 in size, consisting 
usually of random peptides.  Insertion of a foreign DNA fragment into the coat 
protein gene of a phagemid vector causes fusion of the peptide with the N-
terminus of the coat protein and is thus expressed externally on the phage 
particle. The genetic information encoding the peptide is held within the phage 
which can be sequenced and therefore connects genotype and phenotype.  
Incubation of the phage library with a target molecule selects the phage that 
bind which can be sequenced to identify the peptide residues involved. This is 
achieved by a process called biopanning which involves immobilising a target 
molecule to a 96 well microtiter plate and adding the phage library to the wells. 
Unbound phage are removed by washing steps followed by elution of the target 
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bound phage which are subsequently amplified and a second library (containing 
increasingly specific phage) produced ready for a second round of biopanning. 
This process is repeated around 3-6 times, after which the phage particles can 
be anaylsed by DNA sequencing.  
 
Figure 2-5 Illustration of steps involved in phage display screening 
The protein of interest is incubated with the phage library and the unbound 
phage is washed off. The bound phage is eluted and amplified within E.coli cells 
and the addition of helper phage. A second phage library is produced and the 
biopanning process is repeated. 
Two separate phage display libraries were used during my research to screen 
for binders to C3 and fibrinogen and the production of these will be described in 
more detail in Chapters 4 and 5. For both libraries the peptide sequences were 
inserted into the coat protein 3 gene (pIII) within a phagemid vector. A 
phagemid is similar to a plasmid but also contains the f1 phage origin of 
replication. The vector was electroporated into electrocompetent E.Coli cells 
containing an F’ pilus. In order for single stranded DNA replication to occur, it is 
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necessary to superinfect the E.coli cells with helper phage (e.g. VCSM13 or 
M13K07), which contain the necessary genes for phage assembly. The 
advantage of infection of a bacterial host cell with a phagemid and helper phage 
in this manner allows the display of larger peptides with fewer copies of the coat 
protein.       
2.9.1 Fibrinogen α chain cDNA phage library 
A phage library consisting of fragments of the α chain of fibrinogen was 
constructed (as detailed in chapter 4) to identify interaction sites between the α 
chain and C3. 
2.9.1.1 Biopanning and enrichment  
Commercial C3 (MyBioSource, CA, USA) was immobilised on a 96-well micro-
titre plate and left overnight at 4oC. Following removal of the coating buffer the 
well was blocked by the addition of 400µl of 3% (w/v) BSA for 1 hour followed 
by washing with TBS/0.5% Tween three times. After suitable washing, 70µl of 
phage was added and incubated at room temperature for 1 hour, followed by 5 
cycles of washing as above in order to remove any unbound phage. To elute 
the bound phage, 30µl of glycine (pH 2.2) was added and the whole mixture 
transferred to a clean eppendorf tube along with 6µl unadjusted 2M Tris to 
neutralise the glycine. To this mixture, 1ml of prepared E.coli cells, XL1-Blue 
MRF’ (Stratagene, La Jolla, CA, USA) was added and incubated at room 
temperature for 15minutes. In order to estimate the number of phage particles 
eluted from round 1 of panning, 10µl was plated on agar containing ampicillin. 
To generate a new, enriched cDNA phage library for a second round of 
biopanning, the infected E.coli cells were superinfected with 1012 plaque forming 
units of VCSM13 (Stratagene) helper phage at room temperature for 30 
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minutes. The culture was transferred to 100ml of LB medium containing 
50ug/ml ampicillin, 10ug/ml tetracycline and 10ug/ml kanamycin and incubated 
at 37oC overnight. The phage was precipitated by centrifuging the culture 
followed by the addition of 0.2 volumes of 40% polyethylene glycol 4000/2.5M 
NaCl. It was then resuspended in 2-3ml of PBS. In total 4 rounds of panning 
were performed after which the phage DNA was extracted using a Wizard 
Minipreps DNA purification system (Promega, Southampton, UK) and sent for 
sequencing. 
2.9.2 Non-antibody scaffold protein (Adhiron) phage library  
Collaborators from the BioScreening Technology group at the University of 
Leeds have developed a phage library containing a non-antibody scaffold 
protein, termed Adhiron. The protein scaffold is based on a consensus 
sequence of plant-derived phytocystatins, a cysteine protease inhibitor. The 
inhibitory sequences within two loops of the protein have been replaced with 
nine randomised amino acid positions in each loop, producing a library size or 
1.3 x 1010 clones. The presence of the peptides within the scaffold maintains the 
conformation of the peptide which is an important consideration when 
investigating protein-protein interactions.  
2.9.2.1 Biopanning and enrichment  
The Adhiron library was used to identify binders to both fibrinogen and C3 and 
the biopanning was similar to that employed with the fibrinogen α chain library.  
There was, however, a difference in the method used to immobilise the target 
protein. Commercial fibrinogen (Calbiochem) or C3 (MyBioSource) were initially 
biotinylated and added to streptavidin coated wells for 1 hour. The Adhiron 
phage library was incubated with fibrinogen or C3 for 2.5 hours, after which the 
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Figure 2-6 Crystal structure of Adhiron (PDB code 46NT) 
The crystal structure of an Adhiron scaffold protein with the loop regions 
containing the random sequence of 9 amino acids shown in red. 
wells were washed 10 times and the bound phage were eluted by the addition 
of glycine and used to infect 1ml of E. coli ER2738 electrocompetent cells 
(Lucigen, Wisconsin ,USA). Colonies of the ER2738 cells were grown on LB 
agar plates overnight followed by inoculation with M13K07 helper phage in 
order to generate a new library for the second round of panning as described in 
2.9.1.1. In total, five rounds of panning were completed, after which individual 
ER2738 colonies were selected for DNA sequencing.  
2.10 Molecular modelling 
The crystal structures of fibrinogen, C3 and C3b (Protein Data Bank [PDB] ID 
codes 3GHG, 2A73 and 2I07 respectively) were visualised using, Pymol 
(Schrödinger, Inc.), which is free for academic groups. There is little information 
currently available regarding the interaction sites of C3(b) and fibrinogen and 
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given that both are relatively large molecules, current molecular modelling 
software is not able to identify sites of protein-protein interaction due to the vast 
computational memory required. By concentrating on the C3 molecule it was 
possible to identify potential sites of protein interaction through the use of the 
molecular modelling software, AutoLigand (Scripps Research Institute). This is 
an automated predictor of ligand binding sites in proteins which works by 
analysing the geometry of a protein surface. The majority of binding sites on a 
protein are within pockets or clefts and this method is able to search the entire 
surface of a protein structure and identify areas of maximal affinity for ligand 
binding sites232. Once suitable areas of binding are identified, the electronic high 
throughput screening software, eHiTS (SimBioSys, Inc.) will be used to target 
these regions. eHiTS is an automated docking tool which allows the rapid 
evaluation of large compound libraries in order to identify ligands which can 
bind to the protein of interest. This algorithm utilises a database of small 
molecules, in this case, the small molecule screening library from Peakdale 
Molecular. It divides the 3-dimensional ligand structures into rigid fragments and 
flexible chains and each rigid fragment is docked into pockets, or receptor sites, 
identified on the surface of the protein. Different orientations or “poses” of these 
fragments that are compatible with chemistry and steric constraints are tested 
within the receptor site and a score is determined based on interacting surface 
points between the ligand and cavity. The flexible chains that connect the rigid 
fragments are fitted to reform the ligand using the lowest energy chain 
configuration possible233. Validation studies of this docking programme has 
demonstrated its ability to replicate ligand binding compared to known crystal 
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structures of bound ligands and it has been used previously as a screening tool 
to identify novel drug targets234-236.  
Protein-peptide interactions are a subset of protein-protein interactions and are 
known to be able to regulate certain biological processes and may be 
manipulated therapeutically given that the interaction surface is small in relative 
terms237. This approach of studying protein-peptide interactions was a logical 
step in order to identify sites of interaction between C3 and fibrinogen through 
the use of peptide sequences, identified from techniques such as phage display 
and microarray screening that bind C3 and fibrinogen.  
Modelling of the predicted binding sites of these peptides with C3 and fibrinogen 
was  achieved through the use of freely available software, PepSite, 
(www.pepsite2.russelllab.org) that is capable of predicting the binding sites of 
peptides, up to 10 aa in length, to a known protein surface (using the PDB ID 
code). PepSite is available via a web server and the initial version has been 
superseded by PepSite2237. The original method studied 405 different protein-
peptide interactions that had a known 3-dimensional structure. From this data 
every peptide residue was allocated a spatial position-specific scoring matrix (S-
PSSM), which essentially encodes the calculated preferred binding environment 
for each peptide residue. PepSite2 utilises these S-PSSMs and scans them 
against the protein structure of interest and predicts preferred sites of amino 
acid binding within the protein, termed hotspots. These hotspots are 
subsequently matched against every residue within the peptide sequence to be 
analysed. The resulting pairs of matched residues are subjected to distance 
constraints so that they lie within a range typically seen in peptide structures237. 
The result is an approximation of the peptide structure bound to the protein 
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surface and is presented visually using a Java viewer, Jmol, and in a table in 
order of statistical significance. The results can also be downloaded as a PDB 
file and visualised using Pymol.  
Molecular modelling technique Description 
Autoligand Searches a known protein structure for 
potential ligand binding sites 
eHiTS Uses a library of small molecules to 
identify ligands to a known protein 
structure 
Pepsite2 Determines predicted binding sites of 
amino acids within a peptide sequence 
(up to 10 amino acids in length) to a 
known protein structure 
AutoDock Predicts the docking poses of 3-
dimensional peptide structures to a known 
protein structure. 
Table 2-1 Summary of molecular modelling techniques used 
Brief description of the molecular modelling techniques utilised and the 
information generated as a result 
Another method of identifying protein-peptide interaction sites is to use the 
docking program, AutoDock (Scripps Research Institute). AutoDock can be 
used when the structure of both the ligand and target molecule are known, but 
the site of interaction is not238. It attempts to dock the peptide or ligand to the 
protein of interest using a grid based method that permits identification of the 
binding energy between the two molecules. A grid is placed over the surface of 
the target protein and a probe atom from the ligand is placed at each grid point 
which then stores the calculated interaction energy between the protein and 
probe. The software also generates different “trial” conformations of the ligand 
based on the types of bonds present and thus generates a number of potential 
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docking sites based on the binding energies produced by the trial 
conformations239. This technique will be employed using peptide sequences 
from fibrinogen identified from the microarray and phage display screening and 
also using Adhirons of interest. A summary of the different molecular modelling 
techniques employed can be seen in Table1-1. The Autoligand and AutoDock 
screening were performed by Dr Katie Simmons, School of Chemistry, 
University of Leeds. 
2.11 Mass spectrometry 
All mass spectrometry laboratory work and data analysis was performed by 
James Ault of the Faculty of Biological Sciences, University of Leeds. 
2.12 Principles of mass spectrometry 
A mass spectrometer consists of three components: an ion source, which 
converts the sample into gas phase ions, a mass analyzer which  separates the 
ions according to their mass-to-charge ratio, and finally a detector, which 
calculates the abundances of each ion present. The data generated are 
displayed as a spectrum of the relative abundance of ions as a function of their 
mass-to-charge ratio (m/z).  
Prior to MS analysis, the C3 protein was reduced in order for the α and β chains 
to be separated and analysed separately. The two chains were separated by 
SDS-PAGE and then fragmented further following enzyme digestion with 
trypsin, which cleaves proteins on the C-terminal side of lysine and arginine 
residues, unless they are immediately followed by proline. As a consequence, 
the treatment of proteins with trypsin generates peptides with an average length 
 
 
82 
 
of approximately ten to fifteen amino acid residues which is well suited for MS 
detection.  
Following fragmentation of the protein, the peptide fragments are subjected to 
tandem MS analysis (MS/MS). The masses of the sample fragments are 
determined in a MS survey scan after which peptide ions of interest are isolated 
according to their mass-to-charge ratio value. Further fragmentation of the 
selected peptide ion species occurs by the addition of an inert gas such as 
Argon that imparts internal energy to the ions as they collide. The fragmented 
ions pass through the mass analyser which determines the m/z values. The 
molecular mass of amino acids that have been affected by PTM is altered and 
can be detected by increments or deficits in mass on the MS/MS spectra.  
This technique very useful for studying changes as a result of PTM as it is 
highly sensitive, and  requires very little sample. It is able to detect changes in 
molecular mass that correspond to modifications at both the peptide and protein 
level and can therefore identify the type and location of the PTM. 
This technique does however have limitations as the processes of digestion, 
ionization and MS/MS activation can lead to dissociation of the PTM from the 
protein. This tends to occur if the covalent bond between the amino acid and 
the PTM is chemically unstable and so the PTM may not be detected. An added 
complication is that the presence of PTM may affect the efficiency of trypsin in 
cleaving the protein, leading to larger peptide fragments that are less suitable 
for analysis.  
2.12.1 Gel processing and tryptic digestion  
25 µL of each sample was buffer exchanged into 50 mM ammonium 
bicarbonate using Vivaspin 500 3000 kDa MWCO centrifugal concentrators 
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(Sartorius Stedim). 3 x 25 µL washes with ammonium acetate were performed. 
Samples were then reduced by addition of DTT to 5 mM with heating to 56 °C 
for 20 min and then alkylated by addition of iodoacetamide to 15 mM with 
incubation in the dark at room temperature for 15 min. Trypsin in 50 mM 
ammonium acetate was then added to the samples in a protein:protease ration 
of 1:50 w/w and incubated for 18 hours at 37 °C with shaking. After briefly 
vortexing and centrifuging, the trypsin reaction was quenched by addition of 5 
µL of formic acid. Digested samples were stored at -80 °C until LC-MS analysis. 
2.12.2 Liquid chromatography-mass spectrometry 
Liquid chromatography-mass spectrometry (LC-MS/MS) analysis of the peptide 
mixtures was performed on an Ultimate 3000 nano LC system (Dionex, 
Amsterdam, Netherlands). 1 µl of each sample was loaded onto a C18 guard 
column and washed with 2% acetonitrile/0.1% formic acid for 5 min at 25 µl/min. 
After valve switching, the peptides were then separated on a PepMap C18, 
100µm i.d.x15 cm analytical column (Dionex, Amsterdam, NL) by gradient 
elution of 2-60% solvent B (0.05% formic acid in 20% water/80% acetonitrile) in 
solvent A (0.05% formic acid in 98% water/2% acetonitrile) over 60 minutes at 
0.35 µl/min. The column eluant was directly interfaced to a quadrupole-ion 
mobility-orthogonal time of flight mass spectrometer (Synapt G2S, Waters UK, 
Manchester) via a Z-spray nanoflow electrospray source. The MS was operated 
in positive TOF mode using a capillary voltage of 3.8 kV, cone voltage of 20 V, 
backing pressure of 7.91 mbar and a trap bias of 4.1 V. The source temperature 
was 80 °C. Argon was used as the buffer gas at a pressure of 9.1×10-3 mbar in 
the trap and transfer regions. Mass calibration was performed by a separate 
injection of sodium iodide at a concentration of 2 µg/µl. [Glu1]-Fibrinopeptide B 
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at 2 µM was infused as a lock mass calibrant with a one second lock spray scan 
taken every 30 seconds during acquisition. Ten scans were averaged to 
determine the lock mass correction factor.  Data acquisition was using data 
dependent analysis with a one second MS over an m/z of 350-2000 being 
followed by three 1 second MS/MS taken of the three most intense ions in the 
MS spectrum above a threshold of 1000 counts per second. Collision energy 
applied was dependent upon charge state and mass of the ion selected. 
Dynamic exclusion of 60 seconds was used. Data processing was performed 
using the MassLynx v4.1 suite of software supplied with the mass spectrometer. 
Peptide MS/MS data were processed with ProteinLynx Global Server (Waters) 
and searched against UniProtKB/SwissProt database (release 2011/12). 
Search was limited to Homo sapiens species. Precursor mass accuracy was 10 
ppm and fragments ion tolerance was 0.1 Da. Trypsin was specified as the 
protease with up to two missed cleavages. Carbamidomethylation was used as 
a fixed modification and variable modifiactions were specified as acetylation, 
glycation, deamidation and oxidation. 
2.13 Statistical analysis 
Analysis of the data was done using Graphpad 6 and statistical significance 
accepted at p<0.05. Between group comparisons of normally distributed 
variables were carried out using independent samples student t-test. 
Comparisons of non-normally distributed variables were carried out using 
Mann-Whitney U tests. More advanced statistical analyses were carried out 
according to type of work conducted and these are further detailed in each 
Chapter as appropriate. Data are presented as mean±SEM unless otherwise 
stated.  
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Chapter 3  
The effects of diabetes on the fibrinolytic properties of 
complement C3 
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Introduction 
Using ex vivo experiments, C3 has shown anti-fibrinolytic effects in individuals 
with and without diabetes6;240. Diabetes studies to date have concentrated 
predominantly on T1DM patients in an attempt to avoid confounding factors 
associated with T2DM that may impact on clot lysis. Experiments have largely 
been conducted using pooled purified C3 from healthy subjects added to pooled 
healthy control fibrinogen or purified fibrinogen from diabetes patients. From the 
limited experiments using pooled purified C3 from diabetes patients, the effect 
on lysis prolongation appears to be exaggerated6. Given the heterogeneity 
associated with T2DM patients, it is likely that a variation in the extent of C3 
induced prolongation of lysis exists between these individuals. Reasons for this 
variation may be related to glycation, or other post-translational modifications of 
C3, glycaemic control, medications and co-morbid conditions such as CVD, 
obesity and dyslipidaemia. Ex-vivo glycation of C3 has been demonstrated to 
affect protein function with regards to its role in killing bacteria94, and thus it may 
be that glycation also affects its incorporation into the fibrin network.  
Although the anti-fibrinolytic effects of C3 appear to be exaggerated in diabetes, 
only individuals with T1DM have been investigated and little is known about the 
relationship between C3 and clot lysis in type 2 diabetes.  
The aim of this Chapter was firstly to study the role of C3 in type 2 diabetes by 
analysing the interaction between C3 plasma levels and lysis time in a large 
cohort of patients. Secondly, I set out to investigate the inter-individual 
variability in C3 induced prolongation of lysis in diabetes by studying the effects 
of purified C3 on fibrinolysis using purified fibrinogen and purified C3 from the 
same individual. Cohorts of T1DM, T2DM and age matched healthy controls 
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were analysed in this section. Thirdly, potential mechanisms for differences in 
the effect of C3 on lysis were examined by investigating potential diabetes-
specific post translational modifications in the C3 protein. 
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3.1 Methods 
3.1.1 Sample collection 
A large cohort of T2DM samples (n=837), provided from collaborators in 
Edinburgh working on the Edinburgh Type 2 Diabetes study (ET2DS)241, was 
available for analysis. The collection of these samples along with clinical data 
was done entirely in Edinburgh as was measurement of plasma proteins such 
as C3, PAI-1 and fibrinogen. I was involved in helping to perform turbidimetric 
analysis on the samples along with other members of the research laboratory 
and therefore only part of this work, relevant to my thesis, will be included here. 
For the purified experiments, the aim was to recruit twenty patients with T1DM 
and T2DM along with twenty age and sex matched, healthy controls for both 
T1DM and T2DM subjects. Data gathered include blood pressure, height, 
weight and body mass index (BMI). Collected data and blood results are stored 
in paper format in a locked office at the Leeds Institute for Genetics, Health and 
Therapeutics (LIGHT) laboratory, and also electronically on a password 
protected computer. Informed consent was obtained from participants in 
accordance with the Declaration of Helsinki (Appendix). Ethical approval for the 
study was provided by the Leeds East, National Research Ethics Service 
(NRES) committee. My role included identification of patients, obtaining consent 
and help research nurses with blood sample collection.  
.  
3.1.2 Sample preparation and storage 
Fasting blood samples were collected without a tourniquet and separated into 
9ml EDTA, 3ml lithium heparin and 5ml and 10ml citrate bottles. The EDTA and 
10ml citrate tubes were kept on ice prior to and following sample collection. 
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Plasma was separated within 2 hours by centrifugation at 4oC, snap frozen in 
liquid nitrogen and stored at -40oC at the LIGHT laboratories. Samples were 
also collected for full blood count, urea and electrolytes, liver function, thyroid 
function, lipid profile, fasting blood glucose and glycated haemoglobin (HbA1c) 
for each subject and these were sent to the Biochemistry department at Leeds 
Teaching Hospital NHS Trust to be analysed. 
3.1.3 Plasma protein analysis 
Plasma levels of fibrinogen, PAI-1 and C3 were measured by the Clauss 
method and ELISA respectively as described in Chapter 2.  
3.1.4 Fibrinogen purification 
Fibrinogen was purified from 15 T1DM patients and controls, along with 20 
T2DM patients and 15 controls. Affinity chromatography was used using an IF-1 
monoclonal antibody as described in Chapter 2. 
3.1.5 C3 purification 
Complement C3 was purified from the same number of individuals as described 
above using the methods outlined in Chapter 2. Collaborators at the University 
Hospital Aachen contributed to C3 purification. More specifically, C3 from all 
type 1 diabetes and matched controls were purified in Aachen.  
3.1.6 Turbidimetric analysis 
Turbidimetric analysis was performed on plasma samples from T1DM, T2DM 
and age/sex matched control individuals along with the Edinburgh Type 2 
Diabetes samples as described in detail in Chapter 2. The clot parameters, lysis 
time, lag phase and final turbidity were measured for each subject.  
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Experiments were also performed using the purified fibrinogen and C3 from 
each individual. A mixture containing 1µM of fibrinogen and 0.9µM C3 from the 
same individual, 0.01µM plasminogen and 0.01µM FXIII was prepared to 100µl 
with Tris buffered saline and added to a well of a 96 well Greiner plate. After 30 
minutes of incubation, 50µl of an activation mix containing 0.37U/ml thrombin, 
3.3nM tPA and 7.5mM CaCl2 in 0.1M NaCl, 0.05M Tris was added. 
Measurements were taken at 340nm every 24 seconds for 6 hours in a plate 
reader as previously described.  
3.1.7 Mass Spectrometry 
In order to identify post-translational modifications of diabetes C3 compared to 
control, 2 separate pools of purified C3 were prepared from 6 diabetes and 6 
control subjects. In order to account for inter-individual variability in C3 
glycation, C3 purified from individuals were also analysed separately (6 from 
each of the following groups, T1DM, T1DM controls, T2DM, T2DM controls). 
Following tryptic digestion of C3, the fragments were analysed using liquid 
chromatography mass spectrometry as described in Chapter 2. 
3.1.8 Statistical analysis 
Between-group comparisons of normally and non-normally distributed variables 
were carried out using T-test and Mann-Whitney test, respectively.  
Associations were tested using Spearman’s correlations (presented as rs). The 
R environment for statistical computing was used to fit regression models, to 
determine independent predictors of clot lysis time and complement C3 plasma 
levels, with both univariable and multivariable models fitted to study the effects 
of multicollinearity. The robustness of multivariable regression models was 
assessed using examination of model residuals by QQ plots, scale location 
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plots and a plot of Cook’s distance. The effect of each of the predictors in a 
regression model was characterised using 95% confidence intervals for the 
regression coefficients. 
Between group comparisons of normally distributed variables in the in-vitro 
studies were carried out using independent samples student t-test. 
Comparisons of non-normally distributed variables were carried out using 
Mann-Whitney U tests. Data are presented as mean±SEM unless otherwise 
stated.  
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3.2 Results 
3.2.1 Association between C3 and LT in T2DM  
The patient and clinical characteristics of the Edinburgh Type 2 Diabetes study 
(ET2DS) samples (n=837) can be seen in Table 3-1. Analysis of the results 
indicated that LT again correlated with C3, fibrinogen and PAI-1 plasma levels 
(r=0.23, p<0.0001 and r=0.20, p<0.0001; respectively). This association 
remained for C3 and PAI-1 following multivariable regression analysis involving 
age, sex, BMI, C3, PAI-1, CRP and fibrinogen. This, however, was not the case 
for fibrinogen and CRP. There was no correlation observed within the cohort 
between C3 and PAI-1 levels (r=-0.006, p>0.1), which is similar to previous 
studies and suggests that C3 plasma levels are independently associated with 
LT in T2DM patients and occurs via a different pathway to that of PAI-1. 
 
Figure 3-1 Predictors of clot lysis time in 837 type 2 diabetes subjects in 
multivariable analysis adjusted for age, gender and BMI 
Results are presented as regression coefficient for changes in plasma levels of 
C3, C-reactive protein (CRP), fibrinogen and plasminogen activator inhibitor-1 
(PAI-1), *p<0.01. The 95% confidence interval is indicated in brackets. 
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Variable Values 
Sex (m/f) 421/402 
Age (range) 67.8 (60-76) 
Duration of DM (years) 8.0±0.2 
Inflammatory parameters  
CRP (mg/l) 3.7±0.2 
C3 (mg/ml) 1.34±0.01 
Fibrinogen (mg/ml) 3.6±0.02 
PAI-1 (pg/ml) 924±33 
Vascular markers  
Systolic BP (mmHg) 133±0.56 
Diastolic BP (mmHg) 69±0.31 
Anthropometrics  
BMI (kg/m2, range) 31.37 (18-55) 
Cardiometabolic factors  
HbA1c, mmol/mol 57.0±0.3 
Plasma glucose, mmol/l 7.5±0.07 
Total Cholesterol, mmol/l 4.3±0.03 
HDL cholesterol mmol/l 1.2±0.01 
Table 3-1 Clinical characteristics of ET2DS subjects 
3.2.2 Clinical characteristics of subjects 
The clinical characteristics of the subjects used for analysis of purified proteins 
are presented in Table 3-2 and Table 3-4. Regarding the T1DM patients and 
controls, there was no difference in age or sex and no difference in markers of 
cardiometabolic disease namely BMI, and blood pressure. As would be 
expected there was a significant difference in HbA1c and fasting plasma 
glucose, but in no other biochemical markers analysed.  
With the T2DM patients and controls there was again no difference in age 
although there was a larger proportion of females in the control group (30% vs 
53%). There was a trend toward higher systolic blood pressure in the T2DM 
group (128±2.41 vs 120±3.4, p=0.056) and a definite increase in BMI compared 
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to the control cohort (31±1.1 vs 25.4±0.9, p<0.001), along with the expected 
elevated HbA1c and fasting plasma glucose. The lipid profile was also different 
between the T2DM group and controls, with significantly lower total and LDL 
cholesterol, and higher HDL cholesterol compared to the controls, but lower 
triglyceride levels observed in the control group. It is worth noting that all of the 
T2DM group were on cholesterol lowering statin medication and 95% were 
taking at least one anti-hypertensive agent. Almost half (45%) of the T2DM 
group had a diagnosis of ischaemic heart disease and 30% had retinopathy. 
Only one of the T1DM suffered from any complications of diabetes (retinopathy) 
and none took any medication in addition to their subcutaneous insulin. Both 
sets of control groups were healthy with no significant medical problems and 
took no regular medications.  
3.2.3 Plasma protein levels 
There was no significant difference between measured plasma levels of 
fibrinogen, C3 and PAI-1 between the T1DM group and controls (Table 3-3). In 
contrast, with the T2DM cohort, the plasma levels of all 3 proteins were 
elevated compared to the controls (Table 3-5).  
3.2.4 Changes in plasma clot parameters with T1DM and T2DM 
The effect of diabetes on clot formation and lysis was studied using plasma 
from the above cohorts and also in a purified system using purified fibrinogen 
and C3 from a selection of subjects in both the T1DM and T2DM groups along 
with corresponding controls.  
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Variable 
T1DM  
(n=15) 
T1DM Control 
(n=15) 
p value 
Age (range) 24.4(18-39) 26.6(21-34) 0.24 
Sex (M/F) 10/5 10/5 
 Duration of diabetes, months  99.9(16.4) - 
 Current smokers, n (%) 3(20) 0(0) 
 Vascular parameters     
 Systolic BP, mmHg  117(3.8) 118(3.3) 0.85 
Diastolic BP, mmHg  76(3.1) 75(2.6) 0.81 
Anthropometrics     
 BMI, kg/m
2  24.8(0.8) 23.8(0.5) 0.32 
Metabolic     
 HbA1c, mmol/mol  78.4(4.6) 35(1.1) <0.0001 
Plasma glucose, mmol/l 12.5(0.9) 4.37(0.2) <0.0001 
Total Cholesterol, mmol/l  4.6(0.3) 4.71(0.3) 0.79 
Triglycerides mmol/l  1.17(0.1) 1(0.1) 0.33 
LDL cholesterol mmol/l  2.61(0.1) 2.66(0.2) 0.82 
HDL cholesterol mmol/l  1.46(0.1) 1.63(0.1) 0.23 
TSH mIU/l  2.33(0.3) 2.34(0.3) 0.98 
Free T4 pmol/l  14.8(0.4) 15.01(0.4) 
 Table 3-2 Clinical characteristics of T1DM cohort and controls 
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Variable 
T1DM  
(n=15) 
T1DM Control 
(n=15) 
p value 
Clot Structure parameters     
 Lag phase, seconds  682(±45) 659(±17) 0.63 
Final turbidity, au  0.176(±0.02) 0.195(±0.01) 0.35 
Lysis time, seconds  430(±11) 426(±13) 0.82 
Plasma protein levels     
 Fibrinogen, mg/ml  2.01(±0.09) 2.16(±0.07) 0.19 
C3, mg/ml  1.34(±0.05) 1.4(±0.06) 0.43 
PAI-1, pg/ml  664.5(±154) 905.5(±162) 0.29 
Table 3-3 Plasma clot structure parameters and protein levels in T1DM 
cohort and controls. 
3.2.4.1 Plasma turbidimetric assays 
There was very little difference between the LT of the T1DM and control groups 
which is contrary to previously published work and may reflect the relative good 
health enjoyed by the T1DM cohort and the relatively small sample size. 
Although numerical differences were evident in fibrinogen, C3 and PAI-1 levels 
comparing patients with controls (higher in patients), none reach statistical 
significance. There was also no difference in the lag phase and final turbidity 
between both sets (Table 3-3). There was however a significant increase in LT 
between the T2DM and control groups, with elevated plasma levels of C3, PAI-
1 and fibrinogen (Table 3-5). 
 
 
 
 
 
 
 
 
97 
 
Variable 
T2DM 
 (n=20) 
T2DM Control 
 (n=15) 
p value 
Age (range) 59(44-70) 59.7(52-73) 0.5 
Sex  (M/F) (14/6) (7/8)  
Duration of diabetes, months  130.7(19.6) -  
Current smokers, n (%) 3(15) 1(6.6)  
Vascular parameters      
Systolic BP, mmHg  128(2.4) 120(3.4) 0.057 
Diastolic BP, mmHg  80(1.7) 81(2.6) 0.74 
Anthropometrics      
BMI, kg/m2  33.1(1.1) 25.4(0.9) <0.0001 
Metabolic      
HbA1c, mmol/mol  64.5(3.6) 37.6(1.1) <0.0001 
Plasma glucose, mmol/l 9.53(0.75) 4.83(0.12) <0.0001 
Total Cholesterol, mmol/l  3.64(0.16) 5.21(0.14) <0.0001 
Triglycerides mmol/l  1.63(0.22) 0.93(0.07) 0.01 
LDL cholesterol mmol/l 1.92(0.12) 2.91(0.15) <0.0001 
HDL cholesterol mmol/l  3.38(0.16) 1.9(0.14) <0.0001 
TSH miu/l  1.8(0.22) 2.12(0.26) 0.36 
Free T4 pmol/l  14.67(0.46) 13.81(0.51)  
Past medical history    
Ischaemic heart disease, n (%) 9(45) -  
Retinopathy, n (%) 6(30) -  
Nephropathy, n (%) 1(5) -  
Hypertension, n (%) 19(95) -  
Table 3-4 Clinical characteristics of T2DM cohort and controls  
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Variable 
T2DM  
(n=20) 
T2DM Control 
(n=15) 
p value 
Clot Structure parameters     
 Lag phase, seconds  634(±30) 567(±17) 0.09 
Final turbidity, au  0.296(±0.02) 0.253(±0.01) 0.07 
Lysis time, seconds  569(±34) 477(±15) 0.03 
Plasma protein levels     
 Fibrinogen, mg/ml  2.80(±0.1) 2.55(±0.09) 0.07 
C3, mg/ml  1.83(±0.08) 1.19(±0.03) <0.0001 
PAI-1, pg/ml  4239(±583) 1301(±263) 0.0002 
Table 3-5 Clot structure parameters and plasma protein levels in T2DM 
cohort and controls 
3.2.4.2 Correlation of plasma protein concentrations with LT 
Combined analysis of the 4 groups as a whole revealed a correlation between 
LT and plasma levels of C3 (r=0.3, p<0.05), fibrinogen (r=0.41, p<0.001) and 
PAI-1 (r=0.49, p<0.0001) as seen in Figure 3-2.  
 
Figure 3-2 Correlation between clot lysis time and plasma levels of C3, 
fibrinogen and PAI-1 plasma levels  
Spearman correlations between clot lysis time and (A) plasma C3 levels, (B) 
plasma fibrinogen levels, (C) plasma PAI-1 levels (r=0.3, p<0.05, r=0.41, 
p<0.001, r=0.49, p<0.0001 respectively) 
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3.2.5 Effect of C3 on LT in T1DM  
Due to difficulties encountered with C3 purification and limited protein obtained, 
it was not possible to conduct the purified turbidity assays on all of the subjects. 
The yield of C3 was disappointingly low and thus only 9 T2DM and control 
fibrinogen and C3 were available for analysis and 6 from the T1DM group. The 
mean LT for T1DM and controls without the addition of C3 was 3238±403 
seconds and 2871±533 seconds respectively (p=0.13). There was a trend 
towards greater difference in C3 induced prolongation of lysis comparing control 
and diabetes subjects (297±148 seconds vs 800±531.7 seconds prolongation, 
respectively; p=0.076, Figure 3-3). There was a wide variation in LT in individual 
samples from control and diabetes groups, particularly in diabetes subjects. In 
the T1DM group the prolongation in LT induced by C3 ranged from 144-1476 
seconds (5-51%), compared to 108-468 seconds (5-17%) in the control group.  
3.2.6 Effect of C3 on LT in T2DM 
The lysis times in the T2DM cohort in the absence of C3 were longer than the 
T1DM cohort to the point whereby the T2DM samples did not lysed to 50% 
within the 2 hours. To counter this problem, the concentrations of tPA and 
plasminogen within the lysis mix were increased 4-fold in order to achieve full 
lysis of the clots. The outcome of this change was noticeably shortened LT in 
the T2DM and control subjects compared to the T1DM cohort, being1104±219 
seconds for the controls and 1501±733 seconds for the T2DM subjects. Given 
these results it was perhaps not too surprising to find that the increase in LT 
following the addition of C3 was less significant.  The mean prolongation in LT 
for the control subjects was 45.3±138 seconds and 136±249 seconds for the 
diabetes group (p=0.65, Figure 3-3). There was a wide variation observed again 
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between the T2DM and control individuals but unlike the T1DM group, the 
addition of C3 appeared to augment fibrinolysis in a number of samples. The 
ranges in LT prolongation were less dramatic and may be a reflection of the 
overall quicker LT observed. For the T2DM cohort LT ranged from -144 to 696 
seconds (-8 to 22%) and from -96 to 336 seconds (-10 to 38%) in the controls. 
 
Figure 3-3 The effects of C3 on lysis time during clot formation 
The mean±SEM of C3 induced prolongation of lysis in (A) T1DM cohort and 
controls and (B) T2DM cohort and controls. Experiments were conducted by 
addition of C3 purified from patient or control plasma added to fibrinogen 
purified from the same individual. The prolongation in lysis was measured by 
subtracting the LT in absence of C3 from LT in the presence of C3. 
3.2.7 Glycation of C3 as a potential mechanism for inter-individual 
variation in lysis prolongation 
3.2.7.1 Sequence coverage of C3 by mass spectrometry 
Sequence coverage of the diabetes pool and control pool was 80% and 75% 
respectively. Both samples contained albumin, possibly due to its ubiquitous 
nature within plasma and its high affinity for binding to circulating plasma 
proteins.  
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3.2.7.2 Post-translational modifications 
No areas of glycation on C3 were identified in the DM and control pools. Given 
the inter-individual variability in the C3 induced prolongation of lysis in both 
T1DM and T2DM cohorts it was decided to also analyse individual samples of 
C3 in case there is also a variation in glycation between individuals. Again there 
were no areas of glycation identified within any of the 12 healthy controls 
studied (6 matching T1DM and the other 6 matching T2DM patients). However, 
when analysed individually, several Lysine residues in the T1DM and T2DM C3  
 
Figure 3-4 LC-MS sequence coverage of pooled diabetes C3 samples 
The amino acid residues in bold were covered by the LC-MS analysis 
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samples were found to be glycated by an increase in mass of 162Da, indicating 
the presence of a hexose molecule. In total, 11 separate Lys residues were 
glycated, 2 occurred only in the T1 samples, 8 occurred only in the T2 samples 
and 3 occurred in both groups. More than one glycation site was noted in each 
sample (range 2-4) with a mean of 3±0.9 modifications in the T1DM samples 
and 2.3±0.5 modifications in the T2DM samples. The locations of the modified 
Lys residues are shown in Table 3-6 and their positions within the C3 molecule 
are illustrated in Figure 3-5. 
Glycation site Number of samples containing PTM 
K 1181 & 1187 
K 1187 
4 
3 
K 665 
K 1117 
K 1505 
4 
4 
2 
K 464 
K 1359 
K 242 
K 699 & 700  
K 839 
K 909 
K 1049 
K 1342 
2 
2 
1 
1 
1 
1 
1 
1 
Table 3-6 Sites of glycation identified by MS in individual C3 samples 
The Lys residues (K) that are glycated and their position within the C3 
sequence are shown along with the number of samples analysed that contained 
the glycation. The light grey row indicates which residues were glycated in 
T1DM only, white row those sequences identified in T1 and T2DM samples, and 
dark grey row the sequences identified in T2DM samples only. 
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Figure 3-5 Glycation sites within C3 identified by mass spectrometry 
The crystal structure of C3 (PDB ID 2A73) is shown with the glycated Lysine (K) 
residues indicated in red along with corresponding position with the sequence of 
C3. 
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3.3 Discussion 
The work in this Chapter was aiming to build on the known association between 
fibrinolysis and C3 plasma levels in T1DM by i) studying the relationship 
between plasma C3 levels and fibrinolysis in a cohort of T2DM patients, ii) 
examining the inter-individual variability in the effects of C3 on fibrinolysis in 
T1DM and T2DM patients and iii) relating the observed differences to the 
degree of incorporation of C3 into the fibrin network and to post-translational 
modifications of C3, in particular glycation.  
In the T2DM cohort there was a strong correlation between C3 plasma levels 
and fibrin clot lysis, which was at least as pronounced as the association 
between PAI-1 and fibrinolysis in this population. Furthermore, there was no 
correlation between C3 and PAI-1 plasma levels, consistent with the 
observations that the two molecules affect separate pathways in the fibrinolytic 
system6. PAI-1 inhibits fibrinolysis by interfering with plasmin generation, 
whereas C3 modulates clot lysis through incorporation into the clot. This is 
thought to increase mechanical resistance to lysis, and may compromise 
plasmin activity6;80. Clinically, this work suggests that measuring PAI-1 plasma 
levels only addresses part of the fibrinolytic potential in diabetes and C3 offers 
an additional assessment tool. Importantly, these results, together with previous 
work on T1DM, indicate that interference with C3-fibrin interactions may offer a 
novel therapeutic target to improve fibrin clot lysis and reduce cardiovascular 
events in individuals with diabetes.   
Regarding the subjects recruited specifically for my PhD, there was a 
correlation between the plasma levels of C3, fibrinogen and PAI-1 and LT in 
both the DM and control groups, which is consistent with previous work.  
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In terms of the T1DM group, the clinical characteristics were very well matched 
to that of the control group apart from HbA1c and fasting plasma glucose as 
would be expected. Somewhat surprisingly, and in contrast to previous studies, 
plasma levels of fibrinogen, C3 and PAI-1 were also similar between the two 
groups and may, in part at least, explain the similarities observed in the clot 
structure parameters, most notably similar LT. Given the relatively small 
numbers in this study, these were not specific aims of my research, and thus it 
is important not to draw too many conclusions. If similar results were obtained in 
a much larger cohort, this may suggest that chronic hyperglycaemia alone is not 
sufficient to prolong fibrinolysis ex-vivo and that the sequeale of diabetes, such 
as inflammation and alterations in haemostatic proteins are more important 
contributors to increased thrombosis potential. The T1DM cohort analysed in 
this work had no complications from diabetes and therefore are arguably a 
“healthy” group of diabetes patients. The study by Hess et al (2012) analysed 
fibrinolysis in a much younger cohort of T1DM (mean age 14.5±0.3 years) and 
although there was a mean duration of 6.32 years since diagnosis in these 
individuals, it is possible that they had higher residual, autoimmune processes 
than this current cohort, which could affect LT and offer some explanation as to 
the differences between these two T1DM groups. 
The T2DM group were reasonably matched for age; however there was a 
greater percentage of females in the control group (30% vs 53%), a significant 
increase in BMI and trend towards an increase in systolic blood pressure in the 
T2DM group. During the recruitment process there was a difficulty in recruiting 
suitable males to act as controls. This was due to the fact that a large proportion 
of men in the target age group were taking some form of medication thus 
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excluding them from the study. Again as would be expected there was 
significant differences in HbA1c and plasma glucose levels between the two 
groups, and a difference was also observed in the lipid profiles. The diabetes 
subjects had a significantly elevated triglyceride levels, commonly seen in 
T2DM, however the control subjects had significantly lower HDL levels and 
higher total and LDL cholesterol. These results are likely to reflect the fact that 
all of the diabetes subjects were taking cholesterol lowering, statin medication. 
In contrast to the T1DM group, and in keeping with previous studies, the plasma 
levels of C3, fibrinogen and PAI-1 were all significantly elevated in the diabetes 
group compared to the control. Unsurprisingly this was associated with 
significant differences in clot structure parameters and lysis, with increased FT 
in the diabetes group and prolonged LT.  The mean LT of the control group was 
also significantly longer than that of the T1DM cohorts and this is possibly due 
to the increased age of the T2DM controls but also due to the higher proportion 
of females in this group, given that female sex is associated with prolonged LT 
in T2DM242. 
 
Effect of C3 on LT in T1DM  
In the purified experiments, pre-incubation of C3 and fibrinogen caused a 
prolongation in LT, compared to fibrinogen alone, and this effect was observed 
with both control and T1DM subjects. Although the mean increase in LT was far 
longer in the diabetes group (800±531sec vs 297±148 seconds) the difference 
between the groups failed to reach statistical significance (p=0.076) presumably 
due to low numbers and large standard deviation. There was wide variability in 
C3 mediated prolongation of LT between individuals in the purified experiments 
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which ranged from 144-1476 seconds (5-51%) in the diabetes subjects, 
compared to 108-468 seconds (5-17%) in the controls. Fibrinolysis was actually 
inhibited following the addition of C3 in one of the control subjects which was 
unexpected and may reflect an undiagnosed coagulopathy. 
 
Effect of C3 on LT in T2DM  
Following the plasma turbidimetric results it was somewhat surprising to find 
very little difference in the C3 mediated prolongation of lysis between the 9 
T2DM and control subjects used in the purified experiments (136±249  seconds 
and 45.3±138 seconds respectively, p=0.65). Possible explanations for this 
observation include the relative short LT as a whole, in comparison to the T1DM 
group. It was necessary to increase the concentrations of tPA and plasminogen 
in the T2DM experiments as the conditions used for the T1DM samples failed to 
achieve sufficient lysis in several subjects, making analysis impossible. 
Shortening the process of clot formation and subsequent LT is likely to make 
the effect of C3 upon lysis less apparent. Another explanation for the 
differences observed between the T1DM and T2DM groups may relate to the 
heterogeneous nature of T2DM patients and thus much larger numbers are 
required to demonstrate the true effect of C3. A wide variation in the lysis 
prolongation was also observed between the T2DM and control individuals and 
surprisingly the addition of C3 appeared to enhance lysis in 3 control subjects 
and 2 T2DM subjects, which is difficult to explain. The prolongation in LT 
ranged from -144-696 seconds (-8-22%) in the diabetes subjects and from -96-
336 seconds (-10-38%) in the controls. A possible explanation may relate to the 
overall reduced LT in this group as a result of the increased tPA concentration. 
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By speeding up the turbidity and lysis experiments, the hypofibrinolytic effect of 
C3 may be diminished or lost altogether due to reduced incorporation of C3 into 
the clot. The supposed reduction in LT observed in 5 samples following the 
addition of C3 may fall within the error of the assay, and in reality C3 has had 
no effect on LT. The inter-individual variation observed in C3 mediated lysis 
prolongation may relate to the degree of incorporation of C3 into the clot, which 
is known to be increased in diabetes. An important factor in this incorporation 
may relate to the glycation of C3, which was assessed using mass 
spectrometry. The data from the pooled diabetes and control C3 samples did 
not reveal any evidence of glycation and was a curious finding as in-vitro 
glycation of several lysine residues within C3 has been reported previously94. 
These results coupled with the variability in C3 mediated lysis prolongation 
suggested that perhaps the glycation of C3 was heterogeneous. Mass 
spectrometry analysis of individual C3 samples was therefore employed which 
identified 13 lysine residues that were glycated within the T1DM and T2DM 
subjects, but not controls. Although in-vivo glycation of C3 has been described 
previously243;244, the residues involved have only been identified by in-vitro 
glycation as above. One of the thirteen residues glycated, K242, was also found 
to be glycated under in vitro conditions by Hair et al (2012). Within the T1DM 
group, each sample had slightly more glycation sites than the T2DM group 
(3±0.9 vs 2.3±0.5), with increased commonality of glycated lysine residues. 
There was a degree of overlap with the T2DM group in terms of glycation sites, 
but there was more heterogeneity within these samples, with glycation of some 
lysines occurring in only one of the six samples. These findings would explain 
the pooled MS results as the presence of multiple, different glycated lysine 
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residues within each sample may not become evident once the samples are 
pooled together.  The amount of glycation sites, variation in frequency of 
occurrence and variation between T1DM and T2DM samples suggests that not 
all lysine residues are equal in terms of their importance in modulating C3-
fibrinogen interactions. Another possible explanation may relate to changes in 
C3 conformation caused by elevated plasma glucose levels, altering its 
function245. Hair et al (2012) found changes in C3 structure at increasing 
concentrations of glucose that were sufficient to impair its interaction with 
staphylococcus bacteria. Several lysine residues were increasingly or 
decreasingly biotinylated at higher glucose concentrations, suggesting 
conformational changes to C3 that were sufficient to make certain lysine 
residues more, or less, available for protein interactions. Transferring this 
hypothesis to clot structure and lysis, it may be that altered conformation of C3 
during conditions of hyperglycaemia, along with glycation of certain lysine 
residues, increases its likelihood to bind to fibrinogen and become incorporated 
into the clot thereby delaying fibrinolysis.  
 
This work confirms that complement C3 plays a crucial role in delayed 
fibrinolysis in T2DM as well as T1DM, and that the mechanism underlying this 
process is different to that of PAI-1. The effect of C3 on clot lysis appears to 
vary between different individuals, and this may relate to differing rates of 
incorporation of C3 into the clot as a result of variations in glycation of the 
molecule. A greater understanding of the interaction sites between C3 and 
fibrinogen may help explain the inter-individual variability observed and shed 
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more light on the role of glycation and glycaemia, enabling a targeted approach 
to inhibit the hypofibrinolytic effects of C3.  
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Chapter 4  
Assessing C3-fibrinogen interactions 
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Introduction 
Despite a growing body of evidence linking complement C3 to CVD, and its 
anti-fibrinolytic effect ex-vivo, which is enhanced in diabetes subjects, relatively 
little is currently known regarding the mechanisms involved. The physical 
presence of C3 within the fibrin network has been repeatedly demonstrated 6;240 
and a reasonable assumption would be that this is related to an interaction with 
fibrin(ogen). Numerous complement proteins and receptors are able to bind to 
C3 and the affinities of this binding alter as C3 is converted to C3b and C3c. 
The determination of the crystal structure of these proteins has demonstrated 
that C3 is a very flexible protein and subsequently undergoes major 
conformational changes, mainly affecting the α-chain, upon activation. Multiple 
hidden binding sites are exposed as C3 becomes C3b allowing key complement 
proteins such as factor H, properdin and CR1 to bind84;86. The exposure of the 
thioester moiety also permits covalent attachment to cell surfaces, enabling 
opsonisation and phagocytosis of foreign material. 
Investigating potential interactions between C3 and fibrinogen may be 
problematic largely due to the relative size of both molecules. In such instances, 
the proteins in question are typically analysed in smaller more manageable 
fragments. Previous unpublished work from our laboratory has identified one 
potential interaction site on the α-chain of fibrinogen with C3 (Figure 4-1). Using 
surface plasmon resonance (SPR), a microarray chip containing fragments of 
the fibrinogen α chain was immobilised and subsequently incubated with C3. 
This identified a possible interaction site between residues 341 and 371 of the 
α-chain of fibrinogen and C3. However, this fragment was only able to partially 
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inhibit fibrinogen binding to C3 and at very high concentrations indicating the 
presence of other, more important interaction sites. 
 
Figure 4-1 Binding of fibrinogen α chain fragments to C3 
Surface plasmon resonance results of different fibrinogen α chain fragments 
binding to C3. The left hand side denotes the fragment and amino acid residues 
contained within. This data suggests that a binding site for C3 lies within 
residues 341-371 of the fibrinogen α chain.  
Further insight into the interaction sites between fibrinogen and C3 may allow 
the development of novel therapeutic agents capable of inhibiting C3 
incorporation into the clot, thus reducing cardiovascular risk. The aim of this 
chapter therefore was to further investigate the interaction between fibrinogen 
and C3. Firstly, to corroborate the SPR findings, a cDNA library of the α-chain of 
fibrinogen was produced for use in a phage display system to identify 
sequences that interact with C3. Secondly, a peptide microarray of the whole of 
the fibrinogen molecule was purchased to confirm potential α-chain interaction 
sites and identify any other sites of interaction within the β or γ chains. Thirdly, 
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the results from these methods were studied using molecular modelling 
software to predict potential binding sites on the crystal structure of C3 and 
model the docking of peptide sequences of interest to C3.   
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4.1 Methods 
4.1.1 Fibrinogen α chain cDNA phage display library 
Constructing a cDNA phage library consisting of fragments of fibrinogen α- 
chain should hopefully allow further identification of peptide sequences involved 
in fibrinogen and C3 interaction. Construction of the cDNA phage library and 
subsequent biopanning rounds were performed with Dr Phil Watson at the 
University of Sheffield. 
4.1.1.1 Creating a Fibrinogen α-chain cDNA phage library 
In order to create a cDNA phage library of the α chain of fibrinogen the first step 
was to produce a large quantity of the α chain itself. A plasmid (p584) 
containing the entire DNA encoding the α chain of fibrinogen was amplified by 
polymerase chain reaction (PCR). To 10µg of the plasmid was added 10mM 
dNTPs, 50mM MgCl2, 2µl 10X buffer, 0.2µl Taq Polymerase (Life Technologies, 
Paisley, UK), 35.3µl dnaH2O and 10µM of both forward and reverse primers.  
Forward primer: CTCTCGAGTGAATTGTCG 
Reverse primer: GTAAAACCTCTACAAATGTGG  
Fifty separate reaction mixtures were produced and the tubes placed in a PTC-
200 Peltier Thermal Cycler (MJ Research, Quebec, Canada), held at  94oC for 
3minutes, before 35 cycles of  94oC for 45 seconds, 55oC for 30 seconds and  
72oC for 90 seconds. This was followed by 10 minutes at 72oC and the reaction 
again held at 4oC until sample collection. The PCR products were pooled and 
1µl was run on a 1% agarose gel containing ethidium bromide, along with a 
base pair marker, at 200V for 1hour. The gel was imaged under UV light with a 
band observed at 2000 base pairs (bp) as expected (Figure 4-2). 
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Purified and precipitated DNA was re-suspended in 90µl of water along with a 
digest mixture in order to randomly produce fragments of the DNA in the region 
of 100-200bp. The digest mixture contained 10µl of 10X buffer (0.5M Tris, 0.1M 
MnCl2, 1mg/ml BSA) and 3µl of a diluted DNAse enzyme. The enzyme was 
diluted by a factor of 1:50 in an enzyme diluent which contained 50mM Tris and 
1mg/ml of BSA.  
 
Figure 4-2 Agarose gels of α chain PCR product following digestion 
A) 1% agarose gel indicating the fibrinogen α chain PCR products with a band 
visible under ultraviolet light at approximately 2000 base pairs as expected. B) 
1% agarose slot gel of digested α chain demonstrating fragments of roughly 
100-200bp produced. 
The digest mixture was incubated at 37oC for 15minutes to allow sufficient 
cutting of the fragments. Once enough suitable fragments have been produced 
the DNA was purified, precipitated and again re-suspended in 90µl of water 
along with 10µl T4 polymerase buffer, 5µl MgCl2 (25nM), 5µl 10mM dNTPS, 2µl 
T4 polymerase and 2µl of DNA polymerase and incubated at room temperature 
for 15 minutes.  The mixture was run on 1% agarose slot gel and the 
subsequent band (Figure 4-2) was cut from the gel under UV light. The sliced 
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gel was transferred into a dialysis tube along with TE buffer in order to recover 
the DNA from the gel. 
4.1.1.2 Vector Purification & Ligation 
A plasmid vector (pCOMB3) was cut to produce a linear plasmid suitable for 
ligation of the fragmented fibrinogen α chain. This produces fragments that are 
around 4000bp as seen on a 1% low melting point agarose gel. The vector was 
then phosphorylated in preparation for ligation. A second, slot gel, was 
performed and as previously, the band of purified vector was cut away from the 
gel under UV light and recovered using a proprietary gel extraction kit 
(Promega). A 20µl ligation mixture was prepared containing 10µl of cut vector, 
7µl of fibrinogen fragments, 2µl of ligation buffer and 1ul ligase. The mixture 
was incubated at 16oC overnight. 
4.1.1.3 Electroporation 
Following heat treatment at 75oC for 10 minutes, 2µl of the ligation mixture was 
added to 50µl of electro competent E.Coli XL1-Blue MRF’ cells (Stratagene, La 
Jolla, CA, USA) in an electroporation cuvette and 1700V passed through. Cells 
are recovered in 500µl of LB medium and after 1hour, 2µl was plated onto 
selective medium containing 50µg/ml ampicillin and left overnight, the 
remainder of the mixture was left on ice. The number of colonies can be 
counted the following day and the cDNA library size estimated. In order to 
prepare the cDNA phage-display library, the electroporated cells were 
superinfected with 1012 plaque forming units of VCMS13 helper phage at room 
temperature for 30 minutes. The culture was transferred to 100ml of LB medium 
containing 50ug/ml ampicillin, 10ug/ml tetracycline and 10ug/ml kanamycin and 
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incubated at 37oC overnight. The phage was precipitated by centrifuging the 
culture followed by the addition of 0.2 volumes of 40% polyethylene glycol 
4000/2.5M NaCl. It was then resuspended in 2-3ml of PBS. The number of 
clones produced can be estimated through titration of the phage library. A 
random selection of colonies can be cultured and sequenced to ensure they 
contain fragments of the α-chain. 
4.1.1.4 Panning and enrichment 
In total 4 rounds of biopanning were performed as described in Chapter 2. 
4.1.2 Peptide Microarray 
A company from Germany, PEPperPRINT, was commissioned to study the 
interaction sites of fibrinogen and C3 through the use of a peptide microarray. 
This work would hopefully confirm any sites of interaction within the α chain 
identified from the phage display experiments and also cover the remainder of 
the molecule. In order to create the peptide chip, the α, β and γ chain of 
fibrinogen were linked with neutral GSGSGSG linkers and translated into 15 aa 
peptides with a peptide-peptide overlap of 14 aa. The resulting peptide 
microarrays contained 1,602 different peptides as duplicates (3,204 peptide 
spots) and were framed by Flag (DYKDDDDKGG) and  HA (YPYDVPDYAG) 
control peptides (118 spots each). A pool of purified complement C3 from 
healthy controls was used in the experiments. 
Pre-staining of the peptide array was done with biotinylated anti-C3 antibody 
(LifeSpan Biosciences Inc, Seattle, USA) at a dilution of 1:1000 followed by 
staining with streptavidin conjugated DyLight680 (Thermo Fisher Scientific) to 
investigate background interactions that could interfere with the subsequent 
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main assays. Incubation of the peptide microarray with C3 at concentrations of 
0.8 µg/ml and 8 µg/ml in incubation buffer  (PBS, 0.05% Tween 20 , 10% 
blocking buffer) was followed by incubation blocking buffer (Rockland buffer 
MB-070) and subsequently with the biotinylated anti-C3 antibody, staining with 
streptavidin conjugated DyLight680 and read-out at a scanning intensity of 7 
(red). In a variant assay, 1 µg/ml Complement C3 was allowed to pre-complex 
with 2 µg/ml biotinylated anti-C3 antibody for 1 h to form a bivalent Complement 
C3-antibody complex. After centrifugation, incubation of one of the peptide 
arrays was done at a relative Complement C3 concentration of 8 µg/ml for 16 h 
at 4°C and slight shaking. Subsequently, staining was done with streptavidin 
conjugated DyLight680 for 15 min at a dilution of 1:1000, 4°C and slight 
shaking. The goal of this variant assay was the compensation of possibly high 
off-rates of the monovalent Complement C3 protein by formation of a bivalent 
complex with a higher avidity. HA and Flag control peptides framing the peptide 
arrays were finally stained as internal quality control to confirm the assay quality 
and the peptide microarray integrity 
Quantification of spot intensities and peptide annotation were done with 
PepSlide® Analyzer and a software algorithm breaks down fluorescence 
intensities of each spot into raw, foreground and background signal and 
calculates the standard deviation of foreground median intensities. Based on 
averaged foreground median intensities, intensity maps were generated for 
each assay. The averaged spot intensities of all assays were plotted against the 
linked fibrinogen sequence from the N- to the C-terminus to visualize overall 
spot intensities and signal to noise ratios The intensity plots were correlated 
with peptide and intensity maps as well as with visual inspection of the 
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microarray scan to identify peptides and consensus motifs that interacted with 
C3. 
4.1.3 Molecular modelling 
In order to identify potential sites of ligand binding on C3, the molecular 
modelling software, Autoligand was employed to scan the whole of the molecule 
as described in Chapter 2. Briefly, Autoligand is an automated predictor of 
ligand binding sites in proteins which works by analysing the geometry of a 
protein surface and identifies areas of maximal affinity for ligand binding232. 
Molecular modelling was also used as a complimentary technique to predict the 
binding sites of  any peptide sequences  identified from the phage display and 
microarray screening with complement C3 and C3b using the website 
Pepsite2®, as described in Chapter 2. Pepsite2 predicts the binding site of each 
residue in a peptide (up to 10 aa in length) to a known protein surface using 
pre-determined preferred binding environments for each residue. The result is 
an approximation of the peptide structure bound to the protein surface. Images 
were viewed and produced using Pymol software. 
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4.2 Results 
4.2.1 Fibrinogen α chain cDNA phage library 
The final fibrinogen α chain cDNA library contained approximately 100,000 
independent phage clones, with α chain fragment inserts between 100-200bp.  
To ensure the cDNA library was capable of binding immobilised protein, several 
biopanning rounds were completed against immobilised polyclonal anti-
fibrinogen antibody (abcam). Following each round there was enrichment of the 
phage library indicating increased selectivity of phage particles. However, 
biopoanning against immobilised C3 did not demonstrate enrichment and 
suggests that the α-chain fragments were not binding to C3. 
4.2.2 Peptide microarray screening 
4.2.2.1 Background interactions 
To investigate for any background interactions between the biotinylated anti-C3 
antibody and fibrinogen peptide microarray, the chip was incubated with the 
antibody at a dilution of 1:1000 followed by staining with streptavidin conjugated 
DyLight680. Figure 4-3 demonstrates the intensity map of the chip with no 
observed background signals indicating that there was no non-specific binding 
of the antibody or streptavidin conjugated DyLight680. 
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Figure 4-3 Incubation with biotinylated anti-C3 antibody followed by 
staining with streptavidin conjugated DyLight680 at a dilution of 1:1000  
No background signalling observed following incubation with biotinylated anti-
C3 antibody and streptavidin conjugated DyLight680 indicating that the anti-C3 
antibody did not cross-react with the fibrinogen microarray peptides. 
4.2.2.2 Complement C3 microarray scans.  
Incubation of the peptide microarray with C3 at a concentration of 0.8 µg/ml 
followed by incubation with the biotinylated anti-C3 antibody at a dilution of 
1:1000 and staining with streptavidin conjugated DyLight680 resulted in a very 
weak and hardly visible spot pattern. Therefore the protein concentration was 
increased tenfold and the assay repeated at a concentration of 8 µg/ml. After 
blocking with Rockland blocking buffer, there appeared to be weak but complex 
staining patterns (Figure 4-4). Analysis of the variant assay, which was done 
with a pre-formed C3-antibody complex to generate a bivalent species, 
demonstrated the highest signal-to-noise ratios and spot intensities.  
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Figure 4-4 Complement C3 microarray scans 
The staining patterns of the C3 microarray scans using C3 at 0.8µg/ml, 8µg/ml 
and in complex with biotinylated anti-C3 antibody at 8µg/ml, all incubated with 
the fibrinogen microarray peptides, washed and stained with streptavidin 
conjugated DyLight680. 
4.2.2.3 Intensity plots and peptide identification 
Data quantification was followed by generation of peptide and intensity maps as 
well as of intensity plots that were leveled to provide a better overview. In 
accordance with the microarray scans and the intensity maps, there were 
complex spot patterns in all assays with varying spot intensities, but also with 
some clear similarities. The brightest spot patterns in the assay with the C3-
antibody complex were highlighted in the intensity plot and also identified in all 
other assays as distinctive features. These spot patterns were based on 
peptides with the consensus motifs AVSQTSSSSFQYMYL (peptide A), 
QCSKEDGGGWWY (peptide B) and YNRCHAANPNGRYY (peptide C), which 
are all located in the β chain of fibrinogen (Figure 4-5). Out of the three motifs, 
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the peptides with the consensus AVSQTSSSSFQYMYL, exhibited less blurry 
spot morphologies in all assays. Taking only the α-chain of fibrinogen into 
account, there were interactions with peptides with the consensus motifs 
FPGFFSPMLGEFV and SGNVSPGTRREY. These interactions were much 
weaker than the β chain peptides, as evidenced by lower spot intensities and 
spot patterns that were less clear. 
 
Figure 4-5 Intensity plots of the C3-antibody complex microarray 
screening 
The peptide sequences are along the x axis with the peptide motifs 
AVSQTSSSSFQYMYL (A), QCSKEDGGGWWY (B) and YNRCHAANPNGRYY 
(C) indicated all of which are located within the β chain of fibrinogen. The 
intensity plot from C3 (8μg/ml) is indicated in blue and the C3-antibody complex 
(8μg/ml) in purple. 
4.2.3 Potential binding sites within C3 
Analysis of the C3 crystal structure (PDB code: 2A73)66  using the AutoLigand 
software revealed 10 potential binding regions, two of which encompassed the 
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same region and so were classed as one (Figure 4-6). Unfortunately due to the 
size of the C3 molecule, it was not possible to investigate these 9 different 
regions using eHiTS as the computational memory required was too large to 
perform such an analysis. eHiTS is generally utilised for much smaller peptides 
and ligands and although disappointing this was not perhaps a surprise. 
 
Figure 4-6 Potential binding sites on C3 
The 9 different regions identified by AutoLigand are shown as coloured spheres. 
4.2.3.1 Binding of fibrinogen peptides to C3 and C3b 
Using the results from microarray screening the position of the peptides within 
the β chain and α chain were determined in terms of the sequence and then 
within the molecule itself.  The sequence positions can be seen below, with 
peptides B and C being within one amino acid of each other and near the C- 
terminus of the β chain. Peptide A is located closer to the N-terminus. In terms 
of physical location within the molecule itself, this can be seen in Figure 4-7. 
Peptide A is close to the central E region as might be expected from the 
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sequence position, whilst the other two motifs are located within the coiled coil 
regions of the β chain as it extends towards the peripheral D regions. 
α-chain 
MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVRGPRVVERHQSACKDSDWPFCSDED
WNYKCPSGCRMKGLIDEVNQDFTNRINKLKNSLFEYQKNNKDSHSLTTNIMEILRGDFS
SANNRDNTYNRVSEDLRSRIEVLKRKVIEKVQHIQLLQKNVRAQLVDMKRLEVDIDIKI
RSCRGSCSRALAREVDLKDYEDQQKQLEQVIAKDLLPSRDRQHLPLIKMKPVPDLVPGN
FKSQLQKVPPEWKALTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSW
NSGSSGPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPGSPRP
GSTGTWNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGSGNARPNNPDWGTF
EEVSGNVSPGTRREYHTEKLVTSKGDKELRTGKEKVTSGSTTTTRRSCSKTVTKTVIGP
DGHKEVTKEVVTSEDGSDCPEAMDLGTLSGIGTLDGFRHRHPDEAAFFDTASTGKTFPG
FFSPMLGEFVSETESRGSESGIFTNTKESSSHHPGIAEFPSRGKSSSYSKQFTSSTSYN
RGDSTFESKSYKMADEAGSEADHEGTHSTKRGHAKSRPVRGIHTSPLGKPSLSP 
 
β-chain 
MKRMVSWSFHKLKTMKHLLLLLLCVFLVKSQGVNDNEEGFFSARGHRPLDKKREEAPSL
RPAPPPISGGGYRARPAKAAATQKKVERKAPDAGGCLHADPDLGVLCPTGCQLQEALLQ
QERPIRNSVDELNNNVEAVSQTSSSSFQYMYLLKDLWQKRQKQVKDNENVVNEYSSELE
KHQLYIDETVNSNIPTNLRVLRSILENLRSKIQKLESDVSAQMEYCRTPCTVSCNIPVV
SGKECEEIIRKGGETSEMYLIQPDSSVKPYRVYCDMNTENGGWTVIQNRQDGSVDFGRK
WDPYKQGFGNVATNTDGKNYCGLPGEYWLGNDKISQLTRMGPTELLIEMEDWKGDKVKA
HYGGFTVQNEANKYQISVNKYRGTAGNALMDGASQLMGENRTMTIHNGMFFSTYDRDND
GWLTSDPRKQCSKEDGGGWWYNRCHAANPNGRYYWGGQYTWDMAKHGTDDGVVWMNWKG
SWYSMRKMSMKIRPFFPQQ  
 
 
Figure 4-7 The location of the peptide sequences that bind to C3 within 
the fibrinogen molecule 
The peptide sequences identified by the microarray screening are illustrated 
within the crystal structure of fibrinogen (PBD code 3GHG). The red spheres 
indicate peptide A (VSQTSSSSFQ), pink spheres indicate peptide B 
(CSKEDGGGWW) and orange spheres indicate peptide C (NRCHAANPNGR). 
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It was not possible to visualise the α chain peptides as the crystal structure of 
the α chain containing those particular peptides is not available (only part of the 
α-chain of fibrinogen has been crystallised). The same sequences of the β 
chain and α chain peptides were entered into the Pepsite2 software to predict 
their binding sites to C3 (PBD code 2A73). All were predicted to bind in a similar 
region on the α chain of C3 within the MG7 domain (Figure 4-8).  
 
 
Figure 4-8 The predicted binding sites of the fibrinogen β chain peptides 
on C3. 
Predicted binding sites of the three fibrinogen β chain peptides, identified from 
the microarray screening, were generated using the web server Pepsite2.  The 
red, pink and orange dots represent residues from peptides A, B and C 
respectively. The α chain is shown in green and β chain in red. 
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The receptors within C3 that were predicted to bind to peptide B 
(CSKEDGGGWW) contained Lysine 839 that was noted to undergo glycation 
from the MS analysis of individual C3 samples (Figure 3-5). Given that 
complement activation is enhanced in diabetes and C3b is the active form of C3 
and has a very different structure, it was decided to repeat the procedure with 
the crystal structure of C3b (PDB code 2I07). As may be expected the predicted 
binding for the same fibrinogen peptides were in a very different region, 
presumably due to the exposure of previously hidden binding sites (Figure 4-9). 
 
  
Figure 4-9 Docking of fibrinogen β chain peptides to C3b 
The similarities of potential docking and binding sites of the fibrinogen β chain 
peptides B and C identified from the microarray screening on C3b. The results 
from AutoDock indicating the peptides docked to C3b are shown as sticks and 
predicted binding sites from Pepsite are shown as spheres.  
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Figure 4-10 Predicted binding of peptides B and C to C3 by AutoDock 
(A) Results of AutoDock predicting the binding of fibrinogen β chain peptide B 
(CSKEDGGGWW) and (B) results of docking peptide C (NRCHAANPNGR) to 
C3. The peptides are represented by coloured spheres. 
4.2.3.2 Docking of fibrinogen peptides to C3 and C3b 
The potential binding regions identified by pepsite2 were used to facilitate more 
rigorous docking of 3D structures of the β chain peptides to C3 and C3b using 
the automated docking suite AutoDock as described in Chapter 2 . The 3 
peptide sequences (A, B, C) were “clipped” from the β chain of the original 
fibrinogen crystal structure (PDB ID 3GHG). The docking of peptides B and C to 
native C3 were in a different location to the binding sites predicted by Pepsite 
as can be seen in Figure 4-10.The docking poses do appear to encompass 
areas containing Lysine residues observed to undergo glycation, namely K665 
for peptide B and K1505 for peptide C. The lowest energy poses for dockings of 
the same peptides to C3b actually matched the binding sites predicted by 
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Pepsite (Figure 4-9). The conformational changes that occur during the 
formation of C3b likely exposes binding sites for fibrinogen that were previously 
hidden in C3, and suggests that C3b may be important in fibrinogen interactions 
in addition to native C3. 
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4.3 Discussion 
Attempting to identify sites of fibrinogen-C3 interaction was not straightforward 
due to a lack of published work on this topic and due to the relative size of both 
molecules. For these reasons several different methodologies were employed 
to gain some insight into where these proteins may interact. 
Results from this chapter shed light on potential interactions between fibrinogen 
and C3 and factors that may influence this interaction. Firstly, the cDNA library 
of the α-chain together with the microarray screening suggest that the β chain of 
fibrinogen  rather than the α-chain is in fact most important in terms of binding to 
C3. Secondly, molecular modelling work has identified areas within both C3 and 
C3b that would amenable to binding of fibrinogen sequences and raises the 
possibility that both C3 and its active component C3b are involved in the 
interaction with fibrinogen. The predicted binding locations suggest that post-
translational modification of C3 by glycation in diabetes may play a role in 
determining the degree of interaction.  
Previous work from colleagues within the research group had identified a 
potential area with the α chain of fibrinogen that may bind to C3 suing surface 
plasmon resonance (SPR). For this reason it was decided to construct a cDNA 
library of the α chain of fibrinogen for use in a phage display system to try and 
identify peptide sequences with the α chain that bind to C3, hopefully 
corresponding to the SPR data. Following several rounds of biopanning, which 
involved incubating the α chain library with immobilised C3, no enrichment of 
the phage particles was observed, indicating that the peptide sequences 
expressed by the phage were not binding to C3.  
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This was obviously disappointing and may indicate that the epitope sites on 
fibrinogen are conformational in nature rather than linear, as is presented by the 
phage library. This would not explain the binding observed with the SPR 
experiments however as this technique also relies on linear binding. A feasible 
explanation is that the SPR results identified only one of a number of interaction 
sites and that additional higher affinity binding sites exist. This was corroborated 
by the fact that the interaction between fibrinogen and C3 was only partly 
inhibited by the α-chain peptide αF1 from Figure 4-1, and using high 
concentrations, indicating the presence of other interaction sites, and would 
therefore be consistent with my findings. 
 
Following these results it was decided to screen the entire fibrinogen molecule 
against C3. This service was offered by a German company, PEPperPRINT 
who were commissioned to generate a microarray peptide chip of the entire 
fibrinogen molecule and with our input, devised experiments to screen against 
purified human C3. This technique indicated that the β chain of fibrinogen 
probably contains more important sites for interaction with C3 than the α chain. 
Some areas within the α chain were identified but these were different to those 
previously noted by my colleague. Crucially, the previously identified area was 
not highlighted as an interaction site suggesting this part of fibrinogen is of 
secondary importance in C3-fibrinogen interaction.  It should be stressed, 
however, that these methods only detect linear binding and fail to identify 
conformational interaction sites. 
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By using molecular modelling techniques it was possible to investigate these β 
chain peptide sequences further with regard to their possible role in binding to 
C3. It was encouraging that the peptides were predicted to bind in the same 
region of C3 using Pepsite, however AutoDock simulated the docking peptides 
B and C to different areas of C3 and given that this modelling relies on the 
conformation of the peptide sequences is likely to be the more credible binding 
sites. The docking poses did appear to encompass regions within C3 that 
contained glycated residues, K1505 for peptide B and K665 for peptide C. 
Given the proximity of these peptide sequences within the β chain of fibrinogen, 
it is likely that both are involved in binding C3. A more realistic model would 
therefore be to try and dock these two sequences as one to C3 rather than as 
separate entities. It is worth noting that K839 from C3 was predicted to be a 
receptor for fibrinogen peptide B, from the Pepsite results, and this same lysine 
was noted to be glycated in one of the T2DM samples. Furthermore, K839 was 
also described by Hair et al (2012) as being increasingly biotinylated, i.e. more 
available for protein interactions, with increasing glucose concentration. This 
combination of evidence supports this region of C3 as being important in C3-
fibringoen interactions and further implicates the roles hyperglycaemia and 
glycation. 
 
Native C3 is clearly important when discussing the link between the 
complement and coagulation systems as evidenced by its role as a substrate 
for many coagulation factors such as plasmin, thrombin and FXa. However, it is 
also worth considering the role of its active component C3b, given that 
activation of the complement system is increased in diabetes. The predicted 
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binding sites of the β chain peptides on C3b, generated by Pepsite, were very 
different to that of C3. This finding was not unexpected given the major 
conformational changes that occur following activation of C3, which exposes 
numerous cryptic binding sites. The areas within C3 and C3b were both within 
the α chain which is known to be more important than the stable β chain in 
interacting with other complement component for example. The site on C3b was 
within the CUB (complement C1r/C1s, Uegf, Bmp 1’) domain which is thought to 
be involved in the binding of complement factors H and I86. In contrast to C3, 
the predicted docking poses of the β chain peptides using AutoDock were in the 
exact same region on C3b as predicted by Pepsite. This commonality of 
findings suggests that this is a genuine binding site for fibrinogen and C3b. It 
may be that fibrinogen is in fact capable of binding to both C3 and C3b, which 
may explain the hypofibrinolysis associated with diabetes, as the increased C3 
activation, and subsequent elevated C3b levels, increases fibrinogen binding 
and consequently increases incorporation into the clot. 
 
The results presented here indicate that the interaction between C3 and 
fibrinogen may occur at sites in the β chain of fibrinogen and α chain of C3. The 
glycation of certain lysine residues within C3 may serve to enhance this 
interaction. It is possible that fibrinogen is able to bind to C3b, the active form of 
C3, which may explain the increased incorporation into the clot in diabetes 
following increased complement activation. This lays the foundations for 
investigating methods that are capable of modulating this interaction, in an 
attempt to improve clot breakdown and hence reduce cardiovascular risk, in this 
susceptible population.  
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Chapter 5  
Modulation of fibrinolysis by interference with plasmin 
inhibitor-fibrinogen interaction 
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Introduction 
Current treatment strategies for primary and secondary prevention of 
cardiovascular disease are largely focussed on inhibition of platelet function, 
and the fibrin network is not usually targeted. However, several pieces of 
evidence indicate that modulating the fibrin network is also effective at reducing 
thrombotic risk246-249. Studies involving warfarin have shown promise in 
reducing this risk but have been largely outweighed by issues such as its non-
specific mode of action, narrow therapeutic window, need for frequent testing 
and increased bleeding risk 250;251. Newer, more specific agents, including 
coagulation factor X inhibitors, have shown a more consistent effect. However, 
the relatively high bleeding risk when combined with antiplatelet therapy has 
limited widespread use252. Given the effectiveness of antiplatelet therapy at 
inhibiting platelet function, further reduction of atherothrombotic events, without 
significant increase in bleeding risk, maybe obtained by targeting the fibrin 
network, specificaly the interaction between fibrin(ogen) and other proteins that 
are incorporated into the clot. Suitable candidates for this type of study include 
C3 as well as the more traditional plasmin inhibitor (PI). Both C3 and PI have 
shown increased incorporation into fibrin networks from diabetes patients 133;253. 
Therefore, interfering with C3 or PI incorporation into fibrin clots represents a 
diabetes-specific strategy to improve the fibrinolytic process and decrease 
thrombosis risk in this population.  
Collaborators from the Bioscreening Technology group at the University of 
Leeds have developed a new artificial binding protein scaffold called Adhiron, 
which is utilised as a novel drug target validation tool. Briefly the Adhiron 
comprises of a protein scaffold based on a consensus sequence of plant-
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derived phytocystatins, a cysteine protease inhibitor. The inhibitory sequences 
within two loops of the protein have been replaced with nine randomised amino 
acid positions in each loop. A phage display library of this scaffold has been 
produced, comprising 1.3 x1010 clones, with high thermal stability (Tm ca. 
101oC) and high quality254. By screening this library against fibrinogen it is 
hoped that peptide sequences capable of modulating clot formation and lysis 
can be discovered. Specific protein-protein interactions can also be examined 
using this technique, for example that of fibrinogen and fibrinolytic inhibitors 
present within the clot such as C3 and PI. 
In order to validate the technique, the library was initially used to investigate the 
interaction between fibrinogen and the classical anti-fibrinolytic agent PI. The 
role of PI in inhibiting fibrinolysis and its interaction with fibrinogen are much 
better understood than that of C3 and so the effect of these binders, if any, 
would be a useful foundation to future work involving C3. 
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5.1 Methods 
The identification and production of Adhirons along with phage ELISA were 
performed by members of the Bioscreening Technology Group, University of 
Leeds.   
5.1.1 Adhiron identification 
Commercial human fibrinogen (Calbiochem) was biotinylated using EZ-link 
NHS-SS-biotin (Pierce), according to the manufacturer’s instructions. The 
biopanning with the Adhiron phage library was performed as described in 
Chapter 2.  Following three rounds of panning, >1000 fold amplification of 
phage was observed over streptavidin control wells. In order to refine the phage 
pool and select specific Adhirons capable of targeting fibrinogen–plasmin 
inhibitor interactions, competitive elution with plasmin inhibitor (50µg/ml) for 20 
min at room temperature was applied in the fourth and fifth rounds of panning. 
Individual ER2738 colonies were selected and confirmed to be specific binders 
to fibrinogen by phage ELISA. 
5.1.2 Phage ELISA 
The selected E.coli colonies were grown in 100µl of 2TY growth medium (bacto 
tryptone and yeast extract) also containing 100µg/ml carbenicillin, at 37oC and 
900rpm for 6 hours, after which a 25µl aliquot was added to 200µl of 2TY and 
carbenicillin as before. After an hour, 10µl of 1011/ml M13K07 helper phage and 
25µg/ml kanamycin were added and left overnight at 25oC and 450rpm. A 
streptavidin coated plate (Pierce) was blocked overnight with 2x casein blocking 
buffer (Sigma) and the plate was then incubated with biotinylated fibrinogen for 
1 hour, followed by another hour with 45µl of growth medium containing the 
phage.  After washing the wells extensively, the bound phage were detected by 
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the addition of a HRP-conjugate anti-phage antibody diluted 1:1000 (Seramun 
Diagnostica GmbH, Germany) for 1 hour and developed with 3,3’,5,5’-
Tetramthylnenzidine (Seramun) and OD measured at 610nm.  
5.1.3 Adhiron production 
The selected Adhirons were produced using the pET expression system, which 
produces large quantities of protein in a relatively short amount of time through 
manipulation of T7 RNA polymerase and the lac repressor protein. The DNA 
sequence encoding the protein of interest is cloned into a pET phagemid vector 
that contains a T7 promoter and lac operator at the 5’ end of the gene encoding 
the protein.  Transcription of the inserted gene only occurs in the presence of 
T7 RNA polymerase and therefore the vector needs to be transformed into a 
bacterial cell that has been engineered to contain the gene for this enzyme, 
usually E.coli strain BL (DE3). Transcription of T7 RNA polymerase within the 
host cell needs to be activated as the host RNA polymerase is blocked from 
binding to the gene by the presence of a lac promoter sequence which binds 
the lac repressor protein (Lacl). Lactose, or a structural mimic such as isopropyl 
β-D-1-thiogalactopyranoside (IPTG), will bind to Lacl and alter its conformation, 
to the extent that its affinity for DNA is greatly reduced, and thus the native 
E.coli RNA polymerase is no longer blocked and transcription of T7 RNA 
polymerase proceeds apace. This in turn causes transcription of the gene 
encoding the protein of interest within the phagemid vector (Figure 5-1).  
The technique employed by the BioTechnology Screening group involves the 
amplification of the DNA coding sequence of Adhirons by PCR and subsequent 
restriction digestion with NheI and PstI, followed by cloning into a pET11a 
phagemid. This vector, containing the target protein gene, was transformed, 
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using heat shock, in to BL21 (DE3) E.coli cells and finally induced by the 
addition of 0.1mM IPTG. The cells were grown for 6 hour in LB medium and 
then lysed using Bugbuster (Novagen). The expressed protein was purified 
using Ni-NTA resin slurry (Qiagen) as per the manufacturer’s instructions.  
 
Figure 5-1 Illustration of the pET expression system 
In the absence of IPTG, host RNA polymerase is unable to transcribe T7 RNA 
polymerase due to the presence of lac repressor protein (Lacl) within the lac 
promoter region. The process is activated by the addition of IPTG which binds 
to and alters the conformation of Lacl, reducing its affinity for DNA. 
Transcription of T7 RNA polymerase occurs followed by transcription of the 
target protein DNA within the pET vector.  
5.1.4 Turbidimetric analysis 
In order to study the effects of the selected Adhirons on clot formation, 
turbidimetric analysis was performed as described in Chapter 2 using both 
pooled plasma and purified fibrinogen. In order to incorporate the Adhirons, the 
protocol was altered slightly. For plasma experiments, 25µl of plasma 
(containing approximately 6 μM fibrinogen) was incubated with 25µl of Adhiron 
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(0.5mg/ml or 30µM) for 30 minutes before the addition of LM and AM. In a 
purified setting, 25µl of Adhiron (0.2mg/ml or 6µM) was added to fibrinogen 
(1mg/ml or 2.94 µM). These concentrations equated to a fibrinogen:Adhiron 
ratio of 1:5 in plasma and 1:2 in purified experiments. To study the effects of 
Adhirons on PI prolongation of lysis, commercial purified fibrinogen (2.94µM) 
was initially incubated with the relevant Adhiron (6µM) for 30 minutes followed 
by further incubation with either tris-buffered saline or, plasmin inhibitor 
(0.43µM). The lysis mix and activation mix were then added as previously and 
the absorbance at 390nm read every 12 seconds for 60 minutes.  
5.1.5 Laser scanning confocal microscopy 
Confocal microscopy was employed to analyse whether the Adhirons were 
affecting the structure of the fibrin network. Hydrated clots were prepared using 
either plasma or purified fibrinogen as described in Chapter 2. Adhirons were 
added to the clot by substituting 7.5µl of PB for the same volume of Adhiron at 
0.5mg/ml for plasma and 0.2mg/ml for purified experiments, maintaining the 
fibrinogen:Adhiron ratio used in the turbidimetric assays. Real time lysis of 
these clots was also performed as described previously. All clots were prepared 
and viewed in duplicate. 
In order to visualise Adhirons in the clots, we labelled these proteins using 
DyLight 488 Microscale Antibody Labelling Kit (Thermo Scientific), according to 
manufacturer’s protocol. Briefly, 8μl of borate buffer (0.67M) was added to 
100μl of Adhiron (1mg/ml) which was then added to the DyLight dye and 
incubated at room temperature and protected from light for 1 hour. Purification 
resin was added to a spin column and microcentrifgue collection tube (all 
provided) and spun at 1000g for 60 seconds to remove the storage solution. 
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The column was placed in a new collection tube and 108μl of the labelling 
reaction added to the column. The labelled Adhiron was collected following 60 
seconds in a centrifuge at 1000g.The Labelled Adhirons at 6μM were incubated 
with purified human fibrinogen from healthy controls (2.94μM) in the presence of 
0.105μM fluorescent labelled fibrinogen (Alexa FluorDye 594; Invitrogen) 
followed by the addition of an activation mix as above to form the clot and then 
transferring to an IBIDI slide to be viewed. Different confocal settings were used 
in order to visualise the two separate colours. The master gain was kept at 967 
for all images, detector gain at 1.02 and pinhole 92µm. The image was split into 
green (Adhiron) and red (fibrinogen) channels which were then superimposed 
onto each other to allow the fluorescence intensity from each pixel to be 
determined. 
5.1.6 Scanning electron microscopy 
Clots were prepared for viewing with a scanning electron microscope in a 
similar manner to that described in Chapter 2 and provided information over and 
above the confocal microscopy images on the effect of Adhirons on clot 
ultrastructure. In order to incorporate the Adhirons, 50µl of plasma was 
incubated with 50µl of Adhiron (0.5mg/ml) and 5µl of AM was added to 45µl of 
the plasma/Adhiron mixture. With purified clots, 50µl of control purified 
fibrinogen (1mg/ml) was incubated with 50µl Adhiron (0.1mg/ml). The 
fibrinogen:Adhiron ratio was thus maintained at 1:5 for plasma and 1:2 for 
purified experiments as per the turbidimetric assays. All clots were produced in 
duplicate. To determine the mean fibrin fibre diameter of each clot, 20 fibres 
were measured from at least 5 different areas of clot for each sample. 
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5.1.7 Enzyme Linked Immunosorbant Assay (ELISA) 
ELISA was initially used to confirm the ability of the Adhirons to bind to 
fibrinogen outside the phage system. A Nunc ELISA plate was coated overnight 
with 200µl of 1µg/ml of Adhiron. A scaffold only Adhiron was used as a control 
along with a well with no Adhiron. After washing, the wells were blocked with 
1% (w/v) BSA followed by the addition of 100µl of fibrinogen (1µg/ml; 
calbiochem) and incubated for 2 hours at room temperature. A goat polyclonal 
anti-fibrinogen HRP conjugated antibody (Dako Cytomatic, Cambridge, UK) was 
added following more washing and incubated for 1 hour at room temperature. 
HRP-conjugate antibody chromogenic substrate 1,2-phenylenediamine 
dihydrochloride (DaoCytomation, Dako) was added and the reaction was 
stopped by the addition of 1.5M H2SO4. The absorbance was measured at 
490nm using a plate reader. 
5.1.8 Western blot to demonstrate binding of Adhirons to different chains 
of fibrinogen 
Initially 25 g of purified, healthy pool fibrinogen was loaded onto the sample 
well of an 8% SDS-PAGE gel prepared using a prep/2-D well comb and the gel 
was run at 200V until good separation of the ladder (PageRuler Prestained 
Protein Ladder, 10 to 170 kDa, (Pierce, Biotechnology, Thermo Scientific, 
Loughborough,UK ). The gel was transferred onto nitrocellulose using a Trans-
Blot Turbo Transfer System (Bio-Rad Laboratories, UK) and a Trans-Blot Turbo 
Mini Nitrocellulose Transfer Pack (Bio-Rad) according to the manufacturer’s 
instructions. The membrane was then incubated overnight at 4°C in a blocking 
buffer of 1x Tris-buffered saline with 1% (v/v) Tween-20 (TBST) and 3% (w/v) 
non fat milk. 
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The Western blot was performed using a Mini PROTEAN II Multiscreen 
Apparatus (Bio-Rad). A two-fold serial dilution of the phage using blocking 
buffer was performed (1:37.5 to 1:2400) along with a control well with just 
blocking buffer and another control with no phage. The samples were loaded 
into the channels of the multiscreen apparatus and incubated for 1 hour at room 
temperature and then aspirated off and the channels washed 3 times with 
TBST, incubating for 15 min per wash. The antibody, Anti-Fd-Bacteriophage-
HRP (Seramun, Heidesee, Germany) was diluted 1:1000 in blocking buffer and 
600 l added per channel and incubated for 1 hour at room temperature 
followed by washing as before. The membrane was washed for a further 15 min 
in TBST and the blot was developed using Luminata Forte Western HRP 
Substrate (Merck Millipore, Germany). 
The western blot was performed by Anna Tang from the Bioscreening 
Technology group, University of Leeds. 
5.1.9 SPR 
Surface plasmon resonance was performed using a Biacore 3000 platform and 
data evaluated using BIAcore 3000 BIAevaluation 4.1 software (GE Healthcare, 
UK). For each Adhiron tested; 2000 RU of purified fibrinogen (Calbiochem) was 
immobilised directly onto a CM5 sensor chip (Fc2) by amine coupling according 
to the manufacturer’s instructions. Immobilisation of fibrinogen was performed 
using immobilisation buffer; 10mM Hepes, 140mM NaCl, 1.5mM CaCl2, 0.005% 
(v/v) surfactant P20, pH 7.4.  A blank reference surface (Fc1) was activated and 
deactivated using a 1:1 ratio of 0.4M EDC and 0.1M NHS at a flow rate of 
20µl/min for 7 minutes, followed by 7 min of 1M Ethanalomine pH 8.0 to block 
remaining active groups. Due to the high binding affinities of the Adhirons for 
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fibrinogen, complete regeneration of the fibrinogen surface was unsuccessful. 
Therefore, a Kinetic titration method was employed as described by Karlsson et 
al 2006255, which removes the need for regeneration. Adhirons of interest were 
reconstituted into SPR running buffer (50mM Tris, 100mM NaCl, 0.005% (v/v) 
surfactant P20, pH 7.4). A 2-fold serial dilution of each Adhiron: A2 (6-100nM) 
and G2, G4 (0.63-10nM) were injected sequentially in order of increasing 
concentrations over the fibrinogen surface. Each Adhiron was injected within a 
single binding cycle over a fresh fibrinogen surface each time. 2 cycles of 5x 
buffer injections were performed prior to the Adhiron binding cycle to generate 
‘blank’ responses for double referencing the Adhiron binding data.  The binding 
titration data was analysed using the double-referenced data in a 1:1 kinetic 
titration model as defined by Karlsson et al 2006. For each Adhiron; rate 
constants [ka (M
-1
 s
-1
) and kd (s
-1
)] and affinities [K
D
 (nM)] were obtained. 
Validity of the kinetic model fitting to the experimental data is given as χ2. 
All SPR experiments were performed by Dr. Kerrie Smith from the Leeds 
Institute for Genetics Health and Therapeutics, University of Leeds.  
5.1.10 Molecular modelling 
In an attempt to more accurately identify the site of Adhiron-fibrinogen 
interaction, predicted binding sites of the random peptide sequences 
constrained within the two loops of Adhirons of interest were generated using 
the website Pepsite2®, as described in Chapter 2. Images were viewed and 
produced using Pymol software. The potential binding regions were used to 
facilitate more rigorous docking of modelled 3D structures of the Adhirons using 
the automated docking suite AutoDock again as described in Chapter 2. 
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5.1.11 Statistical analysis 
Between group comparisons of normally distributed variables in the in-vitro 
studies were carried out using independent samples student t-test. 
Comparisons of non-normally distributed variables were carried out using 
Mann-Whitney U tests. Data are presented as mean±SEM unless otherwise 
stated 
  
 
 
147 
 
5.2 Results 
5.2.1 Fibrinogen binding Adhirons released by PI 
From the phage display screening, 48 phage colonies eluted from fibrinogen by 
the addition of excess PI were tested in an ELISA to confirm binding to 
fibrinogen. As can be seen in Figure 5-2, non-specific binding of the phage was 
observed and these phage colonies were discarded. It was not possible to 
sequence all 48 colonies due to financial constraints and so following the phage 
ELISA 24 high affinity fibrinogen-binding phage colonies, that were released by 
PI, were selected at random for sequencing (denoted by the red line below the 
well number in Figure 5-2). This identified 8 different Adhirons as detailed in 
Table 5-1, which were subsequently produced as individual proteins. Due to 
potential future patent considerations of the Adhirons only the first amino acid is 
indicated for each loop sequence. Experiments were designed to investigate the 
interaction between fibrinogen and these Adhirons, and their effects on clot 
structure and lysis time.  
5.2.1.1 Effect on clot lysis in plasma 
The ability of Adhirons to alter plasma clot lysis was assessed using 
turbidimetric assays. Time to 50% clot lysis was 780±25sec with 5 Adhirons 
increasing this by a mean of 727 sec (range 108-1512, Table 5-1). Two 
Adhirons (G4 and G6) resulted in a small reduction in clot lysis by 48 and 36 
secs, although these were not statistically significant (p>0.1), whereas G2 had 
no effect (LT 774±69 secs).  
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Figure 5-2. Fibrinogen binding Adhirons released by excess PI.  
Top image, phage ELISA results with absorbance of phage to biotinylated 
fibrinogen immobilised on streptavidin coated wells in grey and empty wells in 
black. 48 phage colonies were added to fibrinogen coated wells and to empty, 
control well, extensively washed and developed by the addition of a HRP 
conjugated anti-phage antibody. The red lines indicate which colony was 
chosen for sequencing. Bottom image, ELISA plate of the same phage ELISA 
with fibrinogen coated wells on the left and empty, controls, wells on the right. A 
failure to turn the reaction mixture blue in the fibrinogen coated wells indicated 
the phage was not binding to fibrinogen, and non-specific binding of the phage 
was demonstrated by blue in the control wells. 
5.2.2 More detailed study of Adhirons 
Given the time constraint, detailed analysis of these Adhirons was carried out in 
only a subset. I chose this subset according to: i) sequence homology with PI 
and, ii) effects on plasma clot lysis.  
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None of the Adhirons described above shared sequence homology with PI, 
suggesting that interaction sites are conformational. Therefore, I decided to test 
one Adhiron that prolonged LT, one that reduced LT and one that had little or no 
effect. Previous work has shown that as little as 6% change in clot lysis time 
may be important clinically256 and therefore a cut off of 5% change in clot lysis 
time by any of the 8 Adhirons was regarded as significant. All 5 Adhirons that 
increased clot lysis did so by more than 5%, with the percentage increase in 
prolongation ranging between 14-194%; (Table 5-1). Only one Adhiron (G4) 
decreased plasma clot lysis by more than 5%, 48±62seconds (6%), and so two 
Adhirons (G2 and G6) essentially had no effect. 
Adhiron Loop 1 Loop 2 Mean LT (secs) Percentage difference in LT 
compared to scaffold 
Scaffold - - 780±50 - 
A2 I******** Y******** 1056±223 35 
B3 L******** W******** 1608±506 106 
F1 Y******** K******** 888±183 14 
F2 W******** W******** 2292±552 194 
F5 T******** R******** 1690±338 117 
G2 Q******** P******** 774±138 -1 
G4 S******** Y******** 732±105 -6 
G6 W******** W******** 744±156 -5 
Table 5-1 The 8 Adhirons identified and lysis times of Adhirons following 
addition to pooled, healthy plasma.  
Due to potential future patent considerations, only the first amino acid is 
indicated for each loop sequence 
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 Figure 5-3 Clot lysis parameters of clots formed with Adhirons as 
measured by turbidimetric assay 
Turbidity and lysis curves of Adhirons in plasma (A) along with the LT 
(mean±SEM) of Adhirons in plasma (B). Control plasma was pre-incubated with 
Adhirons followed by the addition of a lysis mix containing tPA and an activation 
mix containing thrombin and CaCl2. A total of 3 independent experiments were 
performed in duplicate .*p<0.05 
Of the five Adhirons that prolonged LT in plasma, it was decided to study A2 in 
more detail given that it had a clear effect on LT without being as extreme as 
Adhirons B3, F2 and F5. Only Adhiron G4 resulted in a reduction in lysis time 
greater than 5% and was therefore chosen alongside Adhiron G2 to act as a 
control Adhiron. 
The effects of the presence of Adhirons on plasma clot lysis was further tested 
using confocal microscopy to i) confirm the turbidimetric findings, ii) visualise 
clot lysis in real time and iii) investigate whether the Adhirons have similar 
effects on fully mature clots. Moreover, confocal microscopy was useful to 
provide preliminary data on Adhiron-induced changes in clot structure. 
Serial photographs of the lysis front were observed and lysis time in the 
presence of scaffold only Adhiron was 463±48 sec. Adhiron G2 had no effect on 
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fibrinolysis (lysis time 453±46, p=0.67), while A2 showed a trend toward 
prolongation of LT (600±109 secs p=0.06) in agreement with the turbidimetric 
analysis. In contrast, Adhiron G4 reduced the lysis time but the effect was much 
more dramatic than that observed with turbidimetric analysis, reducing LT to 
308±101sec (p<0.05, Figure 5-4). The effects of Adhirons on LT using 
turbidimetric assays (during clot formation) and confocal microscopy (of fully 
mature clots) are shown in Table 5-2. 
 
Adhiron Difference in LT compared 
to scaffold from plasma 
turbidimetric assay (%) 
Difference in LT compared to 
scaffold from real time lysis of 
plasma confocal clots (%) 
G2 -1 -2 
G4 -6 -33 
A2 35 30 
Table 5-2 The effects of Adhirons G2, G4 and A2 on LT in turbidimetric 
assay and real time lysis of mature plasma clots. 
5.2.2.1 The effects of selected Adhirons on clot lysis in a purified system 
To understand the effects of Adhirons on PI-induced prolongation of clot lysis 
time, I used purified proteins (fibrinogen, PI and Adhirons). All samples were 
supplemented with FXIII to ensure crosslinking of PI into the fibrin network. 
In the absence of PI, LT following the addition of an empty scaffold protein to 
fibrinogen was 606±82 sec. The addition of Adhiron A2 prolonged LT to 993±85 
sec (p<0.05), whereas Adhirons G2 and G4 had no significant effect at 708±51 
and 672±34 sec, respectively (p>0.1 for both).  
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Figure 5-4. The effect of Adhirons G2, G4 and A2 along with scaffold 
Adhiron on real time lysis of plasma clots 
(A) LSCM images of the real time lysis of plasma clots in the presence of G2, 
G4, A2 and scaffold indicating the increased and decreased LT caused by G4 
and A2 respectively, shown graphically (mean LT±SEM) in (B). Clots were 
prepared by incubating control plasma with Adhiron and 488 Alexa labelled 
fibrinogen followed by the addition of thrombin and CaCl2. The LT represents 
the time taken for a lysis mixture containing tPA and plasminogen to completely 
dissolve the clot within the viewing field. Experiments were performed in 
duplicate on 3 separate occasions. 
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In the presence of PI, LT was prolonged to 1440±273 sec, which was further 
increased to 1880±300 sec (p<0.05) following the addition of Adhiron A2, 
indicating an additive effect of PI and A2 on clot lysis. In contrast, G4 inhibited 
the effect of PI on LT, which was reduced from 1440±273 to 940±175 sec 
(p<0.05). Finally, G2 had no significant effect on PI-mediated prolongation of 
clot lysis (1188±303 sec p=0.16). The results can be seen in Figure 5-5 
 
Figure 5-5 The effect of Adhirons on LT in the presence of PI in a purified 
system 
Adhiron G4 significantly reduces PI prolongation of lysis, with a significant 
increase observed with A2. No difference was noted in LT with the addition of 
G2. Purified fibrinogen was pre-incubated with Adhiron followed by addition of 
either Tris buffered saline or PI. A total of 3 independent experiments were 
performed in duplicate. *p<0.05,** p<0.005.  
5.2.2.2 The effects of Adhirons on clot structure  
Given the effects of Adhirons on fibrinolysis, I further studied the effects of these 
peptides on fibrin network structure. This was performed using turbidimetric 
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analysis, scanning electron microscopy and confocal microscopy of clots 
prepared from plasma samples or purified fibrinogen. 
Plasma samples 
In a plasma system and in the presence of the scaffold only Adhiron, FT was 
0.228±0.007. Higher final turbidity was noted following incubation with Adhiron 
G2 (0.246±0.013), G4 (0.250±0.005) and A2 (0.322±0.006, p<0.05 for all). 
Given that plasma clot final turbidity represents both fibre thickness and clot 
density, I further analysed clot ultrastructure using scanning electron 
microscopy. Control plasma clots, with the scaffold Adhiron added, had an 
average fibrin fibre diameter of 106.8±22.1 nm. Fibre thickness was not affected 
by the addition of G2 (109.3.4±23nm; p=0.39), whereas G4 resulted in 
increased fibre diameter (124.6±24.9nm; p<0.05). The reverse was observed in 
the presence of Adhiron A2 with fibre diameter decreasing to 95.3±22.7nm 
(p<0.05). The 3-dimensional structure of plasma clots prepared with the 
Adhirons was analysed by preparing z-stack images using the LSCM. The 
addition of Adhirons G2 and G4 both appeared to affect the structure of the clot 
in the same way which is unusual given the differences observed with the SEM 
clots. The structures appear less dense with increased porosity. The addition of 
A2 produces even more changes to the architecture of the fibrin network, again 
with increased pores compared to control clots, but in the areas where fibrin 
bundles have formed these appear thicker. These results are summarised in 
Figure 5-6. 
Purified systems 
To further understand the direct role of Adhirons on clot structure, I performed 
purified experiments to eliminate the potential influence of various plasma 
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proteins. Using the conditions described above for purified experiments, FT with 
scaffold Adhiron alone was 0.147±0.02 which was similar in the presence of G2. 
(0.1548±0.04, p=0.89). The numerical difference with G4 failed to reach 
statistical significance (0.1823±0.04, p=0.26), whereas Adhiron A2 caused a 
significant increase in FT to 0.2405±0.02 (p<0.01).  
Scanning electron microscopy showed that fibre diameter with the scaffold 
Adhiron was 85.9±22.5nm, which did not change in the presence of G2 
(80.7±17.1nm p=0.16) or G4 (82.3±18.3nm p=0.37). In contrast, Adhiron A2 
produced clots with significantly thinner fibrin fibres at 72.6±17.5 p<0.001).  
 
The z-stack images of the purified clots can be seen in Figure 5-7. The clots 
containing Adhirons G2 and G4 have a structure that is more similar to the 
control clots and is more in keeping with the EM data. Adhiron A2 again 
produces a clot with increased pores and fewer fibrin bundles compared to 
control.  
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Figure 5-6. LSCM and EM images of plasma clots prepared with Adhirons 
G2, G4 and A2. 
(A) LSCM z-stack images of plasma clots and (B) EM images of plasma clots all 
produced following addition of scaffold, G2, G4 and A2 to control plasma. Clots 
made with G4 had significantly thicker fibrin fibres compared with scaffold 
Adhiron, whereas A2 produced thinner fibres (C) with a pronounced effect on 
clot structure. The final turbidity (mean±SEM) of the plasma clots from the 
turbidimetric assays are shown in (D). 20 fibres were measured from different 
areas of at least 5 different EM images of each Adhiron. *p<0.05.  
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Figure 5-7. LSCM and EM images of clots prepared from purified 
fibrinogen with Adhirons G2, G4 and A2. 
(A) LSCM, z-stack images of purified clots and (B) EM images of purified clots 
generated by the addition of scaffold, G2, G4 and A2 to purified fibrinogen. 
There was no difference in mean (±SEM) fibre diameter between scaffold, G2 
or G4 but A2 again produced thinner fibres (C) and altered fibrin network 
architecture on LSCM images. The final turbidity (mean±SEM) of the purified 
clots from the turbidimetric assays are shown in (D). 20 fibres were measured 
from different areas of at least 5 different EM images of each Adhiron and the. 
*p<0.05.  
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5.2.2.3 Incorporation of Adhirons into the clot 
Given that Adhirons resulted in a change in clot structure, it was decided to 
investigate whether Adhirons are directly incorporated into the clot or simply 
exert their effect through interference with clot formation.  
 
 
Figure 5-8 LSCM images of dual labelled clots with pixel intensity 
(A) Images of clots viewed by laser scanning confocal microscopy which were 
prepared using Scaffold Adhiron and Adhirons G2, G4 and A2 (6μM) labeled 
green and fibrinogen (2.94 µM) labeled red. Top left clockwise, Scaffold, G2, 
G4, A2. The bottom images represents the overlay of red and green pixels, 
increased yellow intensity represents increased Adhiron incorporation. (B) 
Mean±SEM pixel intensities of clots seen in A. *p<0.05.  
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By fluorescent labelling of fibrinogen (red) and Adhirons (green), it was possible 
to determine the degree of incorporation of the Adhirons into the fibrin clot using 
laser confocal microscopy. Clots prepared using in house labelled scaffold 
showed no significant incorporation into the fibrin clot, with similar findings 
mean pixel intensities observed with Adhirons G2 and G4 (pixel intensity 
30.3±3.7, 33.4±1.1 and 32.2±1.8, respectively; p>0.1 compared with scaffold 
only). In contrast, Adhiron A2 showed significantly increased incorporation into 
the fibrin network with an increase in mean pixel intensity to 42.5±2.8 (p<0.05). 
5.2.3 Fibrinogen-Adhiron interaction  
5.2.3.1 Enzyme Linked Immunosorbant Assay (ELISA) 
ELISA was initially used to confirm the ability of the Adhirons to bind to 
fibrinogen outside the phage system. All 3 Adhirons showed significant binding 
to fibrinogen with A2 producing the highest OD at 490nm (Figure 5-9). The OD 
for scaffold, G2, G4 and A2, were 0.037±0.014, 0.22±0.04 (p<0.05), 0.25±0.06 
(p<0.05) and 0.74±0.17 (p<0.05), demonstrating that the purified Adhirons were 
capable of binding to immobilised fibrinogen. 
5.2.3.2 Surface Plasmon Resonance (SPR) 
Although ELISA showed binding between fibrinogen and selected Adhirons, the 
system is not accurate to analyse binding affinities. Therefore, we employed 
SPR and demonstrated high-affinity binding of Adhirons, G2, G4 and A2 to 
immobilised fibrinogen, which was concentration dependant. The binding 
affinities were all in the nanomolar range with KD of 13.8nM, 1.1nM and 1.85nM 
for A2, G2 and G4 respectively (Figure 5-9). 
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Figure 5-9 Binding of Adhirons G2, G4 and A2 to fibrinogen demonstrated 
by ELISA and SPR 
(A) Binding of immobilised Adhirons , G2 G4 and A2 to human fibrinogen using 
enzyme linked immunosorbant assay (ELISA), captured by HRP conjugated 
polyconal goat anti-human anti-fibrinogen antibody. (B) Surface plasmon 
resonance (SPR) using a kinetic titration assay of Adhiron G4 binding to 
fibrinogen. The blue line represents the experimental data, the black line 
represents the kinetic titration fitting to a simple 1:1 interaction model. Adhiron 
A2 and G2 were treated using the same methodology. SPR rate constants and 
binding affinities (C) of Adhirons A2, G2 and G4 
5.2.3.3 Western Blot  
In order to establish which fibrinogen chain is the main binding site for the 
selected Adhirons, a Western Blot was performed. Adhiron G2 showed binding 
to a band corresponding to the 48 kDa γ chain of fibrinogen. Adhirons A2 and 
G4 produced similar bands corresponding to the fibrinogen 66kDa α chain 
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(Figure 5-10). Probing a phage expressing a non-fibrinogen binding Adhiron 
indicated that the phage itself was not involved in binding. 
 
Figure 5-10 Immunoblotting of phage Adhirons to fibrinogen chains 
Western blot of phage Adhirons against fibrinogen illustrating Adhirons G4 and 
A2 binding to the α chain (66kDa) as indicated by the top arrow (lanes 1 and 2) 
and Adhiron G2 binding to the γ chain (48kDa) as indicated by the bottom arrow 
(lane 3). Lane 4 non-fibrinogen binding Adhiron. 
5.2.3.4 Predicted binding of Adhirons to fibrinogen 
Following the western blot results and due to the large size of fibrinogen, it was 
decided to focus on binding hotspots of loops 1 and 2 of Adhirons G4 and A2 
located on the α chain of fibrinogen using the Pepsite2. This identified the 
central E region of the α chain of fibrinogen to be the most likely area that the 
Adhirons were binding (Figure 5-11). These results were used to focus the 
AutoDock docking runs.  
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Figure 5-11 Predicted binding sites of Adhirons G4 and A2 to the α chain 
of fibrinogen 
Red dashed lines indicate magnified image of G4 binding sites and blue dashed 
lines indicate magnified image of A2 binding sites. Yellow spheres are loop1 
amino acids on G4, whilst cyan spheres are loop2. Red spheres are loop 1 
amino acids on A2 and blue spheres loop 2.  
Homology models of Adhiron G4 and A2 were produced using the 
SWISSMODEL257 server based on the published Adhiron crystal structure (PDB 
code 4N6T). The predicted structure of loops 1 and 2 for each Adhiron were 
then docked to the central E region of the α chain of fibrinogen using the 
automated docking suite AutoDock239. For the docking calculations, the loop 
backbone was fixed and the amino acid side chains were allowed to be flexible.  
As illustrated in Figure 5-12, both G4 and A2 were predicted to bind within the 
central E region of fibrinogen, in close proximity to each other and in the same 
regions as predicted by Pepsite2.  
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Figure 5-12 Predicted docking of Adhirons G4 and A2 to the α chain of 
fibrinogen.  
Red dashed lines indicate magnified image of G4 binding sites and blue dashed 
lines indicate magnified image of A2 binding sites. Yellow sticks are loop1 
amino acids on G4, whilst cyan sticks are loop2.  Red sticks are loop 1 amino 
acids on A2 and blue sticks loop 2. 
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5.3 Discussion 
This Chapter describes a novel technique to manipulate fibrin clot lysis using 
small conformational artificial peptides. The scale and quality of the Adhiron 
phage library permits rapid and reliable screening of a target protein with a large 
number of potential binding sequences of amino acids. This initial screening 
identified several Adhirons that bind to fibrinogen and are displaced by PI, and 
which are able to alter fibrin clot properties and fibrinolytic efficiency.  
Of the 8 different Adhirons identified, I chose 3 Adhirons to investigate in more 
detail. The chosen Adhirons prolonged, reduced or had no effect on clot lysis 
time. Adhiron G4 was able to significantly enhance lysis of clots made from 
plasma or purified proteins in the presence of PI. Interestingly, the effect of 
Adhiron G4 on fibrin clot lysis was far more impressive when studied in fully 
mature clots (i.e. confocal microscopy) than during clot formation (i.e. 
turbidimetric assays). This is perhaps not surprising as PI incorporation into the 
clot during clot formation is limited due to the nature of the technique, whereas 
lysis conducted on mature clots allows more time for incorporation of PI into the 
clot allowing the “blocking effects” of G4 to become more obvious.  
Western blot analysis confirmed that Adhiron G4 interacts with the α-chain of 
fibrinogen and molecular modelling predicts that G4-fibrinogen interaction 
occurs at the central E-domain. Factor XIII induced cross linking of PI to 
fibrinogen is known to occur at Lys303 within the αC domain of the α-chain. 
This flexible αC domain, containing Lys303, has not been successfully 
crystallised to date and so was not available for further interrogation using 
Pepsite2. Given that the α-chain contains over 600 residues and the C-terminus 
binds to the β-chain within the central E domain it may be difficult to explain the 
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PI-inhibitory effects of G4. A possible explanation is that as the αC domain 
flexes back from the D region towards the E region, the change in conformation 
brings Lys303 in closer proximity to the E domain than its sequence suggests.  
Although Adhiron G4 showed high binding affinity to fibrinogen, it failed to show 
significant incorporation into the clot. This may be related to the methodology 
used as fluorescent labelling of Adhiron G4 may have affected its ability to be 
incorporated into the clot. This, however, is unlikely given the successful 
incorporation of A2 into the clot (detailed below). Despite the failure to detect 
G4 in the clots, this Adhiron was still able to affect clot structure, resulting in the 
formation of thicker fibres, confirmed by scanning electron microscopy. There 
are two explanations for the discrepancy between the absence of G4 
incorporation into the clot and an effect on structure. First, it is possible that the 
sensitivity of confocal microscopy was too low to detect low level of Adhiron 
incorporation. Second, Adhiron G4 may enhance lateral aggregation during 
fibrin clot formation, without incorporation into clots, through a mechanism that 
remains unclear but may involve interference with αC domain tethering to the E 
region or fibrinopeptide A and B release. This is supported by the molecular 
modelling results, predicting the binding of the three-dimensional structure of 
the two loops of G4 to the E region of the α chain. Given that PI is cross linked 
to the Lys303, it is likely that these effects are independent of PI and lysis is 
enhanced due to the generation of thicker fibrin fibres, which is known to 
facilitate plasmin activity.  
The main aim of this Chapter was to validate the use of a phage display library 
to identify Adhirons capable of interfering with PI-fibrinogen interaction, prior to 
its use with C3. With this in mind it was envisaged that the Adhirons identified 
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would facilitate clot lysis, however, a number of Adhirons that prolonged clot 
lysis were also isolated, one of which was further studied in detail. Adhiron A2 
acted in a similar manner to PI both in plasma and purified systems and showed 
high binding affinity to fibrinogen. Confocal microscopy demonstrated significant 
incorporation of Adhiron A2 into the clot, which was associated with structural 
changes in the fibrin network. The presence of Adhiron A2 resulted in the 
formation of clots with thinner fibres and denser structure, contributing to 
resistance of these clots to lysis258. Interestingly, FT of both purified and plasma 
clots was higher in the presence of Adhiron A2, consistent with the formation of 
thicker fibrin fibres. However, EM showed that the opposite is the case with 
Adhiron A2 resulting in the formation of compact clots with thinner fibres. This 
highlights an important deficiency of the turbidimetric assay and demonstrates 
that multiple techniques are necessary to properly study fibrin network structure. 
Molecular modelling predicted that the three-dimensional structures of the two 
loops in A2 may also bind to the E region within the α chain of fibrinogen, 
relatively close to the predicted binding sites of G4 loops. This may be difficult 
to explain given the different effects of both Adhirons on clot formation and lysis. 
If A2 is binding in this region, one explanation may be that it is having the 
opposite effect to that of G4 in terms of fibrinopeptide A and B release and αC 
disengagement, thus reducing lateral aggregation of protofibrils and forming a 
clot composed of thinner fibrin fibres that is more resistant to lysis. Another 
possibility is that the presence of A2 within the fibrin structure directly affects the 
plasmin degradation of fibrin fibres.   
Both Adhiron G4 and A2, modulating clot lysis, showed binding to the α-chain of 
fibrinogen, which is established to be important for interaction with other 
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proteins. In contrast, Adhiron G2, which had no significant effect on clot 
structure or lysis, demonstrated binding to the γ-chain of fibrinogen. One 
criticism that may be directed at this finding is the absence of interaction sites 
between PI and the γ-chain of fibrinogen, questioning the release of Adhiron G2 
by PI. This may be due to the presence of PI interaction sites on the γ-chain of 
fibrinogen, which have not been described before. However, this is unlikely and 
the more plausible explanation is related to “spatial displacement” of the 
Adhiron by PI, which can occur despite different binding areas on the fibrinogen 
molecule. Further work is required to accurately identify interaction sites 
between relevant Adhirons and fibrinogen. Given the likely conformational 
nature of the interactions, linear peptide studies will not be useful and site 
directed mutagenesis offers a tool to pinpoint binding sites, which will lead to 
identification of novel therapeutic targets.  
The identification of the Adhirons that bind fibrinogen and are released by 
excess PI certainly validates the use of the phage library to target the fibrin 
structure in an attempt to modulate clot formation and lysis. Not only was one 
capable of reducing the anti-fibrinolytic actions of PI, as was the intention at the 
outset, but an Adhiron that appeared to have an agonistic effect on PI was also 
discovered. These Adhiron sequences may be used to generate constrained 
peptides capable of interfering with fibrinogen-PI interaction and ultimately small 
molecules for use therapeutically to both facilitate clot lysis, as in CVD, and 
inhibit fibrinolysis in individuals with bleeding disorders or following major 
trauma. An analogue of another fibrinolytic inhibitor, PAI-1, which has been 
modified to have an extended half life, has been trialled as a topical therapy to 
minimise bleeding40 and this may be a potential use of Adhirons such as A2. 
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The results are encouraging and provide sufficient evidence to justify the use of 
the same phage library to screen for binders to fibrinogen that are released by 
C3 and also binders to C3, released by excess fibrinogen. 
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Chapter 6  
Interference with C3-fibrinogen interactions as a novel 
methodology to modulate clot lysis 
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Introduction 
The previous chapter was largely aimed at assessing the validity of a phage 
display library as a method of identifying fibrinogen-specific Adhirons that can 
modulate clot formation, structure and lysis. The discovery of several Adhirons 
that interfere with dynamic clot turbidity experiments certainly emphasise the 
potential use of this technique. Given the lysis prolongation that occurs with C3, 
and its exaggeration in diabetes samples, it was hoped that Adhirons can be 
identified that act at fibrinogen-C3 interaction sites and form the basis of future 
novel, diabetes specific, therapeutic agents for use in CVD.  
Agents that inhibit different components of the complement system have been 
trialled in CVD with limited success. A C5 monoclonal antibody, pexelizumab, 
has been used following myocardial infarction (MI) and coronary artery bypass 
grafting with inconsistent reductions in mortality and major cardiac events216-218. 
Inhibition of the C1 esterase enzyme appears to reduce myocardial reperfusion 
injury but this has not been translated into improved mortality outcomes post 
MI219;221. It is intuitive that the complement and coagulation pathways are so 
closely linked for example following vascular injury, localising components such 
as C3 to the site of injury thus preventing external pathogens from entering the 
blood stream259;260. This cross-communication can also have deleterious effects 
in other circumstances, such as the prolongation of clot lysis mediated by the 
presence of C3 within the clot. Specific targeting of these effects, rather than 
systemic, non-specific inhibition of complement proteins, may prove 
increasingly beneficial. 
In the previous Chapter, I have shown that Adhirons can be used to modulate 
PI-induced prolongation of clot lysis. In this Chapter, I attempt to interfere with 
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C3-mediated prolongation of fibrinolysis using Adhirons. I try to further refine the 
technique by implementing a dual approach to investigate i) fibrinogen-binding 
Adhirons that are released by excess C3 and ii) C3 binding Adhirons that are 
released by excess fibrinogen. Identifying C3-specific fibrinogen binding 
Adhirons may help to block C3 binding to fibrinogen, and hence abolish the 
effect of this protein on clot lysis. On the other hand, isolating fibrinogen-specific 
C3-binding Adhirons may offer a tool to absorb out C3 and prevent the protein 
from binding to fibrinogen.   
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6.1 Methods 
6.1.1 Adhiron identification 
The Adhiron phage library was screened against biotinylated fibrinogen as 
discussed in Chapter 2, and after three rounds of panning the bound phage 
were eluted by addition of C3 (0.5mg/ml) to identify phage binding at the 
fibrinogen-C3 interaction site. The screening was also performed in reverse, by 
incubating the phage library with biotinylated C3 and eluting bound phage with 
excess fibrinogen (1mg/ml) following the first three rounds of panning.   
6.1.2 Adhiron production 
The selected Adhirons were produced as described in Chapter 5. 
6.1.3 Turbidimetric analysis 
Turbidimetric analysis was used as a high throughput assay to investigate the 
role of Adhirons on plasma clot lysis. These were performed as described in 
Chapter 2 and also in Chapter 5 following the addition of Adhirons to plasma 
and fibrinogen. To investigate the effects of the Adhirons released from 
fibrinogen by excess C3 on prolongation of lysis, human C3 (1.34µM) was 
added to fibrinogen that had been pre-incubated with the Adhiron of interest as 
described for PI in Chapter 5. 
6.1.4 Laser scanning confocal microscopy 
This technique was used to investigate lysis of mature clots in real time and to 
study major differences in the structure of hydrated clots. Fibrin networks were 
prepared as described in Chapter 2, using the same microscope settings. The 
addition of Adhirons to plasma and purified clots was performed as described in 
Chapter 5. 
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6.1.5 Scanning electron microscopy 
To analyse the effects of Adhirons on the ultrastructure of fibrin networks, clots 
were viewed under an EM after preparation as described in Chapters 4 and 5. 
6.1.6 Molecular modelling 
Predicted binding sites of the random peptide sequences constrained within the 
two loops of Adhirons of interest were generated using the website pepsite2®, 
as described in Chapter 2. Images were viewed and produced using Pymol 
software.  
6.1.7 Statistical analysis 
Between group comparisons of normally distributed variables in the in-vitro 
studies were carried out using independent samples student t-test. 
Comparisons of non-normally distributed variables were carried out using 
Mann-Whitney U tests. Data are presented as mean±SEM unless otherwise 
stated 
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6.2 Results 
6.2.1 Fibrinogen binding Adhirons released by C3 
The Adhiron library was screened against immobilised fibrinogen in the same 
manner as section 6.3.2, but in order to identify Adhirons that may be binding at 
fibrin-C3 interaction sites, excess C3 was added to elute the bound phage from 
fibrinogen. In total 16 different colonies were selected to be sequenced (as in 
section 5.2.1), revealing 8 different sequences that were available for analysis 
(Table 6-1). 
Adhiron Loop 1 Loop 2 
A2 Y******** K******** 
A5 Y******** ******** 
A6 M******** H******** 
C1 D******** Y******** 
C2 V******** K******** 
C6 K******** K******** 
D2 Y******** Q******** 
F5 I******** K******** 
G2* G******** H******** 
G6 Y******** Q******** 
Table 6-1 Fibrinogen binding Adhirons that were released by excess C3 
Due to potential patent considerations only the first amino acid for each loop 
sequence is indicated 
6.2.1.1 Effect on clot formation and lysis 
Plasma experiments: In this set of experiments, time to 50% clot lysis was 
564±24sec following the addition of the scaffold Adhiron to pooled control 
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plasma. Two Adhirons had striking effects on clot formation and lysis (Figure 
6-1). Adhiron G2* (to differentiate from Adhiron G2 that was released by the 
addition of PI in Chapter 5 will be presented as G2*) markedly reduced the lag 
phase and the clot produced was not lysed during the 2 hours, remaining at its 
maximum absorbance. Adhiron C2 also produced unusual results in that there 
was no change in the absorbance in this well, suggesting that either no clot was 
formed or that lateral aggregation was inhibited, thus preventing the exponential 
rise in absorbance typically observed. Of the remaining 6 Adhirons, their effects 
on LT were more subtle, with Adhirons A2, A5, A6 and G6 increasing LT to 
664±29sec, 858±68sec, 646±25sec and 656±24sec respectively (p<0.05 for 
all). Three Adhirons had little effect on clot lysis (C6 550±31sec, D2 602±15sec, 
F5 635±24sec, p>0.1 for all compared with scaffold only Adhiron, (Figure 6-1).  
 
In purified experiments the effects of this group of Adhirons were less dramatic, 
indicating possible interactions with plasma proteins. The control clots 
(fibrinogen and scaffold protein) produced LT of 390±8sec which was not 
significantly altered by the addition of Adhirons A2, A6, C6, D2 and G6 (LT 
380±32sec, 354±24sec, 362±20sec, 358±26sec, 366±35sec respectively). 
Adhirons A5 and F5 significantly reduced LT to 306±19sec and 306±16sec 
respectively (p<0.05 for both). Both C2 and G2* formed clots in these 
experiments and these were fully lysed within the allotted time but with 
significantly increased LT of 805±105sec and 1311±171sec respectively 
(p<0.05 for both).  
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Figure 6-1 Clot lysis parameters of plasma clots formed with fibrinogen 
binding Adhirons (released by C3) as measured by turbidimetric assay 
Turbidity and lysis curves of fibrinogen binding Adhirons, released by C3, in 
plasma (A) and the LT (mean±SEM) of these Adhirons in plasma (B). Control 
plasma was pre-incubated with Adhirons followed by the addition of a lysis mix 
containing tPA and an activation mix containing thrombin and CaCl2. A total of 3 
independent experiments were performed in duplicate .*p<0.05. 
6.2.2 Selection of Adhirons for further analysis 
Similarly to the experiments with PI-related Adhirons, I chose 3 Adhirons to 
study in detail based on i) sequence homology with C3, ii) an effect on clot lysis. 
Adhiron A6 was chosen as loop 2 shared a sequence homology with a spatially 
exposed portion of C3, whereas, Adhiron G2* consistently produced a drastic 
effect on clot formation and prevented fibrinolysis within the allocated time. A 
third Adhiron, C6, was chosen due to its negligible effect on clot lysis to act as a 
control alongside the scaffold Adhiron. 
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6.2.3 Adhiron A6 
As mentioned, the sequence of amino acids within loop 2 of Adhiron A6 shared 
a sequence homology with residues 38-47 of C3 (Figure 6-2). It was tempting to 
hypothesise therefore that this portion of C3 may be involved in fibrin-C3 
interaction and thus A6 warranted further study.  
 
Figure 6-2. Sequence homology between Adhiron A6 and complement C3 
Loop 2 of Adhiron A6 that shares a sequence homology with a portion of C3 (A) 
and the position of this portion of C3 within the crystal structure (B) 
6.2.3.1 The effect of A6 on C3 mediated lysis prolongation 
Experiments were designed to study the effect of A6 on LT in a purified setting 
using purified commercial fibrinogen (Calbiochem), in the presence and 
absence of C3. In the absence of A6, C3 prolonged LT from 644±13secs to 
728±25 secs. By pre-incubating A6 with fibrinogen, before the addition of C3 to 
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the mixture, it was possible to completely abolish the prolongation of LT 
observed with C3 alone, LT 632±24 secs (p<0.05, Figure 6-3). 
 
Figure 6-3 Effect of A6 on LT in the presence and absence of C3 
Pre-incubation of A6 with fibrinogen prior to adding C3 to the mixture abolishes 
C3 induced prolongation of lysis. Purified fibrinogen was pre-incubated with A6 
or C3 and in a separate experiment followed by addition of either Tris buffered 
saline or C3 to fibrinogen-A6 mixture .Experiments were performed in duplicate 
on 3 separate occasions and results expressed as mean±SEM. 
6.2.3.2 Effect on clot formation and lysis  
As described previously, A6 actually caused a prolongation of LT in plasma 
which is unexpected given its performance in reducing C3 mediated 
prolongation of lysis. If A6 is binding to fibrinogen at a relevant site of interaction 
between fibrinogen and C3 then it may be expected to see a reduction in LT 
with the addition of A6. 
As described in Chapter 3, there is a wide inter-individual variability in the 
prolongation of lysis following addition of C3, which may relate to the degree of 
C3 incorporation into the clot and to the presence of glycation. Given that 
pooled healthy plasma was used in the initial turbidimetric screening assays, I 
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conducted further experiments using individual plasma samples in the presence 
and absence of Adhiron A6, (6 non-diabetes, 6 diabetes patients and a pool of 
both). Of the 14samples, 11 had a significant increase in LT, with 2 only of the 
diabetes patients producing a reduction in LT (Figure 6-4). Analysing the two 
groups separately (diabetes and non-diabetes), the non-diabetes group had a 
significant increase in LT following addition of A6 (529±16secs vs 612±36secs, 
p<0.05) with very little difference observed with the diabetes group (663±49secs 
vs 685±57secs, p>0.5). 
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Figure 6-4 Effect of Adhiron A6 on LT in individual samples 
The percentage difference in LT (A) following the addition of A6 to individual 
plasma samples (6 diabetes and 1 pooled sample along with 6 non-diabetes 
and 1 pooled sample). (B) The mean (±SEM) LT for the diabetes group (top) 
and non-diabetes group (bottom) with and without A6.   
6.2.3.3 Effect of A6 on clot structure  
There was no difference in the appearance of plasma clots prepared for LSCM 
with the addition of scaffold, Adhiron A6 or C6 (Figure 6-5). The mean fibrin 
fibre thickness was also similar between the 3 groups (106.8±2.2nm, 
104.9±2.2nm and 109.2±2.2nm p>0.05).  
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Figure 6-5. LSCM and EM images of plasma clots prepared with Adhirons 
A6 and C6 with EM fibre thickness. 
(A) LSCM images of plasma clots and (B) EM images of plasma clots, all 
prepared by the addition of scaffold, A6 and C6 to control plasma. There was no 
difference in mean (±SEM) fibre diameter between the 3 different clots (C). 20 
fibres were measured from different areas of at least 5 different EM images of 
each Adhiron. *p<0.05.  
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In purified experiments, there was again no observed difference between LSCM 
clots with the addition of scaffold, A6 or C6 (Figure 6-6). Mean fibrin fibre 
diameter measured from EM clots following the addition of scaffold was 
85.9±2nm as mentioned previously and this was also not affected by the 
addition of A6 or C6, 86.6±1.6nm and 85.3±1.5nm respectively (p>0.5 for both). 
The lack of effect of Adhiron A6 on fibrin network architecture in both plasma 
and purified experiments suggests that its effect in turbidimetric studies are 
related to the interaction between the fibrin-A6 complex and surrounding 
proteins such as C3.  
6.2.3.4 Predicted binding of A6 to fibrinogen 
Following the results of the microarray screening of C3 and fibrinogen indicating 
that C3 is likely to bind to portions of the β chain of fibrinogen (as discussed in 
Chapter 4), the sequences for the two random loops of A6 were individually 
entered into the Pepsite2 website to predict where A6 might be binding to the β 
chain of fibrinogen (PDB code 3GHG). The strongest binding prediction for the 
two loops on the β chain was adjacent to the C-terminal peptide sequences 
(peptides B and C) identified by the microarray screening (Figure 6-7). 
Re-analysing the predicted binding sites of peptides B and C on C3b not only 
demonstrates that they are predicted to bind in close proximity to the portion of 
C3b that shares a sequence homology with Adhiron A6 (Figure 6-8), but also to 
a predicted binding site identified by the initial AutoLigand screening (indicated 
by the grey spheres in Figure 4-6). This commonality strengthens the evidence 
that this area of C3b may be a genuine, additional interaction site with 
fibrinogen, in particular the β chain. 
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 Figure 6-6 LSCM and EM images of purified clots prepared with Adhirons 
A6 and C6 with EM fibre thickness. 
(A) LSCM images of purified clots and (B) EM images of purified clots prepared 
by the addition of scaffold, A6 and C6 to purified fibrinogen. There was no 
difference in mean (±SEM) fibre diameter between the 3 different clots (C). 20 
fibres were measured from different areas of at least 5 different EM images of 
each Adhiron. *p<0.05.  
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Figure 6-7 Predicted binding of A6 to fibrinogen 
The predicted binding areas of A6 (loop 1 red, loop 2 blue) within the β chain of 
fibrinogen (PDB code 3GHG) as determined by the website pepsite2. The 
multicoloured spheres within the fibrinogen molecule represent peptides B and 
C, identified by the microarray screening as potential fibrinogen-C3 interaction 
sites.  
6.2.4 Adhiron G2* 
From the initial turbidity and lysis experiments with the Adhirons released by C3 
it was evident that Adhiron G2* had a drastic effect on clot formation at the 
fibrinogen:Adhiron molar ratio of 1:5. The extent of the changes made it an ideal 
candidate to study in further detail. Its effect on clot formation, lysis and 
structure were assessed at different concentrations in plasma and purified 
settings attempting to mirror fibrinogen:Adhiron molar ratios of 1:5, 1:0.5 and 
1:0.05 in plasma and 1:2, 1:0.2 and 1:0.02 in purified experiments. 
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Figure 6-8 Predicted binding of fibrinogen β chain peptides on C3b 
The predicted binding sites (from Pepsite) of peptides B (pink spheres) and C 
(orange spheres) from the microarray screening on C3b are in close proximity 
to the portion of C3(b) that shares a sequence homology with Adhiron A6 (blue 
spheres). 
6.2.4.1 Effect on clot formation and lysis 
The first thing to note from the plasma experiments is the dramatic reduction in 
lag phase, which suggests that it is interacting at a site involved with 
fibrinopeptide A release. It is clear that lateral aggregation is permitted given the 
sudden rise in absorbance, but the lack of a lag phase implies that elongation 
and protofibril formation is perhaps diminished (Figure 6-9). At the greatest 
concentration, the clot is not lysed after the allocated time, and the final turbidity 
or maximal absorbance is reduced compared to the scaffold Adhiron 
(0.1750±0.02, 0.2598±0.0, p<0.05). Dilution of Adhiron G2* corrects the effect 
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on the lag phase and the clot is broken down to 50% of its final turbidity (LT 
1493±51secs, p<0.05). Unexpectedly, however, reducing the concentration by 
10 fold to 3μM lowers the final turbidity even further to 0.0625±0.005. 
At the lowest concentration of 0.3µM, equal to Adhrion:fibrinogen molar ratio of 
1:20, the effects of G2* are eventually lost, with all parameters of LT, FT and lag 
phase similar to the scaffold Adhiron (LT 957±86secs p=0.3,  FT 0.2335±0.003, 
p=0.06).  
In purified experiments, the dose response of G2* was similar to plasma (Figure 
6-9). It is difficult to be certain whether the effect on lag phase transfers to the 
purified setting as the exponential increase in absorbance that occurs with 
lateral aggregation begins far quicker than in plasma, although there is a 
suggestion that at the highest concentration (6µM) the lag phase is reduced. 
The highest concentration is lysed in the purified experiments and the LT 
normalises with the reduction in concentration (1569±138sesc, 609±77secs, 
414±11secs, and scaffold 492±49secs). A similar trend to plasma is noted with 
regard to FT of the clots. The highest concentration again has a slightly lower 
FT than the scaffold Adhiron (0.126±0.02 vs 0.1908±0.02 p=0.13), and this is 
reduced further still with a 10 fold reduction in G2* concentration (0.049±0.01, 
p<0.05). The final and lowest dilution of G2* produces a curve that is similar to 
the scaffold, and the apparent lower FT was not significant (0.1558±0.007, 
p=0.4).  
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Figure 6-9 Clot lysis parameters of clots formed with varying 
concentrations of Adhiron G2* as measured by turbidimetric assay 
A-C Turbidity and lysis traces, lysis times and final turbidity from G2* at 30µM, 
3µM and 0.3µM in plasma and D-F at 6µM, 0.6µM and 0.06µM in purified 
system. The absence of the red bar in figure B is due to the fact that the clot did 
not lyse within the allotted time at this concentration of Adhiron G2* (30µM). 
Clots were prepared by the addition of G2* at varying concentrations to control 
plasma or purified fibrinogen. A total of 3 independent experiments were 
performed in duplicate. *p<0.05. Results are presented as mean±SEM. 
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Figure 6-10. LSCM and EM images of plasma clots prepared with varying 
concentrations of Adhiron G2* with EM fibre thickness and final turbidity. 
(A) LSCM images of plasma clots prepared in the absence and presence of G2* 
at 30µM, 3µM and 0.3µM respectively. (B) EM images of plasma clots in the 
absence and presence of G2* at the same molar concentrations (C). Mean 
(±SEM) fibre thickness of EM clots at 3µM and 0.3µM. It was not possible to 
measure the fibrin fibres at the highest concentration of 30µM hence the empty 
bar. Twenty fibres were measured from different areas of at least 5 different EM 
images of each Adhiron. *p<0.05.   
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6.2.4.2 Effect on clot structure 
In keeping with the dramatic effect that G2* had on clot LT and final turbidity, 
significant structural changes were noted in the fibrin network following the 
addition of G2* to plasma and fibrinogen (Figure 6-10).  In plasma and at 30µM 
clot architecture is greatly affected. The confocal and EM images demonstrate 
that fibrin fibres appear to be clumped together in dense areas. Such is the 
extent of this clumping it was not possible to measure the individual fibrin fibre 
diameter from the EM images at this concentration. At the middle concentration 
(3µM), the fibrin fibres are a little more distinct and thus the diameter can be 
measured, showing a significant reduction in diameter compared to the scaffold 
Adhiron (58.56±1.6nm, 106.8±2.2nm p<0.05), which fits with the reduced FT 
observed at this concentration.  
The areas of clumping appear less dense on the Z-stack images compared to 
the highest concentration and would explain the higher FT observed at 30µM. 
The lowest concentration of G2* produces a clot that is much more 
recognisable in terms of fibrin fibres and overall structure. The mean fibrin fibre 
diameter at 0.3µM was 99.09±2.7nm (p=0.05) suggesting that even at this 
relatively low concentration G2* is still able to interfered with fibrin clot 
formation. 
In the purified experiments the same trend was observed in terms of disruption 
to clot structure (Figure 6-11). At 6µM again the fibrin fibres could not be reliably 
measured and the clumping of fibrin bundles appeared denser than at 0.6µM. 
The average fibrin diameter was significantly reduced by 0.6µM (56.65±1.6nm 
vs 85.86±2nm, p<0.001) and although, as with the plasma clots, 0.06µM of G2* 
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produced a much more normal clot, the fibrin fibres were still significantly 
thinner than scaffold Adhiron (73.17±1.4nm p<0.001).  
 
Figure 6-11. LSCM and EM images of purified clots prepared with varying 
concentrations of Adhiron G2* with EM fibre thickness and final turbidity. 
(A) LSCM images of purified clots prepared in the absence and presence of G2* 
at 6µM, 0.6µM and 0.06µM respectively. (B) EM images of purified clots in the 
absence and presence of G2 at the same molar concentrations. (C) Mean 
(±SEM) fibre thickness of EM clots 0.6µM and 0.06µM. It was not possible to 
measure the fibrin fibres at the highest concentration of 6µM, hence the empty 
bar in (C).20 fibres were measured from different areas of at least 5 different 
EM images of each Adhiron. *p<0.05.   
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To ensure that the unusual clots observed at the highest concentration were in 
fact a fibrin clot network, real time lysis of the confocal clots was performed. The 
clots did indeed lyse but without the presence of a “lysis front” typically 
observed when lysis is preformed under visualisation with the LSCM (Figure 
6-12). Instead the lysis mix appears to attack the clot from all sides, presumably 
as it flows through what appear to be large pores within the clot. As expected 
following the turbidimetric experiments, LT is prolonged significantly. 
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Figure 6-12 Real time lysis of Adhiron G2* 
The top image illustrates the movement of a lysis front through a control clot 
(fibrinogen and scaffold), whereas the bottom image no lysis front is observed 
following the addition of Adhiron G2* to fibrinogen (images are all in the same 
orientation) and the LT of the clot is much longer. Clots were prepared by 
incubating control plasma with Adhiron and 488 Alexa labelled fibrinogen 
followed by the addition of thrombin and CaCl2. Clot lysis was initiated by the 
addition of a lysis mixture containing tPA and plasminogen to the edge of the 
clot. 
 
6.2.5 C3 binding Adhirons  
The Adhiron phage library was screened against immobilised C3. Fibrinogen 
was added in excess to the display to out compete Adhirons at the C3-
fibrinogen interaction site. Following phage ELISA and sequencing of 8 different 
colonies, 4 C3 binding Adhirons with different sequences were identified and 
available for analysis (Table 6-2). 
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Adhiron Loop 1 Loop 2 
G7 N******** L******** 
A7 V******** N******** 
C8 T******** N******** 
B3 S******** T******** 
Table 6-2 C3 binding Adhirons that were released by excess fibrinogen 
Due to potential future patent considerations only the first amino acid from each 
loop sequence is indicated. 
6.2.5.1 Effect on clot lysis 
Of the 4 C3 binding Adhirons, only one (B3) demonstrated any effect upon the 
turbidimetric assays in both plasma and purified settings. The resulting turbidity 
and lysis curves and lysis times can be seen in Figure 6-13. In a plasma system 
Adhiron B3 significantly prolonged LT (3419±278secs vs 870±73secs, p<0.05). 
There was no effect on LT from the 3 remaining Adhirons  
6.2.6 Selection of Adhirons for further analysis 
As with the previous groups of Adhirons, a limited number were chosen for 
further analysis based on i) sequence homology and ii) effect on clot lysis. None 
of the 4 C3 binding Adhirons shared sequence homolgy with fibrinogen. Adhiron 
B3 was the only one to effect clot formation and lysis and was studied along 
with G7 to act as a control with the scaffold Adhiron.  
Confocal microscopy was used to further test the effect of these Adhirons on 
clot lysis by studying the real time lysis of mature plasma clots in the presence 
and absence of B3 and G7. The addition of Adhiron B3 to plasma significantly 
slowed the rate of clot lysis compared to the scaffold alone, whereas G7 had no 
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effect on LT (Figure 6-14) which was in agreement with the initial turbidimetric 
assays.  
 
Figure 6-13 Clot lysis parameters of clots formed with C3 binding 
Adhirons as measured by turbidimetric assay 
Turbidity and lysis curves of C3 binding Adhirons in plasma (A) and the LT 
(mean±SEM) of the Adhirons in plasma (B). Control plasma was pre-incubated 
with Adhirons followed by the addition of a lysis mix containing tPA and an 
activation mix containing thrombin and CaCl2. A total of 3 independent 
experiments were performed in duplicate. *p<0.05 
6.2.6.1 Effect on clot structure 
Clots prepared for scanning electron microscopy using pooled healthy plasma 
incubated with scaffold Adhiron produced fibrin fibres with an average thickness 
of 106.8±2.2nm which was reduced to 64.9±1.5nm by Adhiron B3 (p<0.001). No 
significant difference in fibre diameter was observed with Adhiron G7 
(102.4±2.4nm, p=0.07). Comparisons of Z-stack images of plasma clots 
prepared with Adhirons G7, B3 and scaffold demonstrated a macroscopic 
alteration in the structure of the clots, with the B3 clots appearing denser than 
the other two (Figure 6-15). 
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Figure 6-14 Real time lysis of plasma clots in the presence of Adhirons B3 
and G7  
LSCM images of real time lysis of clots prepared with scaffold, B3 and G7 (A) 
demonstrating prolonged lysis following incubation with B3 compared to 
scaffold. The LT (mean±SEM) from the experiments (B) is significantly 
prolonged with B3. Clots were prepared by incubating control plasma with 
Adhiron and 488 Alexa labelled fibrinogen followed by the addition of thrombin 
and CaCl2. The LT represents the time taken for a lysis mixture containing tPA 
and plasminogen to completely dissolve the clot within the viewing field. 
Experiments were performed in duplicate on 3 separate occasions. 
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Figure 6-15 LSCM and EM images of plasma clots prepared with Adhirons 
G7 and B3 with EM fibre thickness. 
(A) LSCM images of plasma clots and (B) EM images of plasma clots prepared 
with scaffold, G7 and B3. Clots made with B3 had significantly thinner fibrin 
fibres compared with scaffold Adhiron and G7 (C). 20 fibres were measured 
from different areas of at least 5 different EM images of each Adhiron. Results 
are presented as mean±SEM). 
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6.3 Discussion 
The use of a phage library to target fibrinogen-C3 interaction sites was able to 
identify binders to both fibrinogen and C3 that affected clot formation and lysis, 
to varying degrees. The main findings of this Chapter can be summarised as 
follows: i) fibrinogen binding Adhirons released by C3 have varying effects on 
the fibrinolytic process, ii) one Adhiron (A6) shared sequence homology with 
C3, abolished C3-induced prolongation of clot lysis in a purified system and was 
predicted to bind fibrinogen in a similar area to C3, iii) despite C3-specific 
activity of A6, this Adhiron failed to reduce clot lysis in plasma system and 
appeared to show differential effect in diabetes and non-diabetes subjects, iv) 
Adhiron G2 demonstrated very significant effect on clot structure and lysis both 
in plasma and purified system, v) C3 binding Adhirons released by fibrinogen 
may also affect fibrin clot structure/lysis.  
The analysis of fibrinogen binding Adhirons that were released following 
addition of excess C3 produced dramatic effects within turbidimetric assays, 
with variability observed between plasma and purified settings.  Several 
Adhirons appeared to be having little effect on clot formation and structure. In 
plasma turbidimetric assays, three Adhirons, A5, C2 and G2, severely affected 
both LT and FT, indeed C2 caused no increase at all in absorbance of the 
reaction mixture, suggesting no clot was formed. These effects were greatly 
reduced in a purified setting, implying that interaction between the fibrin 
network, Adhiron and plasma proteins affects both clot structure and fibrinolysis. 
 
Following incubation of fibrinogen with Adhiron A6 prior to the addition of C3 it 
was possible to abolish C3 induced prolongation of lysis. Clots containing A6 
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appeared structurally very similar to control with no difference observed in the 3 
dimensional structure of the fibrin network from LSCM images and no difference 
in fibrin fibre thickness from EM images. It is likely that the presence of A6 
inhibits C3-fibrinogen interaction to a certain extent, thus reducing incorporation 
of C3 into the fibrin network and facilitating fibrinolysis. However, the lack of 
effect of A6 in plasma setting, and indeed the prolongation of lysis in some 
individuals is puzzling and indicate that A6 mimics the action of C3 in a plasma 
environment. Moreover, there does appear to be a difference between diabetes 
and non-diabetes individuals in terms of their response to A6. A significant 
increase in LT was observed with non-diabetes individuals, with a definite 
reduced effect in diabetes patients, and enhanced LT in two individuals. It may 
be that A6 has a diabetes specific effect relating to glycation of fibrinogen and 
or C3, with the possibility of additional interaction sites between A6 and 
fibrinogen. Although results were disappointing, molecular modelling provided 
further evidence of the potential importance of A6. The predicted binding sites 
of both loops of A6, using Pepsite, were in close proximity within the β-chain of 
fibrinogen. What was more encouraging was that these predicted binding sites 
were in the same region of the β chain that included the peptides B and C 
identified by the microarray screening. Furthermore, these β chain peptides 
were predicted to bind to C3b in an area adjacent to the portion that shared 
sequence homology with A6. This commonality of results provides compelling 
evidence that these are genuine interaction sites between C3b and fibrinogen, 
in addition to the binding of native C3 to fibrinogen. This may provide further 
explanation to the lack of effect of A6 in plasma, in particular that of healthy 
controls. It may be that A6 is able exert some of its effect by inhibiting C3b 
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incorporation into the clot, and that reduced activation of the complement 
pathway in healthy individuals translates into lower levels of C3b compared to 
diabetes. This however would not explain the increase in LT observed in the 
T2DM control samples and many of the T2DM samples. The most likely 
explanation for the failure of A6 to facilitate lysis in plasma is related to 
interaction with other plasma proteins. Further experiments using 
immunoprecipitation techniques may help to investigate this possibility and this 
remains an area for future research. Although a promising start, further work is 
required to identify Adhirons capable of interfering with the interaction between 
C3(b) and fibrinogen. 
Although the main aim of this work was to identify Adhirons capable of reducing 
C3 medicated prolongation of lysis, similar to the PI results, several Adhirons 
were identified that dramatically altered clot structure and with it fibrinolysis. 
Adhiron G2 was studied in more detail and images of the clot structure revealed 
a very abnormal appearance. The fibrin fibres appear very thin and fragile and 
at increasing concentration they clump together, thus creating the impression of 
thicker fibres or denser clot network from the FT values. As the concentration of 
G2 is reduced there is less clumping and therefore the FT reduced, reflecting 
the thinner fibres. Even at very low molar concentration (1:0.2 
fibrinogen:Adhiron molar ratio), Adhiron G2 significantly alters the clot structure 
and prolongs LT in both plasma and purified experiments. At the highest 
concentration studied, there is a clear reduction in lag phase, suggesting that 
lateral aggregation of the fibrin protofibrils is enhanced. It is possible therefore 
to hypothesis that G2 is interacting with fibrinogen at the sites of fibrinopeptide 
A and B release. Although these results are very striking and certainly warrant 
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further investigation, it is likely that they are C3 independent effects. In terms of 
fibrinogen-C3 interactions, the results obtained with Adhiron A6 are far more 
relevant and exciting.  
Fewer C3 binding Adhirons were identified and of the four available for analysis, 
only B3 produced any significant effects.  There was a reduction in FT in both 
plasma and purified settings, suggesting formation of thinner fibrin fibres which 
was confirmed by measurement of fibres from EM clots. Adhiron B3 also 
significantly and reproducibly increased lysis time in turbidimetric assays in 
plasma, suggesting an interference with the process of fibrinolysis. The effects 
of B3 on clot structure are difficult to explain as in theory, it should represent a 
portion of fibrinogen binding to C3 and shouldn’t therefore have the dramatic 
effects observed. A possible explanation may be that B3 is able to non-
specifically bind to fibrinogen, as well as C3, and is not actually involved in the 
interaction site between the two.  Given the more compact structure induced by 
Adhiron B3, by whatever means, it is possible that this results in increased 
incorporation of anti-fibrinolytic agents into the clot during formation, thus 
prolonging lysis.  
 
Overall, the results presented in this Chapter are encouraging in terms of 
utilising this Adhiron library to target the interaction between C3 and fibrinogen 
and modulate clot lysis. Further refinement of the technique, to identify Adhirons 
with varying binding affinity for example, may lead to the discovery of Adhirons 
with similar pro-fibrinolytic properties in plasma as well as in purified settings. 
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Chapter 7  
Conclusions and future work 
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The increasing prevalence of diabetes worldwide shows little sign of abating, 
with estimations from the International Diabetes Federation that over 500 million 
will be affected worldwide by 2035, an increase of 55% from the current levels 
of 382 million in 2013. Diabetes is associated with a number of health 
complications and is most strongly linked with cardiovascular disease (CVD). In 
addition to increased risk of myocardial infarction (MI), the prognosis following a 
vascular event in diabetes remains worse than individuals with normal glucose 
metabolism5. This association is related to clustering of cardiovascular risk 
factors in diabetes, coupled with a deranged haemostatic system that is driven 
by inflammation, insulin resistance and hyperglycaemia. A pro-thrombotic 
environment is generated secondary to a number of abnormalities including 
increased platelet activation and elevated levels of proteins such as coagulation 
factors VII and VIII, fibrinogen and plasminogen activator inhibitor 1 (PAI-1)35, 37.  
In addition to increased prothrombotic protein levels, diabetes is associated with 
functional abnormalities in various proteins in the coagulation pathways, which 
contribute the thrombotic milieu in diabetes. Moreover, increased incorporation 
of proteins such as plasmin inhibitor (PI) and complement C3 contribute to a 
hypofibrinolytic state6;133, compounding matters further. Interaction between the 
complement and coagulation pathways is increasingly understood providing a 
link between the inflammation observed in diabetes and the pro-thrombotic 
environment.  
Current treatment strategies for preventing atherothrombotic events in diabetes 
are aimed at the cellular phase of coagulation and inhibition of platelet 
activation. The fibrin network has been successfully targeted in the treatment of 
acute arterial thrombotic occlusion through the use of fibrinolytic compounds, 
 
 
203 
 
although the introduction of primary percutaneous intervention for MI now 
largely limits this option in some centres to the treatment of acute stroke 
disease only. Inhibiting coagulation factors to prevent arterial thrombotic events 
has been trialled using warfarin and more recently factor X inhibitors but 
concerns persist regarding the bleeding risk associated with broad inhibition of 
clot formation using these agents. Targeted interference with fibrinolysis is a 
potential area for the development of new therapeutic agents, such as inhibition 
of fibrinogen interactions with the anti-fibrinolytic compounds PI and C3. The 
aims of my work were therefore to i) further study the role of C3 in 
hypofibrinolysis in relation to diabetes ii) elucidate potential binding sites 
between fibrinogen and C3 and iii) modulate fibrin clot lysis by targeted 
interference with fibrinogen-PI and fibrinogen-C3 interactions.   
 
The effects of diabetes on the fibrinolytic properties of C3 and potential 
mechanisms 
The analysis of plasma C3 levels in a cohort of 838 T2DM patients 
demonstrated a strong correlation with clot lysis time and confirms the 
contribution of C3 to hypofibrinolysis in T2DM in addition to T1DM as previously 
described6. The lack of association between C3 and PAI-1 levels strengthens 
the belief that both molecules contribute to the resistance of fibrinolysis in this 
population via different mechanisms. Fibrinolysis is reduced by PAI-1 due to the 
inhibition of plasmin generation, whereas increased incorporation of C3 into the 
fibrin network appears to increase the mechanical resistance to lysis. This 
notion is supported by the observation that C3 incorporation into the clot 
correlates with lysis time 214.  
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Turbidimetric experiments using fibrinogen and C3 purified from T1DM, T2DM 
and matched controls demonstrated a prolongation in clot lysis time by C3 and 
this effect appeared to be most pronounced in the T1DM cohort. It may be 
unfair to compare the T1DM and T2DM groups however given that the 
concentration of tPA in the T2DM experiments was adjusted to facilitate clot 
lysis and permit analysis of the samples. It is likely that the C3 mediated 
prolongation of lysis in these samples was artificially low compared to the T1DM 
group. There was a wide variability in LT prolongation in both diabetes samples 
and controls. This observation implies a variation in the degree of C3-fibrinogen 
interaction and subsequent incorporation of C3 into the clot and may relate to 
differences in glycation of fibrinogen and C3, and also interaction with other 
coagulation factors such as FXIII which is responsible for cross-linking C3 to 
fibrin.  
Although in-vivo glycation of C3 has been demonstrated previously, the site(s) 
of glycation has not been described. Mass spectrometry analysis of pooled DM 
and control samples failed to demonstrate measurable glycation. Individual 
sample analysis did however reveal multiple Lysine residues with evidence of 
glycation with a large amount of heterogeneity between samples. Moreover, the 
T1DM samples contained more glycation sites per sample than the T2DM group 
with a greater degree of overlap between samples. These findings may explain 
the increased prolongation in lysis time caused by C3 observed in the T1DM 
group compared to the T2DM and suggests that glycation of certain, key, Lysine 
residues is an important factor in the interaction of fibrinogen with C3 and its 
incorporation into the clot. In addition to post translational modifications caused 
by hyperglycaemia, elevated glucose concentrations may contribute further by 
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altering the structure of the C3 molecule, exposing hidden residues and 
increasing their affinity to other proteins. An example of this mechanism is the 
glycation of Lysine 839 (K839) which was noted in one T2DM sample. The 
study by Hair et al (2012) described increased biotinylation of K839 with 
increased glucose concentration and thus interaction between C3 and 
fibrinogen at this site may be dependent upon conformational changes within 
C3 induced by hyperglycaemia.  
 
Future work 
The turbidimetric experiments using purified proteins from diabetes and control 
subjects demonstrated a trend towards increased lysis prolongation by C3 in 
diabetes compared with controls but fell short of achieving statistical 
significance. This is likely a matter of sample size as evidenced by the inter-
individual variability in lysis time. Repeating the experiments with a larger 
sample size would be an obvious direction for future work related to this area. 
Consideration, however, needs to be given to the amount of work this would 
entail and the additional information derived from it. The purification of C3 from 
individual samples is very time consuming and protein yield can be 
unpredictable as occurred in this project. The addition of perhaps 5-10 extra 
samples would likely reach statistical significance with the T1DM group and 
possibly the T2DM. Another interesting addition to this work would be to study 
the effect of C3 glycation on C3 incorporation. This would require analysing 
more diabetes samples by mass spectrometry and quantifying the amount of C3 
incorporated into the clot of the same sample. This might help to identify any 
glycated Lysine residues that are linked with C3 incorporation. 
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Assessing C3-fibrinogen interactions 
Perhaps the most striking result obtained from this section of work was the 
discovery that the β chain of fibrinogen was important in binding to C3 rather 
than the α chain as was previously thought.  This finding was from the results of 
the phage display screening with the cDNA library of the fibrinogen α chain and 
microarray screening. Both experiments rely on linear interaction, however, It 
may be worth noting that both C3 and fibrinogen are presented as linear 
peptides in the phage display system, whereas only the immobilised fibrinogen 
fragments are presented in a linear fashion with the microarray screening as C3 
is added to the plate in solution, thus preserving it conformation. Although three 
different peptide motifs from the β chain appeared to be involved in binding to 
C3, two of these (peptides B and C) were separated by a single amino acid and 
thus it is possible that they represent a single interaction site. Such large scale 
screening of fibrinogen and C3 was required given the lack of published work 
regarding possible sites of interaction. The use of molecular modelling 
techniques allowed these peptides to be tested for their likelihood of binding to 
C3 and identify potential interaction sites. Peptides B and C were predicted to 
bind in very close proximity to each other on C3, strengthening the argument 
that they represent one interaction site. Residues on the surface of C3 that were 
predicted to bind to these peptides included K839, further implicating the role of 
hyperglycaemia in binding fibrinogen to C3. Unfortunately 3-dimensional 
structures of the β chain peptides were predicted to dock to different regions of 
C3, however these sites did appear to encompass other glycated Lysine 
residues. The predicted docking pose of peptide B was in the C345C domain an 
area that includes glycated lysine residue K1505. Peptide C was predicted to 
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dock to C3 around the MG6 domain containing glycated lysine residue K655. A 
potentially important finding from this work is the discovery that the active 
component of C3, C3b may also be able to bind to fibrinogen and be 
incorporated into the clot structure. Although there is a big difference in the 
structure of the two molecules, they share a very similar molecular weight and 
assuming it is the physical presence of C3 that leads to the resistance to lysis 
then it is feasible that C3b shares this property. The amino acid sequence and 
3-dimnesional structure of the β chain peptides were predicted to bind in 
virtually the same region of C3b, indicating that fibrinogen may be binding to 
activated C3b as well as native C3. This observation may be of particular 
relevance to diabetes given that the complement pathway is increasingly 
activated in diabetes, generating elevated C3b levels. Indeed, preliminary 
experiments by another member of the team has shown that C3b was able to 
increase clot lysis. However, only a limited number of experiments were 
conducted and this will require detailed investigation using samples from 
different individuals and remains an area for future research.  
 
Future work 
To assess whether the β chain peptides identified from the microarray 
screening are genuine sites of interaction with C3 it would be worth producing 
them as peptides and assessing their interaction in an ELISA and also in 
turbidimetric assays. By pre-incubating C3 with the peptides, they should in 
theory prevent fibrinogen binding to C3. In the case of turbidimetric analysis this 
should enhance fibrinolysis and in an ELISA a lower OD if an anti-fibrinogen 
antibody is used as the secondary antibody. 
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In order to confirm the interaction site of fibrinogen and C3 it may be possible to 
co-crystallise the D-fragment of fibrinogen (containing the sequences of 
peptides B and C) with C3. The fibrinogen molecule has a whole is difficult to 
crystallise due to its size and mobile αC domain and therefore the microarray 
results allows a more focussed approach.  
 
Modulating clot lysis by interfering with fibrinogen-PI interactions 
The use of the Adhiron library to screen for fibrinogen binders capable of 
disrupting clot formation and lysis is a new and useful technique for the 
identification of novel therapeutic agents. The method also allows great 
flexibility in selecting Adhirons of interest as demonstrated by the use of PI in 
the latter rounds of panning to elute Adhirons binding to fibrinogen at sites of PI 
interaction.  These Adhirons bind to fibrinogen with high affinity, alter the 
composition of the fibrin network and modulate fibrinolysis in plasma and in 
purified setting in the presence and absence of PI.  
Adhiron G4 enhanced lysis time in plasma and in purified experiments in the 
presence of PI, suggesting that it is exerting an inhibitory effect on PI-fibrinogen 
binding. Immunoblotting identified that G4 is binding to the α chain and the use 
of molecular modelling narrowed the area to the central E region. This is a 
considerable distance from the known interaction site of PI and fibrinogen 
(Lys303 in the αC domain) and thus it is difficult to postulate how G4 is directly 
inhibiting the actions of PI from such a relatively remote area. Difficulties in 
crystallising this region of the α chain meant it was not possible to interrogate it 
in terms of Adhiron binding. The clots produced in the presence of G4 contained 
thicker fibrin fibres than controls and may offer an explanation for its effect on 
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clot lysis. Fibre diameter is governed by lateral aggregation which relies upon 
the release of fibrinopeptides (Fp) A and B from the α and β chains respectively. 
FpA release allows the formation of elongated protofibrils, which are 
subsequently linked to other protofibrils following FpB release and 
disengagement of the αC domain from residues 1-66 within the β chain of the 
central E region. It may be that G4 facilitates the dissociation of FpB and the αC 
region thus increasing lateral aggregation, producing clots with thicker fibrin 
fibres that are known to be less resistant to fibrinolysis by plasmin. The lack of 
change in the lag phase suggests that the rate of FpA dissociation is 
unaffected.  
By using PI to elute fibrinogen bound Adhirons during the latter biopanning 
rounds, it was envisaged that these Adhirons would facilitate clot lysis by 
interfering with PI-fibrinogen interaction. In fact the Adhirons identified 
predominantly inhibited lysis. Of the five that prolonged lysis in plasma, only 
Adhiron A2 was studied in greater detail, with consistent prolongation in lysis in 
plasma and purified settings, and an additive effect on lysis prolongation in the 
presence of PI. Compared to the Adhirons G2 and G4, it showed increased 
incorporation into the clot with the formation of thinner fibrin fibres. SPR studies 
showed high affinity binding of Adhiron A2 to fibrinogen, whereas 
immunoblotting demonstrated an interaction with the α chain of the protein. 
These techniques were complemented by molecular modelling that predicted 
the binding site to be within the E region of the α chain, in very close proximity 
to that of G4. Given the very different effects of these two Adhirons on clot 
formation and lysis it is interesting that predicted binding sites on fibrinogen are 
similar. It may be that subtle changes in the binding sites have opposing effects 
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on fibrinopeptide release and αC disengagement, leading to reduced lateral 
aggregation and thinner fibres in the presence of A2. One possible explanation 
for the differing effects is related to the incorporation data. It is possible that the 
two Adhirons bind on a similar region but the sequence difference allows A2 
incorporation into the clot (thus preventing lysis) whereas G4 binds and and 
prevent PI incorporation without getting cross-linked itself (thus facilitating lysis). 
Although my aim was to identify Adhirons that facilitate fibrinolysis, the “by 
product” of discovering anti-fibrinolytic Adhirons may prove to have important 
implications. These could be developed further for use therapeutically in 
patients with bleeding tendencies or perhaps as clotting agents following major 
trauma. There are precedents to such an approach as an analogue of PAI-1 is 
under development as a topical agent to minimise bleeding.   
 
Future work 
In addition to analysing the other Adhirons that prolonged lysis in greater detail 
there is further work that can be done in an attempt to clarify the binding sites of 
Adhirons A2 and G4. A modified ELISA could assess the binding of these 
Adhirons to commercially available D and E fragments of fibrinogen. Adhirons 
can be variable in their ability to stick to ELISA plates and thus biotinylating the 
Adhirons prior to incubating them on streptavidin coated plates would eliminate 
this problem and maintain the conformation of the Adhiron when presented to 
the fragments. Many commercially available polyclonal anti-fibrinogen 
antibodies are able to bind to D and E fragments, as well as the whole 
molecule, and so could be used to monitor the degree of binding.  
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If Adhirons are to be developed for use therapeutically then they would need to 
be assessed in animal models. This could be done relatively simply initially by 
substituting human plasma for murine plasma in turbidimetric assays in vitro. 
More detailed analysis could involve administering the Adhirons intravenously to 
mice followed by blood sampling and turbimetric analysis ex-vivo.  
 
Modulating clot lysis by interfering with fibrinogen-C3 interactions 
Using the same Adhiron library to study fibrinogen-C3 interactions identified 
binders to both fibrinogen and C3 that were capable of disrupting clot formation 
and lysis. In particular, one Adhiron, A6, that was eluted from fibrinogen by 
excess C3 shared a sequence homology with a portion of C3, suggesting that 
this region of C3 might be involved in binding to fibrinogen. Further analysis in 
purified turbidimetric assays revealed that A6 was able to abolish C3 mediated 
prolongation of clot lysis without altering the final clot structure and moreover, 
molecular modelling analysis predicted a binding site that was in close proximity 
to regions within the β chain of fibrinogen implicated in binding to C3. 
These positive results were tempered slightly by a lack of effect in plasma 
turbidity and lysis experiments. Pooled plasma samples did not reveal a 
reduction in lysis time and analysis of individual plasma samples demonstrated 
a reduction in only 2/6 diabetes samples and 0/6 control samples. It may be that 
A6 is interacting with other plasma proteins, thus reducing its ability to bind to 
fibrinogen. Given the variation observed in LT between control and diabetes 
samples, an alternative explanation is that the effects of A6 are diabetes 
specific; relating either to increased glycation of fibrinogen and or C3, or 
perhaps changes in the conformation of C3 due to hyperglycaemia that impact 
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on ability to bind to fibrinogen.  Diabetes is associated with enhanced 
complement activation, which translates to increased conversion of C3 to C3b. 
The discovery that the fibrinogen β chain peptides (identified form the 
microarray screening) were predicted to bind adjacent to the area of C3b 
containing the sequence homology to A6 raises the possibility that C3b is able 
to bind to fibrinogen in addition to C3. It maybe that A6 is more efficient at 
blocking the binding of C3b to fibrinogen in plasma, and a change in the C3:C3b 
ratio in diabetes plasma results in decreased C3b incorporation into the clot 
compared to healthy controls.  
Much like the work regarding interfering with fibrinogen-PI interactions, several 
Adhirons released from fibrinogen by C3 prolonged clot lysis. Adhiron G2 
greatly prolonged lysis time in plasma and purified assays, along with a 
reduction in final turbidity of the clot and lag phase. These changes in clot 
parameters persisted even at relatively low fibrinogen:Adhiron molar ratios and 
correspond with dramatic changes to the clot structure. Electron and confocal 
microscopy revealed very thin fibrin fibres that appear to clump together at 
higher concentrations of G2, greatly distorting clot architecture and increasing 
its resistance to fibrinolysis by plasmin. The mechanisms behind these changes 
have not been studied but the shortened lag phase, particularly in plasma, 
coupled with the generation of thin fibrin fibres suggest that protofibril elongation 
is affected along with lateral aggregation and so the gaze of suspicion should 
fall on interference with fibrinopeptide A and B release. 
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Future work 
In order to further investigate the possibility that A6 is interacting with other 
plasma proteins and thus explain its lack of effect in plasma, its behaviour in 
fibrinogen depleted plasma could be tested. The Adhirons contain a His-tag and 
thus by coating magnetic IgG beads with an anti-His antibody the beads could 
be used to draw out A6 from the fibrinogen depleted plasma and with it other 
proteins that may have bound. The eluted A6-antibody complex could then be 
run on an SDS-PAGE electrophoresis gel to look for a shift in the observed 
band.  The site of interaction of A6 with fibrinogen could be confirmed in a 
similar manner to the PI released Adhirons, to i) identify which chain is involved 
by immunoblotting and ii) determine which region of fibrinogen by incubating 
fragments D and E to biotinylated A6 captured on streptavidin coated plates.  
Another modified ELISA could be performed to demonstrate inhibition of 
fibrinogen-C3 interaction. By coating an ELISA plate with fibrinogen in the 
presence and absence of A6 followed by incubation with C3 and detection with 
a polyclonal anti-C3 antibody, a lower OD in the presence of A6 would suggest 
reduced binding of C3 to fibrinogen. The same method could be used to test for 
C3b binding to fibrinogen in the presence and absence of A6.  
An alternative strategy would be to repeat the initial screening of fibrinogen with 
the Adhiron library. Only high affinity binders were tested initially and lower 
affinity Adhirons may also have a role, as reversibility of action is important in 
clinical applications. Therefore, by altering the stringency during the panning 
rounds, using different incubation times and washing steps Adhirons with 
different binding affinities can be identified.  It should be noted that only 
fibrinogen and C3 from healthy controls were used in the initial panning 
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experiments and therefore using fibrinogen and C3 purified from pooled plasma 
samples of patients with diabetes would ensure that alternative fibrinogen-C3 
interaction sites in diabetes are accounted for.  
 
In summary, my work helped to shed more light on the role of complement C3 
in hypofibrinolysis in diabetes and identified some of the interaction sites of this 
protein on fibrinogen. Moreover, the new methodology that I developed, 
employing Adhirons, opens the door for identification of novel therapeutic 
targets that can be used to enhance the fibrinolytic process and reduce 
thrombosis risk in vascular conditions. Moreover, these Adhirons may be used 
to impair fibrinolysis and subsequently limit blood loss in bleeding complications 
following trauma, surgical intervention or over-treatment with anticoagulants.  
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PARTICIPANT INFORMATION SHEET 
 
PART 1 
 
You are being invited to take part in a research study.  Before you decide it is important 
for you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully and discuss it with others if you 
wish.  
  
PART 1 tells you the purpose of this study and what will happen to you if you take part. 
 
PART 2 gives you more detailed information about the conduct of the study. 
 
Ask us if there is anything that is not clear or if you would like more information.  Take 
time to decide whether or not you wish to take part.    
Thank you for reading this. 
 
What is the purpose of the study? 
People with diabetes have an increased risk of developing heart disease, compared to 
people without diabetes.  This can lead to a heart attack which is caused when a blood 
vessel supplying the heart becomes blocked.   This blockage is caused when small cell 
particles clump together and form a clot.  In this study we are interested in looking at 
some of the processes involved in the formation of blood clots in more detail. In 
particular, we will study a new protein, called complement C3, which may have an 
important role in blood clot stability and resistance to breakdown in people with 
diabetes, leading to increased risk of heart attacks.  
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We are asking people with both type 1 and type 2 diabetes, taking different treatments, 
with and without some of the problems that can be associated with diabetes to take 
part.  We will also ask some people who do not have diabetes to take part as “control” 
subjects.  In total 120 people will be asked to take part. The results from the different 
groups will then be compared. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part.  If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form.  If you 
decide to take part you are still free to withdraw at any time.  If you withdraw after you 
have given a blood sample, unless you object, your data and samples will remain on 
file and will be included in the final study analysis.   
 
What will happen to me if I take part? 
We will ask you to come to the LIGHT Laboratories in the University of Leeds on 1 
occasion where you will see Dr King or Penny Rice, the study research nurse.  The 
appointment will be in the morning and will last about 20 minutes.  You will need to fast 
from midnight on the day of your visit (water is allowed) and not take any morning 
medication you would normally have. If you bring them  
with you we will provide breakfast of toast and a drink after the appointment and you 
can take them at this time. 
If you are a participant with diabetes please check your blood sugar when you get up in 
the morning as per your normal routine.  If your reading is low or you are experiencing 
symptoms consistent with low sugar levels do not fast and treat this low sugar as you 
would normally.  You can still attend the study appointment. 
At this study visit you will be asked to sign a consent form.  You will have a 60 ml blood 
sample taken (this is about 4 tablespoons). Some of the sample will be sent for routine 
laboratory tests and the remainder will be used to analyse some of the proteins that 
affect blood clotting.  We will also ask you some general health questions and check 
your weight and blood pressure.   
 
What are the possible disadvantages and risks of taking part? 
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You will have to attend an appointment in the morning lasting about 20 minutes.  We 
will arrange this at a time to suit you and can reimburse travel expenses.  Having a 
blood sample taken can be uncomfortable and you may develop a bruise over the site.  
This will disappear after a few days.  Some people feel light-headed or faint giving a 
blood sample and there is also a very slight risk of developing an infection at the site 
where the sample is taken. 
 
What are the possible benefits of taking part? 
There will be no direct benefit to you from taking part in this study but we hope the 
results will give us more information about the factors affecting the development of 
heart disease.  This may help with future treatments for cardiovascular disease in 
people with diabetes. 
 
What happens when the research study stops? 
Any other medical care you are receiving will continue as before.   
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should contact one of the 
researchers who will do their best to answer your question.  Our contact numbers are 
at the end of this information sheet.   
If you are harmed by taking part in this study there are no special compensation 
arrangements.  If you are harmed due to someone’s negligence, then you may have 
grounds for a legal action but you may have to pay for it.   
If you wish to complain formally you can do this through the NHS Complaints 
Procedure.  Details can be obtained from the hospital.   
 
Will my taking part in this study be kept confidential? 
All information which is collected about you during the course of this research will be 
kept strictly confidential.  Details are in Part 2 of this information sheet. 
 
Contact Details 
If you require any further information please contact us on the telephone numbers 
below. 
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Thank you for reading this information sheet and for considering participating in this 
research. 
Dr. Rhodri King   Sr. Penny Rice – Research Nurse 
TEL: 0113 3437719   0113 3437702 or 07762 824470 
This completes Part 1 of the information sheet.  If this information has interested you 
and you are considering participation please continue to read Part 2 before making a 
decision 
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PART 2 
 
What happens if I don’t want to carry on with the study? 
If you change your mind about participating you can withdraw from the study.   A 
decision to withdraw, or a decision not to take part, will not affect the standard of care 
you receive or your relationship with any medical staff involved in your care.  If you 
withdraw after you have given a blood sample, unless you object, your data and 
samples will remain on file and will be included in the final study analysis.  If you object 
to this your sample and all study data will be destroyed and you will not be included in 
the analysis. 
 
Will my part in this study be kept confidential? 
If you consent to take part in this study, the records obtained while you are in this study 
as well as related health records will remain strictly confidential at all times. Study 
information will be held securely on paper and electronically in the LIGHT Building at 
the University of Leeds under the provisions of the 1998 Data Protection Act. Your 
name will not be passed to anyone else outside the research team or the sponsor, who 
is not involved in the trial. You will be allocated a trial number, which will be used as a 
code to identify you on all samples.  This number will also be used on all study forms 
and databases.  We will keep a separate record of your name and a contact detail for 
the duration of the study which will be destroyed when the study is completed.  
Your records will be available to people authorised to work on the trial but may also 
need to be made available to people authorised by the Research Sponsor, which is the 
organisation responsible for ensuring that the study is carried out correctly. A copy of 
your consent form may be sent to the Research Sponsor during the course of the 
study. By signing the consent form you agree to this access for the current study and 
any further research that may be conducted in relation to it, even if you withdraw from 
the current study.  
 
The information collected about you may also be shown to authorised people from the 
UK Regulatory Authority and Independent Ethics Committee; this is to ensure that the 
study is carried out to the highest possible scientific standards.  All will have a duty of 
confidentiality to you as a research participant. 
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In line with Good Clinical Practice guidelines, at the end of the study, your data will be 
archived securely for a minimum of 15 years. Arrangements for confidential destruction 
will then be made.  
 
Informing your General Practitioner (GP) 
Your GP will not be told you are taking part in this study.  However if we find any 
abnormalities in your routine blood tests we will inform you, and with your permission, 
your GP, and any other doctors who may be treating you.  We will also document in 
your hospital notes that you are taking part in a study. 
 
What will happen to any samples I give? 
All samples will be labelled with a study number which will be unique to you.  Only 
Sister Rice will be able to identify you from this number.  The blood samples will be 
analysed in the LIGHT Laboratories in the University of Leeds.   
If you agree we will store some of your blood sample in the freezer in the LIGHT 
Laboratories for use in future studies.  However, if you prefer not to do this, any 
remaining blood sample will be destroyed once this study concludes.  Your sample will 
remain anonymous to other researchers at all times even after this study has ended. 
 
Will any Genetic testing be done? 
General genetic testing is not a part of this study.   
 
What will happen to the results of this study? 
The results of the study will be available after it finishes and we will be able to send you 
a summary if you are interested.  Results will usually be published in medical journals 
or be presented at scientific conferences. The data will be anonymous and none of the 
people who take part in the trial will be identified in any report or publication.  
 
Who is organising and funding this research? 
This research is organised by the Leeds Teaching Hospitals Trust and the University of 
Leeds and funded by the Sir Jules Thorn charity. 
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Who has reviewed the study? 
The scientific content of the study has been through national reviewing processes.  The 
study was given favourable ethical opinion for conduct in the NHS by Leeds East 
Research Ethics Committee. 
 
Contact for further information 
You are encouraged to ask any questions you wish, before, during or after taking part. 
If you have any questions about the study or the procedures involved, or would like to 
read the research on which this study is based please speak to your study nurse or 
doctor.  Our contact details are at the end of Part 1 of this information sheet. If you 
require any further information or have any concerns while taking part in the study 
please contact one of us. 
 
Alternatively if you or your relatives have any questions about this study you may wish 
to contact your GP or specialist member of staff in the diabetes centre to discuss it 
further. 
The hospital also has a Patient Advisory Liaison Service (PALS) who may be able to 
offer independent advice.  
 
If you decide you would like to take part you will be asked to read and sign the consent 
form. You will be given a copy of this information sheet and the consent form to keep. A 
copy of the consent form will be filed in your patient notes, one will be filed with the 
study records and one may be sent to the Research Sponsor. 
 
You can have more time to think this over if you are at all unsure. 
 
Thank you for taking the time to read this information sheet and to consider this study 
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CONSENT FORM 
 
Complement C3 and inflammation in diabetes 
 
Subject Identification Number:  
                  Please initial box 
 
1. I confirm that I have read and understand the information sheet dated ……… 
(version ......) for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at 
 any time, without giving any reason, without my  medical care or legal rights being affected. 
 
3.  I understand that sections of my medical notes may be looked at by authorised 
individuals from the Sponsor for the study, the UK Regulatory Authority of the  
Independent ethics Committee in order to check that the study is being carried 
out correctly.  I give permission, provided that strict confidentiality is maintained, 
for these bodies to have access to my medical records for the above study and 
any further research that may be conducted in relation to it.  I also give permission 
for a copy of my consent form to be sent to the Sponsor for the study. 
regulatory authorities where it is relevant to my taking part in research. 
I give permission for these individuals to have access to my records. 
 
4. I agree that my blood sample is a gift and may be retained for use in future 
 research.  I agree to transfer any property rights to the samples I provide to the  
 University of Leeds on the understanding that it will only  be used for research. 
 I understand that even if I withdraw from this study the data and samples  
 collected from me may be used in analysing the trial results, unless I specifically 
  withdraw consent for this.  I understand that my identity will remain anonymous. 
 
5. I consent to the storage including electronic, of personal information for the 
 purposes of this study.  I understand that any information that could identify  
 me will be kept strictly confidential and that no personal information will be  
 included in the study report or other publication. 
 
6. I agree to take part in this study. 
 
 
 
_______________________ _________________                  ________________ 
Name of Patient Date Signature 
 
 
 
_________________________ ________________                    ________________ 
Name of Person taking consent Date Signature 
 
 
 
 
 
 
 
 
 
 
 
